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SUMMARY
The characterisation of adrenoceptor subtypes has traditionally been achieved using 
pharmacological methods. However, in recent years molecular biology and biochemical 
methods have become increasingly popular. Transgenic technology has provided a 
merging of pharmacology and molecular biology, whereby molecular biology is used to 
identify and manipulate the gene of interest whilst pharmacology is used to investigate 
the functional consequences of these genetic manipulations.
The process of subtyping oti-adrenoceptor subtypes is often made more complicated by 
a lack of reliable subtype selective drugs, in particular for the aiB-adrenoceptor, for 
which there are no such compounds. The aiB-adrenoceptor KO mouse created by 
Cavalli et al (1997) provides a unique environment in which to study ai-adrenoceptor 
subtypes. The study of these KO mice may provide a valuable insight into the functional 
role of individual ai-adrenoceptor subtypes. For this reason my project investigated the 
functional consequences of deleting the ocib-adrenoceptor using traditional 
pharmacological methods including radioligand binding and wire myography and the 
more recently developed method of confocal microscopy.
In Chapter 2 ,1 describe the effects of deletion of the aiB-adrenoceptor from the brain 
and livers of WT and KO mice. Using five subtype selective ligands (prazosin,
RSI00329, (R)-A-61603, L765,314 and BMY7378), radioligand binding was used to 
characterise the ai-adrenoceptor subtypes in WT and KG brain and liver tissue. The 
WT brain was found to contain a heterpgeheous population of ai-adrenoceptors, 
consisting of aiA- and aiB-adrenoceptors\ whilst the KO brain had a smaller receptor
number compared to the WT and a pure population of aiA-adrenoceptors. In the WT 
liver (4 month old) a pure population of aiB-adrenoceptors was determined to be 
present, consistent with previous reports (Cavalli et al, 1997; Yang et al, 1998). The KO 
liver (4 month old) was unexpectedly found to contain a population of a i- 
adrenoceptors: characterised to be aiA-adrenoceptors. Preliminary results from studies 
of 3 month old KO livers revealed that there are negligible amounts of ai-adrenoceptors 
present at this age, whereas in 3 month old WT liver ai-adrenoceptor density is higher 
compared with 4 month old livers. This study demonstrates the loss (without apparent 
replacement) of the aiB-adrenoceptor from the KO brain and the substitution of the aiA- 
adrenoceptor to compensate for the loss of the a^B-adrenoceptor in the KO liver. This 
upregulation of the a i a-adrenoceptor appears to occur between 3 and 4 months of age.
Chapter 3 describes a general pharmacological characterisation of the mouse carotid 
artery and a detailed investigation into the characterisation of the ai-adrenoceptor 
subtype mediating contraction in WT and KO carotid arteries. The general 
pharmacology of the carotid artery was studied using a number of vasoactive 
compounds. Surprisingly, very few were capable of producing a response in this tissue. 
The agonists which contracted the tissue were NA, PE, (R)-A-61603 and 5-HT with a 
rank order of potency of:-
NA > (R)-A-61603 = 5-HT > PE in the WT carotid artery and 
NA > PE = 5-HT = (R)-A-61603 in the KO carotid artery.
The pECso for phenylephrine was significantly higher in the KO compared with the WT 
carotid artery. Noradrenaline produced biphasic curves in WT and KO carotid arteries
The rank order of potency for those agents which relaxed the tissue were:- 
ACh > ISO > UK14304
The relaxant properties were only studied in WT arteries.
Prazosin, 5-methylurapidil, L765,314 and BMY7378 were used to characterise the ai- 
adrenoceptor subtype mediating contraction to phenylephrine in WT and KO carotid 
arteries. From these results the WT and KO carotid artery appear to mediate contraction 
predominantly through the am-adrenoceptor although there is evidence that a 
component of the contraction in the WT carotid artery may be mediated by the otm- 
adrenoceptor.
In a separate series of experiments, concentration response curves to phenylephrine in 
carotid and mesenteric arteries from mice that either overexpressed the ais- 
adrenoceptor or expressed a constitutively active am-adrenoceptor, displayed no 
significant differences in sensitivity compared with control mice, providing no evidence 
for an enhanced am-adrenoceptor component to these transgenic models.
Adventitial fibroblasts have recently been shown to express ai-adrenoceptors (Faber et 
al, 2001) and the adventitia has been implicated in a number of pathological conditions 
e.g. atherosclerosis, restenosis. Chapter 4 describes a study investigating the effects 
which deletion of the ctm-adrenoceptor has on the structure of the adventitia of WT and 
KO carotid arteries. The number and density of adventitial cells in the KO carotid artery 
was found to be significantly smaller than in the WT carotid artery. The implications of 
this are not yet certain, but the aiB-adrenoceptor has been implicated in growth (Chen et
111
al, 1995; Zhang and Faber, 2001) which may account for the observed differences in the 
KO carotid artery compared with the WT.
The results presented in this thesis have gone some way to furthering our knowledge of 
the aiB-adrenoceptor and demonstrate that the effects of deleting the aiB-adrenoceptor 
depend not only on the tissue in which it is expressed, but also on the cell type. The 
merging of transgenic technologies with pharmacological techniques 
(pharmacogenomics) provides the pharmacologist with information which would not be 
possible with drugs alone and looks set to be a way forward in clarifying the confusing 
pharmacology arising from the use of inadequate drugs.
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CHAPTER 1 -  GENERAL INTRODUCTION
1.1. INTRODUCTION
Adrenoceptors mediate the central and peripheral actions of the primary sympathetic 
neurotransmitter, noradrenaline and the primary adrenal medullary hormone (and 
central neurotransmitter), adrenaline. Adrenoceptors are present in both the periphery 
and the central nervous system where they are found on many neuronal populations as 
well as in tissues (Bylund et al, 1994). a i -Adrenoceptors, which will be the focus of this 
thesis, participate in many essential physiological processes such as sympathetic 
neurotransmission, modulation of hepatic metabolism, control of vascular tone, cardiac 
contraction, and the regulation of smooth muscle activity in the genitourinary tract 
(Garcia-Sainz et at, 1999).
1.2. HISTORICAL PERSPECTIVE
1.2.1. Classification of adrenoceptors
The classification of adrenoceptors has been an ongoing process for over a century. It 
began in its simplest terms in 1896 when Oliver and Schafer demonstrated that injection 
of extracts of the adrenal gland caused a rise in arterial pressure. It wasn’t until 1913 
that Dale showed that not only could adrenaline (which had been isolated and identified 
as the active component by this time) produce a rise in arterial blood pressure through 
vasoconstriction, but that it could also produce vasodilation. The vasoconstrictor effect 
predominates and this was the effect observed by Oliver and Schafer. Dale avoided 
interpreting this result in terms of a distinction between categories of receptor (Rang 
and Dale, 1995) and 35 years passed before Ahlquist (1948) proposed the existence of 
two adrenoceptor subtypes based on different rank orders of potency within a series of
structurally related natural and synthetic agonists. He called them a- and |3- 
adrenoceptors and their relative potencies were found to be as follows
Ot:- Noradrenaline > Adrenaline > Isoprenaline 
(3 >  Isoprenaline > Adrenaline > Noradrenaline
This quantitative approach used by Ahlquist was in contrast to the qualitative analysis 
his peers were using which tended to place too much emphasis on the nature of the 
response rather than the potency of the drugs producing the response. As a result of this 
there were attempts to classify the effects of sympathomimetic amines as ‘excitatory’ or 
‘inhibitory’ and to assign these responses separate second messengers (sympathin E and 
sympathin I), which were activated by one adienoceptor (Cannon and Rosenbleuth, 
1933). This distinction proved to be useless in the identification of adrenoceptor 
subtypes. Ahlquist’s nomenclature was universally accepted and was supported by the 
discovery of highly selective and potent antagonists for the different subtypes (Ruffolo 
et al, 1991). But the use of these antagonists suggested the existence of further 
subdivisions of both a- and ^-adrenoceptors. The subclassiEcation of (3-adrenoceptors 
is beyond the scope of this thesis and from this point this thesis is concerned only with 
a-adrenoceptors, in particular ai-adrenoceptors.
The subclassification of a-adrenoceptors was proposed by Langer in 1974 but the 
starting point for this chain of events was a paper by Brown and Gillespie (1957) which 
reported that the a-adrenoceptor antagonists, dibenamine and phenoxybenzamine, 
increased the release of noradrenaline by sympathetic nerve stimulation from the cat 
spleen. Initially this phenomenon was not explained in the context of subtypes of a- 
adrenoceptors. Brown and Gillespie explained it as being a result of blockade of
postjunctional a-adrenoceptors, preventing the released noradienaline from acting on 
the a-adrenoceptors on the effector cells, leading to an increase in noradrenaline 
overflow. Thoenen et a/ (1964), who also showed an increased overflow of 
noradrenaline when a-antagonists were used, believed it resulted from inhibition of 
neuronal uptake (Ruffolo et al 1991). It was only when Starke et a l{ \9 1 \)  demonstrated 
that the effect was independent of uptake blockade and that a-agonists were capable of 
reducing the stimulation-evoked release of noradrenaline from nerves (Docherty, 1989) 
that it seemed more likely that this effect was being mediated by prejunctional a- 
adrenoceptors. As the evidence for prejunctional a-adrenoceptors grew, Langer (1974) 
proposed the first subdivision of a-adrenoceptors based on their anatomical location. 
The postjunctional a-adrenoceptor, which mediates the effector organ’s response, was 
to be termed a i and the prejunctional a-adrenoceptor, which regulates neurotransmitter 
release, was to be termed ai. Studies of the interactions of agonists and antagonists with 
these a-adrenoceptors extended this subclassification scheme to a functional 
subdivision (Berthelsen and Pettinger, 1977) which was finally replaced by a 
pharmacological subclassification after the identification of potent and highly selective 
ai- and a 2-adrenoceptor agonists and antagonists (Bylund et al, 1994). Therefore an a- 
adrenoceptor which was activated by methoxamine, cirazoline or phenylephrine and 
blocked by prazosin, WB4101 or corynanthine was an ai-adrenoceptor. Whereas an a- 
adrenoceptor which was activated by a-methylnoradrenaline, UK-14,304, B-HT 920 or 
B-HT 933 and blocked by yohimbine, rauwolscine or idazoxan was an as-adrenoceptor.
1.2.2. cxi-Adrenoceptor heterogeneity
Initially, Langer’s subdivision of a-adrenoceptors into a i and a 2 appeared to hold true. 
However it soon became apparent that the situation was not as simple as first presumed, 
as an increasing amount of data was published which didn’t appear to fit convincingly 
into either subdivision. For example, McGrath (1982) showed that the contractile 
response of the in situ anococcygeus was shown to have a prazosin-resistant response, 
but no part of the response could be ascribed to a 2-adrenoceptors. pA2 Values were 
obtained using the agonists, amidephrine and xylazine (ai- and ai- agonists 
respectively) and the antagonists, corynanthine and rauwolscine ( a r  and a 2- 
antagonists respectively). The pA2 values were consistent with the relative potency of 
the antagonists against the ai-agonists and revealed no evidence for a postjunctional a 2 - 
adrenoceptor (M'^Grath, 1982). Where did this response fit into the a i /a 2 
subclassification?
It was also apparent that results from radioligand binding studies and physiological 
studies didn’t add up. For example, binding studies by Wood et al (1979) showed that 
methoxamine and phenylephrine, which in functional studies were more potent in 
contracting postsynaptic smooth muscle than in inhibiting presynaptic noradrenaline 
release did not seem to follow the same trend in radioligand binding studies. They also 
found that uterus tissue which had been previously classified as containing mainly ai- 
adrenoceptors was found to have high affinity for the a 2-selective agonist, a- 
methylnoradrenaline. Wood et al (1979) recognised that heterogeneity existed within 
each a-adrenceptor subclass and that the a i /a 2 designation described by Langer served 
only as a starting point from which further subclassification was necessary.
McGrath (1982) was the first to propose a subdivision of ai-adrenoceptors when he 
classified them into aia- and aib-adrenoceptors based on data from the rabbit basilar 
artery and the rat anococcygeus. In both these tissues phenylethanolamines produced 
dose response curves with a ‘shoulder’ indicative of a response with two components.
In contrast the ‘ non-phenylethanolamine ’ agonists produced virtually no response in the 
rabbit basilar artery and a monophasic curve in rat anococcygeus. McGrath suggested 
that the ‘low concentration component’ of the response to phenylethanolamines and the 
response to ‘non-phenylethanolamines ’ was mediated by one type of ai-adrenoceptor 
which he designated aia while the response to high concentrations of 
phenylethanolamines was mediated by a second subtype which he designated aib. The 
rabbit basilar artery, it was suggested, has a ‘low dose component’ of the response to 
noradrenaline which corresponds more closely to the ‘aib-’ than the ‘aia-’adrenoceptor 
in rat anococcygeus which would explain the lack of response of the tissue to ‘non- 
phenylethanolamines’.
Attempts to discover any antagonists capable of distinguishing between aia and aib- 
adrenoceptors had limited success, warning against the premature suggestion of receptor 
subtypes. Subsequent evidence suggested that the results, instead of being a 
consequence of ai-subtypes, may actually be produced by a single type of a i- 
adrenoceptor which was able to mediate more than one response, possibly at the second 
messenger level (Wilson et al, 1991).
Despite general reservations about the concept of further subdivision of a i- 
adrenoceptors, the amount of published data which could be not be classified into 
simply a i or a^ was mounting. Hoick et al (1983) demonstrated that clonidine and
methoxamine produced differential interactions at postjunctional oci-adrenoceptors of 
the rabbit pulmonary artery suggesting that there were multiple subtypes. Medgett and 
Langer (1984) using the superfused tail artery found that two populations of ai- 
adrenoceptors existed. One had high affinity for prazosin and the other had low affinity. 
Medgett and Langer interpreted their high and low affinities for prazosin as an 
indication that prazosin, which is regarded as being highly selective for ai- 
adrenoceptors, was differentiating between two subtypes. Drew (1985) and Flavahan 
and Vanhoutte (1986) separately reviewed the literature on the affinity values of 
prazosin and demonstrated that prazosin had a range of affinities on smooth muscle that 
spread over two orders of magnitude, which they independently interpreted as an 
indication that further classification of a-adrenoceptors was required.
In 1986, Morrow and Creese provided evidence that ai-adrenoceptor subtypes existed. 
The two subtypes, which were identified by binding studies in the rat brain were found 
to have very different rank orders of antagonist affinities. Half of the sites exhibited the 
pharmacological profile :-
WB4101 > prazosin > phentolamine > indoramin > dihydroergocryptine
and they called this site aiA.
In contrast the second subtype demonstrated the rank order of:- 
prazosin > indoramin > dihydroergocryptine > WB4101 > phentolamine
and this was called aiB-
Although prazosin was able to label the two binding sites it couldn’t distinguish 
between them, whereas [^H]-WB4I01 was only able to label one of these sites, the aiA 
and was found to have a much lower affinity for the other binding site, the a is  (Morrow 
and Creese, 1986).
After this initial subclassification many studies were conducted into the characterisation 
of these subtypes. Han et al (1987a) produced results in accordance with Morrow and 
Creese. They also found that prazosin had similar affinities for both subtypes but that 
WB4101 and benoxathian bound with 2 separate affinities, ai a-Adrenoceptors had high 
affinities for the two drugs and aiB-adrenoceptors were found to have low affinities.
Han et al not only looked at the affinities of antagonists at a  i-adrenoceptors but also 
looked at their mechanism for increasing intracellular calcium in smooth muscle. Their 
results showed that the «ib subtype regulates inositol phospholipid hydrolysis and gives 
rise to contractions which are independent of extracellular calcium while the aiA 
subtype appears to control the opening of dihydropyridine-sensitive membrane channels 
to allow influx of extracellular calcium (Han et al, 1987a). Jagadeesh and Deth (1987) 
also found that WB4101 distinguished between subtypes of «i-adrenoceptors in bovine 
aortic plasma membranes but additionally found that prazosin identified two sites, a 
contradiction to Morrow and Creese’s results. Gross et al (1988) demonstrated that a 
derivative of urapidil, 5-methylurapidil, bound to two sites in the rat hippocampus and 
the vas deferens, displaying approximately 50-fold selectivity for the high affinity site 
over the low affinity site. In agreement with Morrow and Creese, prazosin was unable 
to distinguish the two sites.
Shortly after Morrow and Creese’s initial identification of two ai-adrenoceptor 
subtypes, Han et al (1987b), who were working with an alkylating analogue of 
clonidine, chloroethylclonidine (CEC), demonstrated that it was able to reduce the ai- 
adrenoceptor population in rat liver and spleen by 70-80% whereas it had no significant 
effect in rat kidney, hippocampus, heart and vas deferens. A follow on paper from this 
(Minneman et al, 1988) which investigated the ai-adrenoceptor subtypes distinguished
by WB4101 and CEC showed that the low affinity sites identified by WB4101 were the 
same sites which were sensitive to CEC inactivation, suggesting that these two drugs 
were distinguishing the same subpopulation of oti-adrenoceptor. These and many other 
papers were in agreement with Morrow and Creese’s initial findings, providing 
conclusive evidence that there were in fact two subtypes of ai-adrenoceptor, the aiA 
and aiB.
The emerging pharmacological properties of the subtypes at this time were that :-
1. Prazosin was unable to distinguish between the two subtypes,
2. WB4101 and 5-methylurapidil bound with high affinity to the aiA-subtype and with 
low affinity to the aiB-subtype,
3. CEC was able to inactivate the ais-subtype, but that the aiA-subtype was relatively 
insensitive to CEC inactivation.
About the same time as the aiA/ciiB classification scheme was being developed, 
Flavahan and Vanhoutte (1986) reviewed the literature that was available at the time 
and came up with a different subclassification based on the wide range of affinities 
which both prazosin and yohimbine demonstrated in vascular smooth muscle. They 
subdivided ai-adrenoceptors into am  and am-adrenoceptors. am-Adrenoceptors were 
defined as having a high affinity for prazosin (pAz values above 9.0) and yohimbine 
(pA] values above 6.4) whereas the am-adrenoceptor has lower affinity for both 
antagonists (pAg values below 9.0 and 6.2 respectively). In 1990 Muramatsu et al added 
weight to this subclassification based on data using a range of antagonists in various 
blood vessels fi'om different species. They found that the results fell into three groups. 
Group I tissues (canine saphenous vein, mesenteric artery and vein) were potently
inhibited by HV723 and WB4101 more so than prazosin, group II (canine carotid artery 
and rat thoracic aorta) were potently inhibited by prazosin more so than HV723 and 
WB4101 and group III (guinea-pig thoracic aorta, rabbit thoracic aorta, carotid artery 
and mesenteric artery) were inhibited by the three antagonists with the same potency. 
Groups II and III fitted in with Flavahan and Vanhoutte’s subclassification with group II 
being assigned as am-adrenoceptors and group III as am-adrenoceptors. This left group 
I, which Muramatsu proposed to consist of tissues containing a novel subtype, the am* 
This subtype has a relatively low affinity for prazosin, a higher than expected affinity 
for yohimbine and a high affinity for HV732.
An important aspect of this proposed subclassification is that it takes into account the 
wide range of affinity values for prazosin, first highlighted by Drew in 1985, whereas in 
Morrow and Creese’s subclassification prazosin fails to distinguish between the 
subtypes. Muramatsu ascribed these subtypes to the am  group since they all have high 
affinity for prazosin.
1.3. a i-A D R E N O C E P T Q R  SU B TY PE -SE LEC TIV E CO M PO U N D S
With the discovery of ai-adrenoceptor subtypes it became clear that there was a limited 
number of compounds which exhibited selectivity for a given subtype and even today, 
15 years on from their discovery, the choice of compounds which are convincingly 
selective is surprisingly sparse. This is generally regarded as the Achilles heel of those 
interested in pharmacologically defining ai-adrenoceptor subtypes. Confusing and 
ambiguous results abound and much of the interpretation of this functional data relies 
on the individual experimenter’s faith in their choice of compounds. What follows is a
brief overview of some of the compounds available and their selectivities for the ai- 
adrenoceptor subtypes, with particular reference to the compounds used in this project.
WB4101 and phentolamine were the antagonists originally found to discriminate 
between aiA- and aiB-adrenoceptors in rat brain (Morrow and Creese, 1986). WB4101 
has since been shown to have high affinity for the aio/d-adrenoceptor subtype (Perez et 
al, 1991; Weinberg et al, 1994; Kenny et al, 1995 and Schwinn et al, 1995) and is used 
to distinguish aiA/a- and am/d-adrenoceptors from aiB/b-adrenoceptors; for which it has 
approximately 10-fold lower affinity (Perez et al, 1991; Weinberg et al, 1994 and 
Schwinn et al, 1995). Phentolamine has also been shown to have higher affinity at aiA/a- 
and aiD/d-adrenoceptors, However its selectivity is less than WB4101 and is somewhat 
variable (Muramatsu et al, 1990; Perez et al, 1991; Weinberg et al, 1994; Kenny et al, 
1995 and Schwinn et al, 1995). As a result of this it is not used to select between 
subtypes but is often the drug of choice in radioligand binding, where it is used to define 
non-specific binding.
5-Methylurapidil, a derivative of urapidil, was first shown to discriminate between ai- 
adrenoceptor subtypes in 1988 (Gross et al, 1988). It displayed high and low affinity 
binding in rat hippocampus, heart and vas deferens, whilst in rat liver and spleen it 
displayed monophasic binding of low affinity. The high affinity site was the qia- 
adrenoceptor, for which 5-methylurapidil has approximately 100 fold higher affinity, 
compared with the low affinity site, now recognised as the am-adrenoceptor. This 
selectivity for the a i A-adrenoceptor has also been demonstrated for all the cloned 
subtypes (Schwinn et al, 1995) and also in functional and binding studies in tissues 
proposed to contain the «i A-adrenoceptor (Kong et al, 1994; Yang et al, 1998 and
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Argyle and M^^Grath, 2000). Its affinity for aiD/d-adrenoceptors is between that for the 
otiA/a- and aiB/b-adrenoceptors (Perez et al, 1991; Schwinn et al, 1995; Kenny et al, 
1995).
Tamsulosin has been used in the treatment of benign prostatic hypertrophy, to relieve 
urinary flow obstruction, which is believed to be caused by an increase in tone in 
prostate smooth muscle as a result of oii-adrenoceptor activation. The ai-adrenoceptor 
involved in prostate smooth muscle contraction is believed to be the a i A-adrenoceptor 
(Forray et al, 1994) for which tamsulosin has been shown to have selectivity (Michel et 
al, 1993; Michel and Insel, 1994). Although selective for the aiA-adrenoceptor its 
degree of uroselectivity appears to be very slight, so that not only does it inhibit the «]- 
adrenoceptors in the prostate but it also potently decreases blood pressure (Martin et al, 
1997), leading to side effects such as postural hypotension.
Prompted by this, a number of studies have been undertaken aimed at producing «ia- 
adrenoceptor antagonists, which are also uroselective. One such study produced two ai- 
adrenoceptor antagonists, Ro70-0004 and RS-100329. Both compounds showed greater 
than 50-fold selectivity for a i a-adrenoceptors over aib- and aia-adrenoceptors at cloned 
human ai-adrenoceptors. This selectivity was also demonstrated in functional studies by 
their ability to antagonise the contractions produced in human lower urinary tract tissues 
and rabbit bladder neck with nanomolar affinities (Williams et al, 1999). The degree of 
uroselectivity of these compounds in an in vivo situation has yet to be assessed.
However their ability to discriminate a i A/a-adrenoceptors from aiB/b- and am/a- 
adrenoceptors makes them valuable tools in pharmacological research.
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The aiA/a-adrenoceptor, as well as having a relatively large number of selective 
antagonists, in comparison to the other subtypes, can also boast of selective agonists. 
Oxymetazoline, which is a partial agonist at ai-adrenoceptors, has been shown to 
possess an approximately 10-fold higher affinity at ai A/a-adrenoceptors than am/b- or 
aiD/d-adrenoceptors (Minneman et al, 1994; Knepper et al, 1995 and Schwinn et al, 
1995). A-61603, which was developed by Abbott Laboratories is a full agonist at ai- 
adrenoceptors and has also shown selectivity for the aiA/a-adrenoceptor, demonstrating 
a 15-20 fold higher affinity at this subtype than at the aib- and aia-adrenoceptors 
(Knepper et al, 1995). Its usefulness as an a i A-adrenoceptor agonist has been 
demonstrated in functional studies (Knepper et al, 1995; Smith et al, 1997, Hrometz et 
al, 1999; Argyle and McGrath, 2000).
The number of selective compounds available for the am/b- and aiD/d-adrenoceptors is 
far fewer than those available for the aiA/a-adrenoceptor. Chloroethylclonidine (CEC) 
was believed to be an irreversible competitive antagonist for the (XiB/b-adrenoceptor 
based on its ability to inactivate the ais-adrenoceptor selectively in various rat tissues 
(Morrow and Creese, 1986; Han et al, 1987b; Minneman et al, 1988). However the 
oiiD/d-adrenoceptor has since been shown to be capable of inactivation by CEC (Perez et 
al, 1991). Further to this Hirasawa et al (1997) demonstrated that CEC is capable of 
inactivating otia- and aib-adrenoceptor membrane preparations, whilst in whole cells it 
can inactivate only the aib-adrenoceptor with any significance. They concluded that this 
discrepancy was due to the subcellular localisation of the ai-adrenoceptors. Using GFP- 
tagged a  1-adrenoceptors they were able to show that aia-adrenoceptors were mostly 
intracellular, whilst aib-adrenoceptors were found on the cell surface. They proposed
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that the highly hydrophilic CEC inactivates the ai-adrenoceptor present on the cell 
surface irrespective of subtype. Studies such as these have placed doubts on the 
reliability of the information that CEC provides.
Spiperone was proposed to be an am-adrenoceptor antagonist with 10-fold selectivity 
for the aiB-adrenoceptor (Michel et al, 1989). However, subsequent studies showed that 
it was unable to discriminate between subtypes (Schwinn et al, 1995) and as a result it is 
not widely used. Cyclazosin, is another such compound proposed to be selective for 
aiB-adrenoceptors. Binding studies displayed 90-130 fold selectivity for the am- 
adrenoceptor (Giardina et al, 1996). But functional studies in the mouse spleen, which 
is regarded as having a homogeneous population of oqB-adrenoceptors (Eltze, 1996), 
found it to have a low affinity and its action was not competitive (Stam et al, 1998) 
placing doubts on its usefulness as an am-adrenoceptor selective antagonist.
In 1998, Patane et al described the synthesis and pharmacological evaluation of a 
structural analogue of prazosin, L765,314, which they deemed to be a potent «ib- 
adrenoceptor selective antagonist. This was based on findings that at rat and human 
recombinant ai-adrenoceptors L765,314 had 10 and 100 fold higher affinity for the a i b -  
adrenoceptor compared with the aid- and aia-adrenoceptors, respectively. This 
selectivity was mirrored in native ai-adrenoceptors. Despite these encouraging results, 
work in our laboratory utilising this compound on recombinant ai-adrenoceptors, has 
failed to achieve the same degree of selectivity (Mackenzie, unpublished observations). 
Hence, to date, there are no convincing selective antagonists or agonists for the aiB/b- 
adrenoceptor.
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BMY7378 is the only widely accepted competitive antagonist, so far, for the am/d- 
adrenoceptor, for which it has been shown to have nanomolar affinity (Saussy et al, 
1994; Goetz et al, 1995). Its affinity at aiA/a- and aiB/b-adrenoceptors is similar and is 
approximately 100 times less than at ctio/d-adrenoceptors. Through the use of this 
compound the contraction in the rat aorta was characterised as being mediated by the 
a i 0 -adrenoceptor, answering the long running question as to its identity (Kenny et al,
1995).
Although there are no officially recognised selective dm-adrenoceptor agonists,
phenylephrine has been shown on a number of occasions to display a higher affinity at 
the aioM-adrenoceptor. Knepper et al (1995) found that phenylephrine had a 10-fold 
higher affinity at aid-adrenoceptors compared with the other subtypes. In native ai- 
adrenoceptors it was 1 0  and 80 fold more potent in contracting the native aw- 
adrenoceptors in rat aorta, than at a i A-adrenoceptors in the rat vas deferens, or aiB- 
adrenoceptors in the rat spleen, respectively (Knepper et al, 1995). Minneman et al 
(1994) demonstrated a selectivity at recombinant ai-adrenoceptors which matched that 
of Knepper et al (1995) but found that phenylephrine had similai' potencies at all three 
subtypes in stimulating inositol phosphate formation.
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1. Prazosin 2. RS 100329
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3. (R)-A-61603
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5. BMY7378
Figure 1.1: - The chemical structures of selective and non-selective ligands described 
in the text and used in the radioligand binding studies in Chapter 2. For R SI00329 R=H.
1.4 .M O L E C U L A R  B IO L O G Y  O F ai-A D R E N O C E P T O R S
M oitow and Creese’s paper in 1986 is regai'ded as being the first paper to clearly show 
the presence of two ai-adrenoceptor subtypes in native tissues. But it was a further 2 
years before the first ai-adrenoceptor was cloned.
1.4.1. Cloning of the aih-adrenoceptor
In 1988, Cotecchia et al described the cloning and sequencing of a purified ai- 
adrenoceptor isolated from a hamster cDNA library. The isolated clone was found to 
have a deduced amino acid sequence of 515 amino acids with a molecular weight of 
56kDa, in agreement with the apparent molecular mass of the deglycosylated ai- 
adrenoceptor (Sawutz et al, 1987). Hydrophobicity analysis revealed 7 clusters of 
hydrophobic residues, 20-25 residues in length, consistent with previously cloned G 
protein coupled receptors (GPCRs). Potential sites for N-linked glycosylation were 
found in the amino terminus, in agreement with previous observations that the oti- 
adrenoceptor is glycosylated with complex N-type linked oligosaccharides (Sawutz et 
al, 1987).
The isolated clone was found to share identity with previously cloned human 
adrenoceptors, particularly in the putative transmembrane domains (TMD) where the 
identities were found to be:- 0 (2 : 44%, Pi:45% and P2 : 42%. Several threonine and serine 
residues were found in the second and third cytoplasmic loops representing potential 
sites for protein kinase C (PKC) phosphorylation. A consensus site for protein kinase A 
(PKA) phosphorylation was found in the third cytoplasmic loop, in the same position as
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in the ai-adrenoceptor. These potential phosphorylation sites suggested that this clone 
could be regulated by phosphorylation.
At this stage it appeared that the clone which had been isolated was indeed an ai- 
adrenoceptor and to confirm this the function of the clone when expressed in cells was 
examined. It was found to bind the ai-adrenoceptor antagonist [^^^I]-HEAT with high 
affinity and was potently inhibited by prazosin, to a greater extent than either yohimbine 
or isoprenaline. In addition noradrenaline was found to dramatically increase the 
incorporation of into phosphatidylinositol. This was indeed proof that the isolated 
hamster clone was an ai-adrenoceptor and in light of the pharmacological developments 
at the time the binding of WB410I and phentolamine was investigated to determine 
which subtype of ai-adrenoceptor had been identified. (These were the 2 antagonists 
which Morrow and Creese found were able to distinguish between subtypes of ai- 
adrenoceptor). The hamster ai-adrenoceptor was found to bind with low affinity to both 
WB4101 and phentolamine and it was concluded that the clone isolated from the 
hamster smooth muscle cell line was the aib-adrenoceptor.
Using a cDNA probe derived from the hamster aib-adrenoceptor, Voigt et al (1990) 
identified the rat aib-adrenoceptor and demonstrated that its pharmacological profile 
was similar to the hamster aib-adrenoceptor; the two clones shared >98% amino acid 
identity. Northern analysis of rat tissues showed mRNA expression for this clone in a 
variety of tissues which were expected to express the aib subtype, namely the heart, 
liver, spleen and cerebral cortex (Bylund et al, 1994). In 1992 the human aib- 
adrenoceptor was cloned and shown to be virtually identical in its amino acid sequence
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and pharmacology to the hamster and rat aib-adrenoceptor clones (Ramarao et al,
1992). The close correspondence between the pharmacological properties of the 
expressed aib-adrenoceptor cDNA from the rat, hamster or human clones with those 
recognised for the am-adrenoceptor indicates that the protein encoded by this clone 
represents the aiB-adrenoceptor identified by functional and radioligand binding studies 
in native tissues (Moitow and Creese, 1986).
In 1995 the International Union of Pharmacology decided that all native receptors 
would be described by upper case subscripts and all recombinant clones would be 
described by lower case subscripts (Hieble et al, 1995). Therefore the a i y-adrenoceptor 
is the native receptor and the aib-adrenoceptor is the recombinant receptor. This 
nomenclature is used throughout to distinguish between recombinant and native 
subtypes.
1.4.2. Cloning of the ain-adrenoceptor
A further 2 years on from the cloning of the aib-adrenoceptor, a second ai-adrenoceptor 
was isolated and cloned, this time from a bovine brain cDNA library (Schwinn et al, 
1990) using a probe derived from the hamster aib-adrenoceptor. Within the open 
reading frame of the clone a peptide was found from which the first 43 residues were 
67% identical with the hamster ai-adrenoceptor’s putative 7* TMD and the beginning 
of the carboxyl terminus. The open reading frame encodes a polypeptide of 466 amino 
acids with a calculated molecular mass of 51kDa. The bovine clone was found to 
contain a striking similarity to other GPCRs that had been previously cloned, in 
particular the hamster aib-adrenoceptor, sharing an identity of 72% with this receptor.
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When Schwinn et al compared the bovine clone they had isolated with the hamster aib- 
adrenoceptor isolated by Cotecchia et al, they found that the clones had 27% amino acid 
identity at the amino terminus, 1 2 % amino acid identity at the carboxy terminus and 
50% amino acid identity in the third cytoplasmic loop. Although the bovine clone and 
the hamster aib-adrenoceptor shared a relatively high identity it seemed doubtful that 
the clone isolated was the bovine homologue of the hamster aib-adrenoceptor since it 
was found that the hamster, rat and human aib-adrenoceptors were 98% identical 
(Ramarao et al, 1992). Additionally, the gene corresponding to the hamster aib- 
adrenoceptor is found on human chromosome 5 whereas the gene corresponding to the 
bovine clone is found on human chromosome 8  (Hieble et al, 1995).
However, many of the features of the hamster aib-adrenoceptor were shared with this 
bovine clone. For example, there were potential sites for N-linked glycosylation in the 
amino terminus, threonine and serine residues were again found in the second and third 
cytoplasmic loops and a consensus sequence for PKA phosphorylation was found to be 
in an analogous position to the hamster aib-adrenoceptor, suggesting that this clone 
could also be regulated by phosphorylation.
As with the hamster aib-adrenoceptor, the information obtained from the amino acid 
sequence of the bovine clone was consistent with that of an ai-adrenoceptor and when 
the clone was expressed in cells it was found to bind [^ ^^ 1]-HEAT with high affinity, 
similar to the aib-adrenoceptor. Competition assays were carried out to a range of a- 
adrenoceptor antagonists and agonists including WB4104 and phentolamine, the 
antagonists used on the hamster aib-adrenoceptor. However the K, values for the bovine
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a i -adrenoceptor were quite different from the hamster aib-adrenoceptor. The bovine ai- 
adrenoceptor was found to have a 10-fold higher affinity for WB4101 and phentolamine 
as well as for corynanthine, indoramin, oxymetazoline and methoxamine, when 
compared with the hamster aib-adrenoceptor. These affinity values for the bovine ai- 
adrenoceptor were in agreement with those previously described for the native aiA- 
adrenoceptor. The bovine clone was found to be less sensitive to CEC inactivation than 
the aiB-adrenoceptor and more sensitive to CEC inactivation than the aiA-adrenoceptor, 
when compared with previous reports (Han et al, 1987b; Minneman et al, 1988).
In addition to this binding data, Northern blot analysis of various rat and bovine tissues 
was performed to determine in which tissues this ai-adrenoceptor was expressed. 
Surprisingly, no expression could be detected in any of the tissues examined which 
included rat cerebral cortex, hippocampus, liver, heart, lung, kidney, spleen, aorta, 
adipose tissue, skeletal muscle and vas deferens as well as bovine cerebral cortex, liver, 
heart, kidney, lung and adrenal gland.
So despite the bovine ai-adrenoceptor clone displaying the pharmacological 
characteristics of the a i A-adrenoceptor, no measurable expression levels could be 
detected in tissues which had been previously described as containing the a%A- 
adrenoceptor, specifically rat vas deferens and hippocampus (Gross et al, 1988). On this 
basis Schwinn et al concluded that they had isolated a novel ai-adrenoceptor subtype 
which they appropriately named the aic-adrenoceptor.
When the human homologue of the aic-adrenoceptor was identified (Hirasawa et al,
1993) it was found to have 92% identity with the bovine aic-adrenoceptor and a similar 
pharmacological profile i.e. high affinity for oxymetazoline, WB4101, phentolamine
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and additionally 5-methylurapidil and it was extensively inactivated by CEC. In 
humans, the tissue distribution in brain, heart and liver, was contrary to the lack of 
expression seen in rat tissues. In 1994, a rat homologue of the bovine aic-adrenoceptor 
was cloned which displayed a similar pharmacological profile to the native aiA- 
adrenoceptor (Laz et al, 1994). Further studies followed, which demonstrated that the 
affinities of an extensive series of competitive antagonists to the expressed aic- 
adrenoceptor correlated highly with their affinities in native tissues that were known to 
possess the ai A-adrenoceptor (Langer et al, 1994; Testa et al, 1995a; Pimoule et al,
1995). This was considered strong evidence that the recombinant aic-adrenoceptor and 
the native ai A-adrenoceptor were identical.
However a number of anomalies still remained, the first of which was to explain the 
difference in the observed sensitivity of both the recombinant and native receptor to 
CEC. It was proposed that this discrepancy resulted from differences in experimental 
conditions, the character of the membrane in which the receptor is expressed and/or 
species differences in the sensitivity of the receptors to CEC (Hieble et al, 1995).
The final discrepancy was the apparent lack of tissue expression of the aic-adrenoceptor 
clone. In the original description of the bovine recombinant aic-adrenoceptor, its 
apparent lack of expression of mRNA when Northern analysis was used in rat tissues 
and its surprising presence in rabbit liver were among the main reasons that it was 
believed to be distinct from the native ociA-adrenoceptor. However, Northern blot 
analysis using rat ai-adrenoceptor probes (Faure et al, 1994) and RNase protection 
assays using rat probes (Price et al, 1994a; Rokosh et al, 1994) has since demonstrated 
the presence of the aic-adrenoceptor in every rat tissue originally described as 
containing the a i A-adrenoceptor.
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Based on this evidence the International Union of Pharmacology decided that the 
designation aic be discontinued and that the native and recombinant receptors be 
refeiTed to as ociA- and aia-adrenoceptors respectively (Hieble et al, 1995). The rat and 
human aic-adrenoceptor isolated by Laz et al (1994) and Hirasawa et al (1993) 
respectively, were soon renamed a%a-adrenoceptors, in recognition that they were the rat 
and human homologue of the bovine ai a-adrenoceptor. The gene encoding the mouse 
aia-adrenoceptor was not isolated or cloned until 1998 (Xiao et al, 1998) demonstrative 
of the indifference shown to studying the mouse genome until genetic engineering 
became popular.
1.4.3. Cloning of the ai,i-adrenoceptor
The third and final a%-adrenoceptor to be cloned was isolated from the rat brain by 
Perez et al in 1991 and was found to encode a protein of 560 amino acids. Hydropathy 
analysis was consistent with a putative 7 TMD structure indicative of a GPCR and as 
with the previous a%-adrenoceptors the highest concentration of identity was in these 
TMD. The percentages of identity were as follows: hamster aib-adrenoceptor; 71%, 
bovine aic-adrenoceptor; 64%, rat pi-adrenoceptor; 40% and rat Mi acetylcholine 
receptor; 30%.
This rat clone was found to have potential sites for N-linked glycosylation in the amino 
terminus and potential sites for PKC phosphorylation, consistent with the two 
previously cloned ai-adrenoceptors, but unlike them this clone had no consensus site 
for PKA phosphorylation.
2 1
When the clone was expressed in cells prazosin was found to inhibit [^H]-prazosin 
binding with an affinity consistent with an ai-adrenoceptor. When competitive binding 
was performed using subtype-selective ai-antagonists the results were unusual. The 
affinities for WB4101 and 5-methylurapidil were higher than expected at an aiB/b- 
adrenoceptor but lower than expected at an aiA/a-adrenoceptor. The clone also 
demonstrated that it could be extensively inactivated by CEC although not to the same 
extent as the aiB/b-adrenoceptor. Hence the results from the pharmacological analysis of 
the rat ai-adrenoceptor appeared to indicate that it was neither an ai A-adrenoceptor or 
an aiB-adrenoceptor. Northern blot analysis on the other hand revealed tissue 
expression in hippocampus, cerebral cortex and vas deferens which had been shown 
previously to contain the aiA-adrenoceptor (Gross et al, 1988). However, on the basis of 
the binding data, Perez et al concluded that their rat -adrenoceptor was a novel clone 
and as such named it the aid-adrenoceptor.
At the same time as Perez et al identified their rat ai-adrenoceptor clone, another group 
reported the isolation of a cDNA sequence which they claimed encoded the putative rat 
aia-adrenoceptor (Lomasney et al, 1991). The DNA sequence they published was 
identical to that of Perez et al except for 2 amino acids of a difference. So where was 
the discrepancy? The differing conclusion as to the identity of the isolated clone seems 
to have arisen as a consequence of the ligands used for the pharmacological evaluation 
of the clones. Perez et al used ligands which were selective for the aiA-adrenoceptor, 
whilst Lomasney et al used mainly non-selective ligands. Perez et al could therefore 
identify their clone as novel from the use of these ligands because the affinities were too 
low to be the pharmacologically defined a i A-adrenoceptor and too high to be the a%B-
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Figure 1.2:- A simplified diagrammatic representation of the history of the subdivision of 
a  1-adrenoceptors. The status of the a^^^-adrenoceptor is still unclear but may be a 
pharmacological phenotype of the a j ^ -adrenoceptor .
adrenoceptor. It is now accepted that both groups had isolated the same novel clone 
which codes for the native am-adrenoceptor, since been shown to be present in the rat 
aorta (Van der Graaf, 1993, Kenny et al, 1995). In 1995 the International Union of 
Pharmacology assigned the novel clone the nomenclature, aia-adrenoceptor.
The human a%a-adrenoceptor was isolated and cloned by two different groups at 
approximately the same time (Weinberg et al, 1994; Schwinn et al, 1995). Weinberg et 
al found their clone to have 82% sequence identity with the rat clone, whilst Schwinn’s 
clone had approximately 87% sequence homology with the rat aia-adrenoceptor and 
both had virtually identical pharmacological properties.
1.5. S IG N A L T R A N SD U C T IO N  O F  a i-A D R E N O C E P T O R S
ai-Adrenoceptors belong to the superfamily of receptors known as G protein coupled 
receptors (GPCR) which, as their name suggests, are receptors which couple to G 
proteins to mediate their effects. G proteins have a heterotrimeric structure consisting of 
an a  subunit and P and y subunits which are closely associated with each other. So far at 
least 21 a  subunits, 5 p subunits and 9 y subunits have been discovered (Ulloa-Aguirre 
et al, 1999). Many of the functional differences between G proteins are found in the a  
subunit which therefore defines the G protein, and it is probably as a consequence of 
this that there are a far greater number of a  subunits than p or y subunits. G a subunits 
have been grouped into 4 subfamilies according to their sequence and function:-
GOs -  hormonal stimulation of adenylyl cyclases e.g. P-adrenoceptors 
GOi/o -  hormonal inhibition of adenylyl cyclases e.g. az-adrenoceptors
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GoCq -  couples receptors to phospholipase C e.g. ai-adrenoceptors 
G «i2  -  the function of this elusive family of G proteins remains unknown.
Regardless of their function, all G proteins operate via the same basic mechanism. In the 
basal state, G proteins exist as heterotri mers and have guanosine diphosphate (GDP) 
bound to the catalytic site of an intrinsic guanosine trisphosphatase (GTPase) present on 
the a  subunit. Activation of the receptor promotes the exchange of GDP for guanosine 
trisphosphate (GTP) which, when bound to the a  subunit, induces the dissociation of the 
receptor a  subunit and Py complex. The Ga-GTP complex and the Py complex are now 
able to regulate effectors. Hydrolysis of GTP to GDP by the a  subunit’s GTPase results 
in reassociation with the Py complex, which can then reenter the cycle (Offennanns, 
1999; Summers and M^Martin, 1993).
ai-Adrenoceptor subtypes couple to the pertussis toxin-insensitive family of G proteins, 
Gq, which regulate phospholipase C (PLC) activity. The Gq family consists of 4 
members whose a  subunits are expressed by individual genes with different expression 
patterns. GOq and G au are the most widely expressed and can be found coexpressed in 
most cells. G au, the murine G protein G a^  and its human counterpart G a^  are more 
restricted in their expression. G au  can be found in the kidney, lung, spleen and testis 
and G ai5/i6 has only been found in haematopoietic cells (Offeimanns, 1999). Despite 
their specific patterns of expression, which may imply cell type specific functions, no 
phenotypic changes were observed in mice carrying inactivating mutations of the G au  
and G ai5 genes (Offermanns, 1999).
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GOq and G an  can potently mediate the activation of PLC induced by any of the 3 a r  
adrenoceptor subtypes whereas G au  and G au /u  are much less potent (Wu et al, 1992). 
A level of subtype specificity appears to exist among the a r  adrenoceptor subtypes in 
their ability to couple to members of the Gq family. The aiB-adrenoceptor couples 
efficiently with all 4 members i.e. Gaq, G an, G au  and G au/u; the aiA-adrenoceptor 
couples with G a q , G an and G au, whereas the am-adrenoceptor only couples 
efficiently to Gaq and G an  (Wu et al, 1992).
The Gq family of G proteins specifically activate the |3 isofoiTn of PLC (Wu et al, 1992) 
to catalyse the hydrolysis of phosphatidylinositol-4,5-bisphosphate with the subsequent 
foimation of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 acts to 
mediate intracellular calcium ([Ca^’^ Ji) release from intracellular stores such as the 
sarcoplasmic reticulum and DAG activates PKC which phosphor y lates specific target 
proteins (Minneman, 1988), including Ca^ "^  channels that may regulate intracellular Ca^  ^
or activate transcription of genes (Graham et al, 1996).
Although ai-adrenoceptors mediate their actions predominantly through the Gq/PLC 
pathway there is a substantial amount of evidence demonstrating their ability to utilise 
other signal transduction pathways (Zhong and Minneman, 1999a). Burch et al (1986) 
has shown that a%-adrenoceptors can stimulate arachidonic acid release in a rat thyroid 
cell line. Perez et al (1993) also demonstrated arachidonic acid release by activation of 
aib- and aia-adrenoceptors expressed in COS-7 and CHO cells. They showed that in 
COS-7 cells (where expression levels of ai-adrenoceptors are high) arachidonic acid 
was released as a consequence of indirect phospholipase A% (PLA2 ) activation, 
involving a pertussis toxin-sensitive G protein and requiring Ca^ "^  influx through
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dihydropyridine-sensitive channels. However, in CHO cells (where expression 
levels of Œ]-adrenoceptors approach in vivo levels) there appeared to be a different 
pathway stimulating the arachidonic acid release. Perez et al showed that CHO cells do 
not have voltage-sensitive Ca^ "^  channels but instead it appeared that the ai- 
adrenoceptors were coupling directly to PLA2 activation. This was the first time that a 
single ai-adrenoceptor had been shown to activate multiple, distinct signal transduction 
pathways in different cell lines.
In rat-1 fibroblasts the release of arachidonic acid by phenylephrine-stimulated ai- 
adrenoceptors appears to be due to phospholipase D (PLD) activation rather than PLA2 
(Ruan et al, 1998). All 3 a i -adrenoceptor subtypes were shown to increase PLD 
activity, with the aia-adrenoceptor coupling more efficiently than either the aib- 
adrenoceptor or the aw-adrenoceptor. Accumulation of adenosine 3’-5’cyclic 
monophosphate (cAMP) was also seen in all 3 subtypes, a phenomenon which has been 
previously demonstrated in other cell types (Schwinn et al, 1991; Perez et al, 1993), 
where it was reported that the increase in cAMP accumulation was not due to a direct 
receptor-mediated activation of adenylyl cyclase but rather due to PKC activation. 
However, Ruan et al (1998) showed that neither the PKC inhibitor, 
bisindolylmaleimide, nor the PKC activator, phorbol 12-myristate 13-acetate, had any 
effect on the phenylephrine induced increase in cAMP level. Instead they provided 
evidence for a direct receptor activation of adenylyl cyclase, by demonstrating that the 
increase in cAMP accumulation could be potentiated by forskolin, an activator of 
adenylyl cyclase and attenuated by SQ22536, an inhibitor of adenylyl cyclase (Ruan et 
al, 1998). It is possible, given the evidence of the ai-adrenoceptor’s potential for
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promiscuity with second messenger pathways that both PKC activation and adenylyl 
cyclase activation could be responsible for the increase in cAMP accumulation.
ai-Adrenoceptors may also couple directly to Ca^ '*' influx. In 1987, shortly after 
Moitow and Creese confirmed the existence of a i -adrenoceptor subtypes, Han et al 
proposed that a i a-adrenoceptors increased [Ca^‘*']i by influx of extracellular Ca^ "^  
through dihydropyridine-sensitive Ca^ "*" channels. The stimulation of inositol phosphates 
was proposed to be the mechanism through which aie-adrenoceptors mediate the 
release of [Ca^^i (Han et al, 1987a). Although it is now agreed that this is not a subtype 
specific process it demonstrates that in certain tissues (in this case rat hippocampus and 
vas deferens) ot]-adrenoceptors can increase [Ca^^ji by a PLC-independent mechanism.
1.6. STRUCTURE OF ai-ADRENOCEPTORS
1.6.1. General
(%i - Adrenoceptors are single polypeptide chains ranging from 429-561 amino acids in 
length (Cotecchia et al, 1988; Schwinn et al, 1990; Perez et al, 1991; Ramarao et al, 
1992; Hirasawa et al, 1993 and Xiao et al, 1998) that are posttranslationally modified 
by the attachment of oligosaccharides, as well as being phosphorylated (Graham et al,
1996). They have the same basic structure as all GPCRs i.e. an extracellular amino 
terminal, an intracellular carboxy terminal and 7 TMD connected by 3 intracellular and 
3 extracellular loops. The amino termini of the original cloned ai-adrenoceptors were 
all shown to contain consensus sites for modification by N-linked glycosylation as well 
as having several threonines and serines in the second and third intracellular loops 
representing potential sites for PKC phosphorylation. A consensus sequence for PKA
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phosphorylation was found to be present in the hamster aib-adrenoceptor and the bovine 
aia-adrenoceptor but not in the rat aid-adrenoceptor (Cotecchia et al, 1988; Schwinn et 
al, 1990; Perez et al, 1991). The amino termini are found to vary considerably in length, 
with the terminus for the aid-adrenoceptor being much longer (approximately 90 amino 
acids) than the terminus for the aia-adrenoceptor (25 amino acids) or the aib- 
adrenoceptor (42 amino acids) (Graham et al, 1996). It has been suggested that this 
longer amino terminus of the aid-adrenoceptor may limit efficient translation or 
membrane insertion (Graham et al, 1996).
The first and second extracellular loops each contain a single cysteine residue and 
analogous cysteines are highly conserved in all GPCRs. In the ^-adrenoceptor and 
rhodopsin these cysteines are essential for the conect folding of the proteins, for 
maturational glycosylation and for expression in the plasma membrane. This is due to 
the involvement of these cysteines in a disulphide bond (Graham et al, 1996). The aiB- 
adrenoceptor has also been shown to contain a disulphide bond. Parini et al (1987) 
demonstrated that this disulphide bond was inaccessible to solvents because 
dithiothreitol alone was found to have no effect on the activity of the receptor but 
instead dénaturation was required before any evidence for a disulphide bond could be 
detected.
1.6.2. Important amino acid residues
Since the discovery of the gene products of ai-adrenoceptors a number of studies have 
concentrated on determining the amino acids responsible for agonist and antagonist 
binding and receptor activation. An elegant study carried out by Hwa et al (1995)
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identified 2  amino acids as being critical to the different binding affinities observed by 
agonists at aia- and aib-adrenoceptors. A double mutant was created by site-directed 
mutagenesis which replaced Leu^ "^^  and Ala^ '^  ^in the aib-adrenoceptor to the 
corresponding amino acids found in the WT aia-adrenoceptor, methionine and valine 
respectively. Binding analysis was carried out on the mutated aib-adrenoceptor, which 
was found to show a binding profile more consistent with an aia-adrenoceptor. When 
the double mutation was reversed (Val^^  ^to Ala and Met^^  ^to Leu), the binding profile 
was also reversed, back to an aib-adrenoceptor-like pharmacology. Some residual 
differences remained with methoxamine and cirazoline indicating that there may still be 
some minor conformational differences in the agonist ligand binding pocket of the aia- 
adrenoceptor. However this study demonstrated that Leu^ '^  ^and Ala^ "^^  in the aib- 
adrenoceptor and their corresponding residues in the aia-adrenoceptor are the most 
critical determinants of the differences observed in agonist binding between these 2  
subtypes (Hwa et al, 1995).
The two or three serines found in TMD 5 have been shown to be highly conserved in 
GPCRs that bind catecholamines with high affinity. The aia-adrenoceptor has two 
conserved serines (Ser^^  ^and Ser^^^) one of which has been shown to be important for 
receptor activation (Ser^^^) (Hwa et al, 1996). The analogous serine to this in the aib- 
adrenoceptor (Ser^°^) has, in contrast, been shown to be involved in ligand binding. It 
was discovered that when Ser^^  ^was mutated to Ala the binding affinities of adrenaline 
and noradrenaline at the aib-adrenoceptors decreased by 250- and 350-fold respectively 
(Cavalli et al, 1996). The other two conserved cysteine residues of the aib-adrenoceptor 
(Ser^ ®^  and Ser^^^) when expressed as a double mutant (both Ser residues were replaced
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with Ala) completely impaired the ability of the aib-adrenoceptor to be activated by 
adrenaline. Yet, when expressed as single mutants, they had no effect on receptor 
activation, indicating that the integrity of at least one of these serines was required for 
receptor activation. Molecular dynamic analysis revealed that Ser^^  ^and Ser^'^ are 
directed towards TMD 6 and TMD 4 respectively and may exert a structural/functional 
role, thus stabilising the active conformation of the aib-adrenoceptor, confirming the 
experimental findings. Therefore, despite the fact that these serines are highly 
conserved, the role that they cany out in aib-adrenoceptors is quite different from other 
catecholamine receptors, including the closely related aia-adrenoceptor.
In addition to deducing the role of the conserved serines in the aib-adrenoceptor,
Cavalli et al (1996) also showed that the aspartate at position 125 is essential for both 
agonist and antagonist binding. When they mutated this residue to alanine the mutated 
aib-adrenoceptor was incapable of binding [^^^I]-HEAT or producing adrenaline- 
induced stimulation of inositol phosphate.
Site directed mutagenesis is a common technique used to identify critical amino acid 
residues and their functions, sometimes with surprising results. A substitution mutation 
(Ala^^  ^was substituted with Glu) in the C-terminal portion of the third intracellular loop 
of the aib-adrenoceptor resulted in a mutated receptor that was constitutively active. 
When this residue was systematically mutated by substituting all of the 19 amino acids 
in turn, it was discovered that all the mutated receptors were constitutively active to 
varying degrees (Kjelsberg et al, 1992).
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Following on from this work, Cotecchia and colleagues have used this technique in 
combination with comparative molecular dynamic simulations of the WT and mutant 
receptors in an attempt to identify key residues involved in the activation of the aib- 
adrenoceptor. The residues Arg^ "^  ^ and Asp^ "^  ^which can be found in the highly 
conserved DRY motif at the cytosolic end of TMD 3 (Scheer et al, 1999) were two of 
the amino acids they directed their efforts towards. Arg^ "^  ^was found to be directed 
towards TMDl and TMD 2 and to be involved in hydrogen bond interactions with 
Asp^\ an amino acid which is part of the highly conserved TMD ‘polar pocket’. 
Constitutively active mutants carrying substitutions at Ala^^  ^were found to ‘push’
Arg^^  ^out of this ‘polar pocket’, with the extent of the ‘push’ being equivalent to the 
degree of constitutive activity of the mutants. When the aspartate of the DRY motif 
(Asp^ "^ )^ was replaced with the non-polar amino acid alanine, the mutated aib- 
adrenoceptor had a high level of constitutive activity. Subsequent substitution mutations 
at this residue of all natural amino acids demonstrated that as with the Ala^^^Glu 
mutations all mutants showed various levels of constitutive activity. From these results 
it appeared that the hydrophobic/hydrophilic character of Asp^ "^  ^which could be 
regulated by protonation/deprotonation of this residue (depending on the substituted 
amino acid’s overall charge) was an important modulator of the transition between the 
inactive and active state of the aib-adrenoceptor (Scheer et al, 1996; Scheer et al, 1997). 
When Asp^ "^  ^is in its anionic form, the interaction of Arg^ "^  ^with Asp^  ^ is highly 
favoured and this maintains the arginine residue and several other amino acids of the 
second and third intracellular loops in a ‘buried’ condition with respect to the cytosol. 
When the receptor is activated, either by protonation of Asp^"^^or by constitutively 
active mutations, Arg^ "^  ^is shifted out of the ‘polar pocket’. The main role of Arg^ "^  ^
appears to be to mediate receptor activation, allowing several amino acids in the second
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intracellular loop and both N-terminal and C-terminal portions of the third intracellular 
loop to have the right configuration for the formation of a site with docking 
complementarity with the G protein (Scheer et al, 1999). This agrees with experimental 
findings that mutations targeting Arg^ "^  ^ totally inactivate the aib-adrenoceptor (Scheer 
et al, 1996).
A number of other amino acid residues have been suggested to be involved in receptor 
activation. Porter et al (1996) proposed that the residues Asp^^  ^and Lys^^  ^had the 
potential to form a salt bridge, which may help to stabilise the receptor in the 
inactivated state. Therefore, if this salt bridge was disrupted by site directed 
mutagenesis with charged or neutral residues (positively charged residues in the case of 
Asp^^  ^and negatively charged residues in the case of Lys^^^) then this would result in a 
constitutively active receptor. Porter et al (1996) elegantly demonstrated that when the 
ionic bond between Asp^^  ^and Lys^^* was broken by amino acid substitution the mutant 
receptors generated were constitutively active, providing strong evidence for the 
existence of a salt bridge maintaining the receptor in its basal confirmation.
This section discusses only some of the amino acid residues which have been implicated 
in some aspect of receptor activation. These papers all show that a constitutively active 
mutant is relatively easy to produce if you know which amino acids to target. Therefore 
it would seem that maintaining the receptor in an inactive state is a more highly 
regulated process than its activation and further studies look set to concentrate on this 
aspect, rather than the easily attainable activation state.
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1.6.3. Genomic organisation
ai-Adrenoceptors are unusual amongst GPCRs and unique within the family of 
adrenergic receptors because they have been found to have a single large intron of 14- 
20kb (Ramarao et al, 1992; Weinberg et al, 1994; Perez et al, 1991; Graham et al,
1996). All a ]-adrenoceptor subtypes have been shown to contain two exons separated 
by a single large intron, which interrupts the coding region at the end of the putative 
sixth transmembrane domain (Graham et al, 1996). The exon/intron boundary follows 
the consensus splice sequence AG/GT and is situated after the first base of the codon 
indicating a type I splice phase (Ramarao et al, 1992). Exon 1 consists of the coding 
region that ends near the distal part of the putative sixth transmembrane domain and 
exon 2 contains the rest of the coding region as well as the 3 ’ non-coding region 
(Ramarao et al, 1992).
1.6.4. Isoforms of the aia-adrenoceptor
The aia-adrenoceptor is unusual, in that it is the only ai-adrenoceptor subtype for which 
several isoforms have been identified. In the process of cloning the human aia- 
adrenoceptor, Hirasawa et al (1995) identified two additional clones. Upon sequencing 
these clones it was found that they encoded part of the aia-adrenoceptor, whilst the 3’ 
portion of these clones was found to be distinct from the full length aia-adrenoceptor 
clone (designated aia-i). The human aia-i-adrenoceptor was a protein of 466 amino 
acids, whilst the two novel clones (designated aia-2 and aia-3) were proteins of 499 and 
429 amino acids respectively. The three aia-adrenoceptor isoform proteins have the 
same TMD part with isoform-specific C-terminals. Hirasawa et al demonstrated that
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these three aia-adrenoceptor isoforms originated from a single gene and that they were 
generated by alternative RNA splicing. The three isoforms were expressed in all tissues 
examined (heart, liver, cerebellum, cerebrum and pituitary) with the aia-i isoform being 
most abundant. The binding and functional properties of the three isoforms were found 
to be similar, demonstrating that aia-2 and aia -3 produced functional proteins.
Further isoforms of the aia-adrenoceptor have since been identified. Chang et al (1998) 
identified four full length and four truncated isoforms. Three of the full length isoforms 
were identical to those isolated by Hirasawa et al (i.e. aia-i, aia-2 and aia-3). However 
the fourth was a novel isoform which they named aia-4 - This isoform was identical to 
the three original isoforms up to position 1269 but was followed by a novel sequence. 
This is the same position that the previously published isoforms diverge, suggestive that 
this was indeed a novel isoform of the aia-adrenoceptor. The aia-4 -adrenoceptor is a 
protein of 455 amino acids. When expressed in COS-7 cells all four isofonns displayed 
similar affinities for the ligands tested. The truncated isoforms did not display any 
specific binding. However, it is not known if they are expressed in the plasma 
membrane following transient transfection and so it is not known if the generated 
products are non-functional. In functional studies aia-4 exhibited lower affinities for 
prazosin and the aiA/a-antagonist, RS-17053, as did the aia-i isoform, indicative of the 
aiL-adrenoceptor. The classical aiA-adrenoceptor i.e. aia-i, has previously been shown 
to display an aiA-adrenoceptor pharmacology in binding studies but in functional 
experiments it resembled the aiL-adrenoceptor (Ford et al, 1997). Recently, all four 
isoforms have been shown to display low affinities for aiA/a-adrenoceptor antagonists in 
functional studies, displaying aiL-adrenoceptor pharmacology (Daniels et al, 1999). It
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was hoped that with the discovery of isoforms of the aia-adrenoceptor that one of these 
would account for the aiL-adrenoceptor. However, after the demonstration by Daniels et 
al that all four isoforms displayed an a%L-adrenoceptor pharmacology in functional 
studies, it seems that no individual isoform represents the distinct pharmacological 
phenotype of the aiA/a~ or the a i L-adrenoceptor. The factors that determine this 
pharmacological pleiotropism remain unknown.
When Chang et al analysed the tissue expression of their novel isoform they discovered, 
surprisingly, that it was the most abundant isoform in the human prostate. It was from 
the human prostate that Hirasawa et al originally cloned the full length human a^ - 
adrenoceptor (Hirasawa et al, 1993) and subsequently cloned aia -2 and aia -3 (Hirasawa 
et al, 1995). Why was it never discovered before?
To date the aia-i, aia-2 , ocia-3 and aia-4 isoforms aie the only full length, functional 
isoforms which have been characterised although a number of truncated isoforms have 
been isolated in addition to those identified by Chang et al (1998). Coge et al (1999) 
cloned nine isoforms of the a%a-adrenoceptor, three of which were the previously 
identified aia-i, aia -2 and aia-3 . The remaining isoforms were found to have lost 
transmembrane domain 7 and were not able to bind [^H]-prazosin specifically. Coge et 
al failed to isolate aia-4 , identified by Chang et al, which may be a result of using 
human liver to isolate their clones rather than the human prostate. However, Chang et al 
demonstrated that the aia-4 isoform was present in the liver in greater amounts than in 
the prostate.
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1.7. m RN A  E X P R E S S IO N  AND D IST R IB U T IO N  O F  a i-A D R E N O C E P T O R S
ai-Adrenoceptors are important mediators of sympathetic nervous system responses and 
as such are found to be present in the majority of tissues. Mapping the distribution of 
ai-adrenoceptor subtypes has been performed mainly by analysis of mRNA expression 
(e.g. reverse transcriptase polymerase chain reaction (RT-PCR), RNase protection 
assays, Northern blotting) because a lack of sufficiently selective antagonists makes 
qualitative analysis by radioligand binding methods difficult to interpret and until 
recently no subtype selective antibodies were available. However, antibodies specific to 
the ai-adrenoceptor subtypes have since become commercially available and have been 
used to identify the expression and localisation of ai-adrenoceptor protein. Studies 
utilising these antibodies have revealed that even expression of the protein of an ai- 
adrenoceptor subtype does not guarantee that the subtype is functional (Piascik et al, 
1997; Hi'ometz et al, 1999; M^Cune et al, 2000).
Most of the mRNA work has been earned out in rats and humans, but as the mouse 
becomes a more popular choice of experimental animal, thanks to the advances in 
genetic engineering, the focus of this work is shifting and studies investigating the 
mRNA expression and distribution of murine ai-adrenoceptors are beginning to emerge 
(Cavalli et al, 1997).
The data which has been collected, detailing the distribution of ai-adrenoceptors, shows 
the existence of multiple subtypes in the majority of tissues examined, regardless of the 
species studied, with one subtype appearing to dominate (Faure et al, 1994; Price et al, 
1994a and b; Schofield et al, 1995, Cavalli et al, 1997). Generally the mRNA analysis
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carried out is non-quantitative. However Schofield et al (1995), devised a quantitative 
RT-PCR method, which relied on known amounts of a competing cRNA product to 
determine mRNA expression and distribution in 19 rat tissues. Their results were in 
agreement with the non-qualitative analyses which had already been published (Faure et 
al, 1994, Price et al, 1994a; Rokosh et al, 1994) but in addition to being able to tell 
where the specific ai-adrenoceptor subtype mRNA was expressed Schofield et al were 
also able to deteimine how much mRNA was expressed. Most of the tissues examined 
were found to express relatively high levels of the aiA-adrenoceptor mRNA, with the 
most significant expression being in the vas deferens, colon, stomach, cerebral cortex, 
heart, small intestine, testis and prostate. aiB-adrenoceptor mRNA was found to have 
the highest levels of expression in the heart, cerebral cortex and liver with lower levels 
of expression being found in the rest of the tissues examined. The otm-adrenoceptor 
mRNA was expressed at its highest levels in the vas deferens, cerebral cortex, aorta, 
adrenal gland and, as with the other subtypes, lower levels of expression were found in 
the rest of the tissues; the exception being the liver where no aiD-adrenoceptor mRNA 
could be detected (Schofield et al, 1995). This is similar to findings in the mouse where 
the expression of am-adrenoceptor mRNA was also detected in all tissues examined 
except the liver (Cavalli et al, 1997). When the expression levels in rat tissues were 
expressed as a percentage of the total a%-adrenoceptor mRNA, a dominant subtype was 
revealed in all tissues except the cerebral cortex. In the pancreas, prostate, small 
intestine, bladder, stomach, colon, kidney and testis, the dominant subtype was the a%A- 
adrenoceptor. In the liver, heart and ureter it was the am-adrenoceptor which 
dominated, whereas in the aorta, adienal gland, trachea, spleen and vas deferens it was 
the aiD-adrenoceptor (Schofield et al, 1995). A previous study has shown that in
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addition to the rat aorta expressing am-adrenoceptor mRNA it also expresses am- 
adrenoceptor mRNA (Ping and Faber, 1993).
In human tissues, the distribution of ai-adrenoceptor mRNA was found to be on the 
whole, similar, although expression of ai-subtypes did differ in some tissues. The aiA- 
adrenoceptor mRNA was found to be dominant in the heart, liver, cerebellum and 
cerebral cortex, (although quantification was in relative, not absolute terms) whilst a is- 
adrenoceptor mRNA was predominant in spleen and kidney and in the aorta and adrenal 
gland it was the am-adrenoceptor mRNA which was found to be most abundant (Price 
et al, 1994b). When competitive RT-PCR was carried out, to allow for quantification of 
the levels of mRNA expression, the results were similar to those obtained by Price et al 
(1994b) who had used a qualitative method. The heart and liver expressed 
predominantly aia-adrenoceptor mRNA, spleen and liver were found to express am- 
adrenoceptor mRNA and the aorta was predominantly am-adrenoceptor mRNA (Faure 
et al, 1995).
The relationship between mRNA and protein expression does not seem to be an obvious 
one. The presence of mRNA in a tissue does not guarantee that the protein will be 
expressed. A prime example of this is the aio-adrenoceptor. Despite the presence of the 
mRNA for this subtype in a number of tissues (detailed above) the protein has still to be 
detected by radioligand binding in rat and mouse tissues (Yang et al, 1997; Yang et al, 
1998; this thesis). However, there is evidence from functional studies that the ocio- 
adrenoceptor is responsible for vascular contraction in the rat aorta, carotid, femoral and 
iliac arteries as well as the mouse aorta and carotid artery (Kenny et al, 1995; Nagadeh,
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1996, University of Glasgow, PhD thesis; Piascik et al, 1997; Hrometz et al, 1999; Daly 
et al, unpublished observations; this thesis).
In combination with functional and radioligand binding experiments it appears that as 
well as possessing the mRNA for multiple subtypes, many tissues also express multiple 
(%]-adrenoceptor subtypes at the protein level. The liver appears to be one of the few 
tissues with a homogenous population of ai-adrenoceptors, although the subtype 
expressed between species can differ. The rat, mouse and hamster appear to express the 
aiB-adrenoceptor (Garcia-Sainz et al, 1994; this thesis), whereas the guinea-pig, rabbit, 
dog and human liver express the aiA-adrenoceptor (Garcia-Sainz et al, 1992, Garcia- 
Sainz et al, 1995a and b).
The functional significance for this heterogeneity among species and even within tissues 
is unknown. It is also unclear whether tissue heterogeneity is a result of multiple cell 
types expressing a single subtype or if it is due to coexpression of subtypes by cells 
(Zhong and Minneman, 1999a). Clearly mRNA analysis on its own is insufficient to 
determine which ai-adrenoceptors are important within a specified tissue. However, 
when combined with functional and radioligand binding experiments it can provide 
further insight into the expression, distribution and functionality of ai-adrenoceptors.
1.8. V A SC U LA R  ai-A D R E N O C E P T O R S
ai-Adrenoceptors are found throughout the arterial and venous circulation where they 
have an important function in the regulation and maintenance of vascular resistance and 
blood flow. In most mammalian species contraction of vascular smooth muscle is
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predominantly mediated via ai-adrenoceptors. Through the desire to characterise and 
subtype these vascular oci-adrenoceptors our knowledge of which subtypes are present 
in a particular blood vessel and contributing to vascular contraction has deepened, 
although not without a certain amount of debate and discussion among groups. The 
presence of a subtype as identified by radioligand binding or mRNA analysis does not 
guarantee that it contributes to contraction. Therefore a functional analysis should 
always be earned out, preferably in conjunction with at least one of the aforementioned 
techniques. The process of subtyping ai-adrenoceptors involved in vasoconstriction 
generally uses Schild analysis to produce a pAz value, representative of the affinity of 
an antagonist at the ai-adrenoceptor in the vessel of interest.
The ai-adrenoceptors in various vascular beds of the rat are well characterised, within 
the limitations of available antagonists. The ai-adrenoceptor subtype(s) involved in 
vasoconstriction of all the major arteries have been identified. A lot of work has also 
been carried out on rabbit and dog blood vessels, with less being known about human 
vessels. Blood vessels from mice have largely been ignored because the mouse is such a 
small animal that most of the arteries have been considered too small to be studied. 
However this trend appears to be changing. As the mouse becomes popular through 
genetic engineering, there is a need for knowledge of its physiology and pharmacology, 
in order to identify the significance of changes brought about by manipulation of its 
genome.
What follows is a brief overview, detailing the subtypes of ai-adrenoceptor proposed to 
be involved in vasoconstriction of some of the more frequently studied arteries.
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1.8.1. Aorta
A lot of confusion and ambiguity suiTOunded the identity of the subtype(s) involved in 
vasoconstriction of the rat aorta, up until about 5 years ago. When ai-adrenoceptor 
subtyping was in its infancy and the choice of subtype selective antagonists was few, 
the rat aorta was characterised as containing the g - adrenoceptor, based on findings 
that CEC almost completely abolished the contractile response to noradrenaline, whilst 
nifedipine had no effect (Han et al, 1990). This was at a time when it was believed that 
€CiA-adrenoceptors were dependent on Ca^^ influx through dihydropyridine sensitive 
Ca^^ channels, therefore it was believed that nifedipine would block aiA-rnediated 
responses. Based on this train of thought it appeared that the aiB-adrenoceptor mediated 
contraction in the rat aorta. However, Muramatsu et a/ (1991a) found the rat aorta to be 
sensitive to the effects of nifedipine and to produce high affinities for WB4101 and 
benoxathian and concluded that the oti-adrenoceptor in the rat aorta was atypical.
Heterogeneity of the oci-adrenoceptors in rat aorta was proposed by Van der Graaf et al 
(1993; 1994; 1996a) when they found that several of the antagonists they had used 
caused steepening of the noradrenaline concentration response curve and could be 
accounted for more accurately with a 2-site receptor model.
The baiTage of conflicting results and conclusions continued when Aboud et al (1993) 
proposed that the rat aorta’s -adrenoceptor population was non-aiA, non-aiB. They 
found WB4101, benoxathian and 5-methylurapidil to bind with high affinity, suggestive 
of an aiA-adrenoceptor. However they found the contractile response to be sensitive to 
CEC. These results were similar to Muramatsu’s (1991a). Aboud et al did tentatively
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suggest that the ai-adrenoceptor was the aiD-adrenoceptor, which had been cloned and 
found to be present in rat aorta by Perez et al (1991).
In 1995, Kenny et al, brought some clarity to the situation by using the recently 
identified aio/d-adrenoceptor antagonist, BMY7378, in their analysis of the rat aorta. In 
their hands BMY7378 had a pKn of 8.3, which in combination with their other 
antagonist data suggested the identity of this mysterious ai-adrenoceptor to be the much 
sought after native otio-adrenoceptor. This has been confirmed by a number of other 
studies (Piascik et al, 1995; Testa et al, 1995b; Deng et al, 1996; Hussain and Marshall, 
1997; Piascik et al, 1997; Guimaraes and Moura, 2001).
Recently the -adrenoceptor population of the rat aorta has been proposed to be 
constitutively active (Gisbert et al, 2000). It was discovered that after depletion of 
intracellular Ca^^ stores and subsequent refilling of these stores by the addition of Ca^ "^ , 
there was an increase in the resting tone of the aorta that wasn’t apparent in the tail 
artery when it was subjected to the same conditions. When these conditions were 
reproduced to investigate the accumulation of inositol phosphates, the basal level of 
inositol phosphate accumulation was significantly increased in the aorta, but not the tail 
artery. Both the increase in resting tone and the increased inositol phosphate 
accumulation could be inhibited by the ai-antagonists, prazosin, BMY7378 and 5- 
methylurapidil. The subtype-selective antagonists produced plCgo’s which conelated 
with binding affinities at am-adrenoceptors, suggesting that it was the am-adrenoceptor 
population of the rat aorta that was constitutively active. This is the first time that 
constitutive activity has been suggested for a functioning native receptor.
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Functional analysis of the rabbit aorta reveals a role for a mixed population of ai- 
adrenoceptors. Satoh and colleagues suggest the presence of aiA- and aiB- 
adrenoceptors, as revealed by sensitivity to CEC inactivation and a biphasic response to 
WB4101. They proposed that the high affinity site observed with WB4101 was the aiA- 
adrenoceptor and the low affinity site was the aiB-adrenoceptor (Takayanagi et al, 
1991). This is consolidated by results obtained with BMY7378, which was found to 
have a low affinity in the rabbit aorta (pA2 = 6.6) ruling out the possibility of a 
contribution to contraction from the am-adrenoceptor (Satoh et al, 1999a; 1999b). 
Muramatsu and colleagues have also studied the rabbit aorta reaching a slightly 
different conclusion. They identified the presence of the aiL-adrenoceptor in the rabbit 
aorta (Muramatsu et al, 1990; Oshita et al, 1993). This was one of the tissues used by 
Muramtasu when he expanded the am-, aiL-subclassification of ai-adrenoceptors to 
include the am-adrenoceptor. The rabbit aorta was shown to have low affinity for 
prazosin (Muramatsu et al 1990). A further study, by the same group, concentrating on 
the rabbit aorta revealed two distinct sites when radioligand binding with [^H]-prazosin 
was perfoiTned on aortic membranes. When this was repeated after pre-treatment with 
CEC the data fitted better to a one-site model. In functional studies investigating the 
contractile response to noradrenaline, prazosin was again found to exhibit two distinct 
affinity values. The affinities of WB4101 and HV723 were approximately equal to the 
low affinity site for prazosin, providing no evidence for the aiA- or aiN-adrenoceptor 
(Oshita et al, 1993). From this data they concluded that the rabbit aorta contains the 
aiB“ and aiL-subtypes of ai-adrenoceptor.
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1.8.2. Carotid artery
Despite the carotid artery being a major conduit vessel carrying blood to the brain, it has 
largely been overlooked when it comes to ai-adrenoceptor subtyping. Instead, it is more 
commonly used as a model to study the effects of vascular remodelling. The 
pharmacology of the carotid artery is the basis for Chapter 3 of this thesis. Therefore our 
present knowledge of its pharmacology, with particular reference to ai-adrenoceptors 
will be discussed in detail later.
1.8.3. Mesenteric artery
Mesenteric arteries are a widely used in vitro preparation because they provide an easily 
isolated supply of resistance arteries in which to study the maintenance and regulation 
of blood pressure. With regard to the subtyping of ai-adrenoceptors, the mesenteric 
arteries are no different from other arteries in that there are always conflicting results as 
to the identity of the particular subtype, based on the drugs used and the experimenter’s 
interpretation of the results.
The ai-adrenoceptor subtype seems to differ between the superior and resistance 
mesenteric arteries. Kong et al (1994) found the superior to contain mainly a ie-  
adrenoceptors based on a relative insensitivity to 5-methylurapidil and a potent 
inhibition by CEC, whilst in the perfused mesenteric vasculature, consisting o f mainly 
resistance arteries, the opposing effects were found to be true. The resistance arteries 
were found to be highly sensitive to aiA-antagonism by 5-methylurapidil and were 
much less sensitive to CEC, resulting in the conclusion that the resistance arteries 
consisted of mostly a] A-adrenoceptors.
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Piascik and colleagues (1997) also identified different subtypes in the superior and 
resistance mesenteric arteries of the rat in an elegant study using an antibody specific 
for the aiB-adrenoceptor, in combination with receptor protection studies. The 
adrenoceptor antibody stained the medial layer of all the vessels examined, which 
included both the superior and resistance arteries of the mesentery, demonstrating 
expression of the aiB-adrenoceptor protein. In functional studies, Piascik et al used 
BMY7378 and A-61603 to protect am - and aiA-adrenoceptors respectively, from 
alkylation by either phenoxybenzamine or CEC. BMY7378 was found to protect the 
superior mesenteric artery from irreversible alkylation by phenoxybenzamine and CEC 
suggesting that contraction in this artery is due to activation of am-adrenoceptors. On 
the other hand, the resistance arteries of the mesentery were not protected by either 
BMY7378 or A-61603 suggesting that it is the a%B-adrenoceptor through which this 
artery mediates contraction. Therefore, as with mRNA expression it seems that protein 
expression of a subtype does not guarantee a functional role. Hussain and Marshall 
(2000) have recently characterised the rat mesenteric artery as mediating contraction 
through the am- and am-adrenoceptors when they found that all subtype selective 
antagonists used produced shallow Schild slopes. 5-methylurapidil was found to have a 
low pKb and BMY7378 a high pKb in this artery.
To add to the confusion, a role for the aiL-adrenoceptor in the resistance vessels of the 
rat mesentery has also been proposed, when Van der Graaf et al (1996b) found prazosin 
to have a low affinity in this tissue. The same group in a later paper found that the rat 
mesenteric artery was insensitive to CEC and produced low pA2 values with BMY7378 
and RS17053 arguing against the involvement of am, am  or a i A-adrenoceptors
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respectively (Starn et al, 1999). These results led to the conclusion that the am- 
adrenoceptor is the predominant a%-adrenoceptor subtype in the rat mesenteric artery.
The apparent confusion over which subtypes are present in the rat mesenteric artery 
may be a result of vessels from different areas in the mesentery being used because not 
all groups stated from which part of the mesentery they had isolated their vessels.
The aiL-adrenoceptor has also been proposed to be responsible for vasoconstriction in 
the rabbit mesenteric artery by two separate groups. Muramatsu et al (1990) found it to 
have low affinity for prazosin and yohimbine, satisfying two of the criteria for an am- 
adrenoceptor (Flavahan and Vanhoutte, 1986) and Van der Graaf et al (1997) found the 
rabbit mesentery to have low affinity for prazosin and a number of selective aiA- 
antagonists, such as 5-methylurapidil, WB4101 and RS-17053. Involvement of the am- 
adrenoceptor was ruled out by a low affinity for BMY7378.
Muramatsu and colleagues have characterised the canine mesenteric artery as belonging 
to the aiN-subtype of ai-adrenoceptors. HV723 has been proposed to be an aiw- 
selective antagonist and it potently inhibits the contractions of the dog mesenteric 
artery. In addition to this it has low affinity for prazosin, WB4101 and 5-methylurapidil 
(Muramatsu et al, 1990; Kohno et al, 1994).
More recently, Daniel et al (1999) found evidence for the involvement of the aiA- 
adrenoceptor in mediating contraction in the dog mesenteric artery. They showed that a 
number of selective aiA-antagonists potently inhibited contraction in the canine 
mesentery when the concentrations of antagonist used were low. But as the 
concentration increased the pKs decreased, to values expected of an aiL-adrenoceptor.
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They concluded that the canine mesenteric artery contains ai A-adrenoceptors with the 
possible presence of an aiL-adrenoceptor.
1.8.4. Miscellaneous
In addition to the blood vessels of the mesentery (discussed above), Piascik et al (1997) 
also studied the caudal, femoral, iliac and renal arteries in an attempt to correlate the 
expression of ai-adrenoceptors on vascular smooth muscle with the regulation of 
contraction in these blood vessels. Using the same techniques as described previously 
for the mesenteric arteries, the aiB-adrenoceptor antibody was found to stain the medial 
layer of all the arteries mentioned above. In the receptor protection studies, BMY7378 
(at a concentration which would occupy more than 90% of the am-adrenoceptor 
population, whilst occupying less than 6% of either the a%A- or aiB-adrenoceptors), 
protected the femoral and iliac arteries but had no protective effect on the caudal or 
renal arteries. In contrast, when A-61603 was used, it showed protective activity in the 
caudal and renal arteries whilst no effect was seen in the femoral and iliac arteries. From 
this, Piascik et al concluded that despite the evidence of expression of the otiB- 
adrenoceptor protein in these vessels it played no part in the regulation of contraction. 
Rather, it was the aio-adrenoceptor that produced a contraction in the femoral and iliac 
arteries and the otiA-adrenoceptor in the caudal and renal arteries. The involvement of 
these subtypes in the contraction of the femoral and renal arteries has since been 
confirmed (Hrometz et al, 1999).
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1.9. a i -A D R E N O C E PT O R S AS M IT O G E N S
Traditionally, mitogenic responses were believed to be mediated primarily by peptide 
growth factors such as epidermal growth factor and nerve growth factor. Mitogenic 
responses are caused by a conserved cascade of events including receptor 
phosphorylation, binding of adaptor proteins (e.g. She and Grb2) and the subsequent 
recruitment and activation of the small molecular weight G protein, Ras (Zhong and 
Minneman, 1999a). Ras activates Raf which then activates downstream mitogen 
activated protein kinase (MARK) cascades (Zhong and Minneman, 1999a). It is now 
apparent that GPCRs are capable of rapidly activating MAPK pathways and that this 
activation plays an important role in the regulation of cell proliferation and growth. 
Despite intensive study the mechanisms underlying these effects remains unknown.
ai-Adrenoceptors are able to activate mitogenic responses in a variety of cell types and 
would appear, increasingly, to play an important role in regulating cell growth and 
proliferation, ai-Adrenoceptor agonists stimulate hypertrophy in cultured neonatal rat 
ventricular myocytes (La Morte et al, 1994) and overexpression of a constitutively 
active mutant of the ais-adrenoceptor in cardiac myocytes induces myocardial 
hypertrophy in transgenic animals (Milano et al, 1994). More recently a transgenic 
mouse, which overexpresses the aiB-adrenoceptor in all tissues which naturally express 
the aiB-adrenoceptor has been shown to display early signs of cardiac hypertrophy 
(Zuscik et al, 2001). A role for ai-adrenoceptors in the regulation of vascular smooth 
muscle growth was revealed in rat aortic smooth muscle cells where a CEC-sensitive 
ai-adrenoceptor was shown to mediate proliferation-independent hypertrophy whilst 
non-CEC-sensitive a%-adrenoceptors opposed this effect. These actions were attributed
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to the aiB- and a i a-adrenoceptors respectively, based on the a i B-adrenoceptor’s 
sensitivity to CEC and the a iA-adrenoceptor’s high affinity for 5-methylurapidii (Chen 
et al, 1995).
ai-Adrenoceptors activate MAPK pathways with coupling efficiencies similar to those 
observed for second messenger responses, in that the aia-adrenoceptor couples most 
efficiently followed by the aib-adrenoceptor, with the aid-adrenoceptor coupling least 
effectively of the three (Zhong and Minneman, 1999b). Activation of the aia- 
adrenoceptor has recently been found to cause a much wider array of transcriptional 
responses than growth factor receptor activation (Minneman et al, 2000), which is 
suiprising given the traditional view that mitogenic signalling is mediated by growth 
factor receptors.
1.10. D E SE N SIT ISA T IO N  AND IN T E R N A L ISA T IO N
Many receptor-coupled cellular responses become desensitised as the result of agonist- 
induced changes in the chemical and physical properties of their signal transduction 
pathways (Cowlen and Toews, 1988). Desensitisation is a loss of functional response 
from the receptor and is an adaptive mechanism thought to facilitate responsiveness of 
the cell to successive multiple extracellular stimuli over time (Chuang et al, 1996). The 
loss of functional response can be short term (seconds or minutes) or long term (hours).
For GPCRs desensitisation is a multistep phenomenon. The first step is the uncoupling 
of the phosphorylated receptor from the G protein resulting in desensitisation of 
receptor function. The receptor is then sequestered into an intracellular compartment
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which is believed to be a mechanism that allows dephosphorylation (by specific 
phosphatases) and resensitisation of the receptor. If the stimulation is chronically 
persistent then the receptor is downregulated. The decrease in receptor number is a 
result of the internalised receptors being degraded, rather than being recycled to the 
plasma membrane and reduction of the steady-state mRNA which is mostly due to a 
decrease in the stability of the mRNA (Chuang et al, 1996).
There are 2 different classes of desensitisation, homologous and heterologous. 
Homologous desensitisation is an agonist-specific process. The decreased 
responsiveness is observed exclusively in the agent (in this case the agonist) that 
originally stimulated the response e.g. neurotransmitter and hormone receptors (Garcia- 
Sainz et al, 2000). With heterologous desensitisation the decreased responsiveness is 
observed in an agent or agents unrelated to the initial stimulus e.g. second messengers 
(Garcia-Sainz et al, 2000). This classification scheme is purely an operational one so it 
is feasible that both processes occur simultaneously in cells.
Homologous desensitisation involves receptor phosphorylation by G protein receptor 
coupled kinases (GRKs). GRKs are a family of at least 6 serine/threonine protein 
kinases that phosphorylate GPCRs only in the agonist-bound state (Garcia-Sainz et al, 
2000). This strict agonist-binding requirement for GRK-mediated phosphorylation 
makes this mechanism strictly homologous. The GRK family includes GRK 1 
(rhodopsin kinase), GRK 2 ((3-adrenergic receptor kinase-1), GRK 3 (g-adrenergic 
receptor kinase-2), GRK 4, GRK 5 and GRK 6 (Grady et al, 1997). When a receptor is 
occupied by an agonist the activated G protein releases the GPy complex. This 
membrane bound Gpy heterodimer and phosphatidylinositol bisphosphate bind to the
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carboxy terminal domain of the GRK which targets the kinase to the receptor (Garcia- 
Sainz et al, 2000). These enzymes then phosphorylate the receptors which markedly 
increases the affinity of the receptor for arrestin, the functional cofactor of the GRKs. 
Without binding of anestin minimal desensitisation occurs but once aiTestin has bound 
desensitisation reaches a maximum (Chuang et al, 1996).
The majority of what we know about desensitisation and internalisation of ai- 
adrenoceptors has come about through studying the am/b-adrenoceptor, purely because 
it was the first ai-adrenoceptor to be cloned for which it was agreed, early on, that the 
native and cloned receptors were identical.
Noradrenaline has been shown to markedly increase receptor phosphorylation of the 
hamster aib-adrenoceptor (Lattion et al, 1994). This can be inhibited by truncation of 
the carboxy terminal of the receptor, implying that this part of the receptor plays an 
important part in receptor phosphorylation and ultimately desensitisation. Further 
studies by Cotecchia and colleagues implicated GRK 2 and 3 as playing a role in 
agonist-induced phosphorylation of the ocib-adrenoceptor. When GRK 2 and 3 were 
overexpressed with the aib-adrenoceptor there was a decrease in the sensitivity of the 
receptor for the agonist and a decrease in its ability to reach the maximum response 
(classical signs of desensitisation) as well as an increase in agonist-induced 
phosphorylation of the receptor (Diviani et al, 1996). In the same study GRK 5 and 
GRK 6 were shown to be capable of increasing the phosphorylation of the aib- 
adrenoceptor, although only GRK 6 was able to increase agonist-induced 
phosphorylation, whilst GRK 5 could increase only basal phosphorylation levels. Using 
site-directed mutagenesis, the phosphorylation sites involved in GRK-mediated
51
desensitisation have been identified as being 3 serine residues (Ser"^ "^^ , Ser"^ ^^  and Ser'^ ^^ ) 
which are located in the carboxy terminal (Diviani et al, 1997).
The consequence of desensitisation of the receptor is its internalisation into the cell. 
Agonist-promoted internalisation of the aib-adrenoceptor is sensitive to cytochalasin D 
(an actin depolymerisation agent) but insensitive to hypertonic treatment (may inhibit 
clathrin-mediated endocytosis) suggesting that the aib-adrenoceptor is endocytosed via 
a non-coated pathway (Hirasawa et al, 1998). Contradicting this are results from 
Fonseca et al (1995) who have proposed that a%b-adrenoceptors are internalised in 
coated vesicles upon discovering that transferrin (a classic endosomal marker which is 
internalised in clathrin coated vesicles) colocalised with the aib-adrenoceptor after 1 
hour of noradrenaline exposure. They also found that internalisation could be blocked 
by hypertonic treatment. These differences could indicate that the mechanism of 
internalisation is dependent on cell type; Hirasawa used CHO cells whereas Fonseca 
used HEK293 cells.
Many GPCRs are desensitised via feedback regulation by second messenger-stimulated 
kinases, such as PKA and PKC. This type of desensitisation can be classed as 
heterologous, since in theory, any stimulant that can increase cAMP or DAG has the 
potential to induce the phosphorylation and desensitisation of any GPCR containing the 
consensus phosphorylation sites for PKA or PKC (Garcia-Sainz et al, 2000). 
Phosphorylation by PKA and PKC can lead to a significant (40-50%) loss of receptor 
function (Chuang et al, 1996).
52
Originally, it was in rat hepatocytes that activation of PKC with phorbol esters was 
shown to block the action of the aib-adrenoceptor (Corvera and Garcia-Sainz, 1984). 
Then Bouvier et al (1987) observed that PKC induced receptor phosphorylation and that 
this phosphorylation was further increased by noradrenaline in vitro. Recently mouse 
fibroblasts expressing the human aib-adrenoceptor have been shown to be 
phosphorylated in response to activation of PKC by phorbol esters (Garcia-Sainz et al, 
2000). The phosphorylation was shown to be associated with blockade of a i b -  
adrenoceptor mediated increases in cytosolic Ca^ "^  and phosphoinositide hydrolysis.
The action of phorbol esters on aib-adrenoceptors seems to involve several processes. 
Blockade of receptor function is very rapid, which is consistent with receptor 
phosphorylation and uncoupling from G proteins (Garcia-Sainz et al, 2000). Receptor 
internalisation in cells endogenously expressing aiB-adrenoceptors has also been 
observed with activation of PKC e.g. hepatocytes (Beeler and Cooper, 1995) and also in 
transfected cells e.g. HEK293 cells (Fonseca et al, 1995).
a ib-Adrenoceptor phosphorylation has also been observed via receptors coupled to Gq, 
Gi and receptors with endogenous tyrosine kinase activity, for a detailed review see 
Garcia-Sainz et al (2000).
1.11. T R A N SG E N IC  T E C H N IQ U E S AND T H E IR  A P P L IC A T IO N  T O  a i-  
A D R E N O C E PT O R S
Over the past decade genetically altered animals have become routine in many areas of 
biomedical research. The animal of choice for such procedures has, on the whole, been
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the mouse, although larger animals have been used with some success. The ability to 
manipulate gene expression in vivo has led to a greater understanding of the 
physiological functions conveyed by genes and in some eases revealed the presence of 
redundant or compensatory signalling systems. A number of transgenic techniques have 
been developed, which include:-
Pronuclear microinjection of DNA;- The DNA of interest is injected into fertilised 
mouse eggs. Integration of the DNA vector into the genome is random. Injected eggs 
are then implanted into pseudopregnant females and following birth and weaning the 
pups are screened to see which have acquired the tr ans gene.
Inducible gene expression system:- This requires 2 separately encoded transgenes, one 
which codes for the protein of interest which is under the control of an inducible 
promoter and the other encodes for a transactivator that is able to modulate expression 
of the receptor in an inducer-specific fashion. This approach provides the experimenter 
with the ability to switch the transgene on and off, as and when required. This avoids 
potential problems associated with transgene expression at unwanted times during 
development. E.g. The tetracycline-inducible Tet transactivator, where the presence or 
absence of tetracycline switches the transgene off or on.
Gene targeting:-
1. ‘Knockout’ strategy:- An endogenous genetic locus can be specifically altered by 
disruption of the normal expression pattern or by replacing the endogenous gene 
with a modified version. A common approach is to inactivate the gene of interest by 
insertion of a reporter or drug resistance gene into the desired locus, via homologous
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recombination in embryonic stem cells. The targeted embryonic stem cells are 
microinjected into blastocysts and allowed to invade and populate the host embryo, 
which is then implanted into a pseudopregnant female. Chimeric pups are identified 
by mixed coat colour since the host embryos and targeted embryonic stem cells are 
derived from mouse strains differing in coat colour.
2. ‘Hit and Run’ strategy:- This procedure attempts to alter genes in a more subtle 
fashion than the ‘knockout’ strategy, which theoretically results in complete loss of 
gene function. The targeting vector containing a mutated sequence is firstly inserted 
to generate a duplication of a portion of the gene. Then, the normal sequence is 
excised. This technique allows for very subtle mutations to be engineered into the 
targeting vector and hence into the genome.
3. ‘Knock-in’ strategy:- This technique replaces one coding sequence with that of 
another, while maintaining the genomic sequence context of the original gene.
All definitions are from Rohrer and Kobilka, 1998 and Wei, 1997.
The application of transgenic techniques to - adrenoceptors has concentrated on the 
aib-adrenoceptor. Cardiac-specific overexpression of a constitutively active mutant of 
the aib-adrenoceptor was initially earned out in mice to study the well-known 
phenomenon of ai-adrenoceptor mediated cardiac hypertrophy (Milano et al, 1994). 
This mutant had been previously shown to possess increased agonist affinity and 
receptor/Gq coupling in the absence of any agonist, when expressed in cells (Cotecchia 
et al, 1990). In this instance it was used to explore the role of ai-adrenoceptor signalling
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and hypertrophic responses in the absence of any underlying hypertension or increased 
afterload (Rohrer and Kobilka, 1998). These animals were found to have elevated DAG 
levels (indicative of PTC activation), increased myocyte cross-sectional area, increased 
heart weight/body weight ratio and an increase in atrial natriuretic factor (ANF) mRNA 
(a well known marker for cardiac hypertrophy) (Milano et al, 1994).
The same group produced transgenic mice with cardiac-specific overexpression of the 
WT aib-adrenoceptor (Akhter et al, 1997). Total cardiac ai-adrenoceptor was 
approximately 40-fold higher than in WT animals, DAG content and ANF mRNA were 
also increased. In fact the increase in ANF mRNA was double that which was seen with 
the constitutively active aib-adrenoceptor mouse. Despite the high levels of ANF 
mRNA the animals showed no signs of cardiac hypertrophy (Akhter et al, 1997). Both 
mouse models show signs of increased signalling but the reasons behind why only one 
of them displays signs of cardiac hypertrophy remains to be explained.
As well as creating mice which overexpress the aiB-adrenoceptor, gene targeting has 
been used to create a mouse with disrupted expression of the aiB-adrenoceptor, which 
results in inactivation of the aiB-adrenoceptor gene (Cavalli et al, 1997). The pressor 
response to phenylephrine has been shown to be decreased in this mouse, although the 
basal blood pressure is unaltered. Isolated aortic rings were shown to have a decreased 
responsiveness to ai-adrenoceptor agonists, although results from our own group find 
the opposite to be true. In isolated aortic and carotid rings the sensitivity to 
phenylephrine in these aiB-adrenoceptor knockout mice is increased. The ai- 
adrenoceptor phannacology of this mouse model is the basis of this thesis and so will
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not be discussed in any more detail here. From this point, KO will be used to refer to the 
aiB-adrenoceptor knockout mouse and WT to the non-knockout mouse.
Towards the end of my project two strains of mice were developed, one which 
overexpressed the (XiB-adrenoceptor and the other which expressed a constitutively 
active aiB-adrenoceptor (Zuscik et al, 2001). The expression of these mutated aiB- 
adrenoceptors was under the control of the mouse promoter, which meant that these 
receptors would only be expressed in cells that naturally expressed the aiB- 
adrenoceptor. The in vitro responses of mesenteric and carotid arteries of these mice to 
phenylephrine are studied in Chapter 3 of this thesis. This was due to initial findings 
that these mice were hypotensive (Zuscik et al, 2001) and the group who originally 
designed the mice wanted to know if this was due to the mutated aiB-adrenoceptors.
57
CHAPTER 2 -  CHARACTERISATION OF THE aj- 
ADRENOCEPTOR SUBTYPES IN BRAIN AND 
LIVER TISSUES FROM WT AND KO MICE
2.1. INTRODUCTION
2.1.1. a i-Adrenoceptors in the brain
ai-Adrenoceptors are present throughout the brain with their distributions varying 
among species. In the rat brain the highest density of ai-adrenoceptors is found in the 
olfactory bulb, particularly in the neocortex and thalamus, with a similar distribution 
being found in the mouse and guinea-pig (Palacios et al, 1987). In the rhesus monkey 
and human the distribution is somewhat different, with the highest densities being 
present in the hippocampus, which in the rat, mouse and guinea-pig had the lowest 
distribution of ai-adrenoceptors (Palacios et al, 1987).
With respect to ai-adrenoceptor subtypes, the brain is typical of most organs in that it 
contains a mixed population of ai-adrenoceptors. It was in rat brain that the presence of 
ai-adrenoceptor subtypes was first discovered when WB4101 was found to bind with 
high and low affinities (Morrow and Creese, 1986). These high and low affinity sites 
were designated aiA- and aiB-adrenoceptors respectively. The heterogeneity of ai- 
adrenoceptors in the rat brain has been confirmed in further studies; most groups concur 
with Moitow and Creese that the rat brain contains a mixed population of aiA- and aiB- 
adrenoceptors (Han et al, 1987b; Minneman et al, 1988; Terman et al, 1990; Yang et al,
1997). However, Oshita et al {1991) detected the presence of three ai-adrenoceptor 
subtypes in the rat cerebral cortex. Saturation binding with [^H]-prazosin revealed two 
sites and inhibition binding with phentolamine and WB4101 showed that the high 
affinity site detected in saturation studies was inhibited biphasically by phentolamine 
and WB4101, as well as there being high and low affinity sites for prazosin. They
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concluded that there were three ai-adrenoceptors present, aiA-, ocib- and aiL- 
adrenoceptors (Oshita etal, 1991).
Although there is no radioligand binding data to support the presence of the am- 
adrenoceptor in the rat brain, the mRNA for this ai-adrenoceptor has been shown to be 
present (Schofield et al, 1995). In addition to this, the ot;o-adrenoceptor protein has 
been detected by Western blotting in the neonate and adult rat brain (Shen et al, 2000). 
This provides more evidence for the unusual nature of the am/d-adrenoceptor. Despite 
the presence of the mRNA for this subtype in the majority of tissues examined, there are 
only a handful of rat tissues known to elicit a functional response through the (%m- 
adrenoceptor. These include the aorta (Kenny et al, 1995; Piascik et al, 1995; Deng et 
al, 1996), the carotid artery (Nagadeh, 1996, University of Glasgow, PhD thesis), the 
iliac artery (Piascik et al, 1995) and the femoral artery (Hrometz et al, 1999). It has 
been suggested that the aio/d-adrenoceptor is poorly expressed in the plasma membrane, 
since studies looking at rat- 1  fibroblasts transfected with the aid-adrenoceptor found it 
to be mainly located intracellularly (M^Cune et al, 2000).
The ai-adrenoceptors in the pig and mouse brain appear to have a phaiTnacological 
profile similar to the rat. The pig cerebral cortex expresses both aiA- and aiB- 
adrenoceptors with a ratio of 64%:36% in favour of the aiA-adrenoceptor (Wikberg- 
Matsson et al, 1998). The mouse brain also contains aiA- and aiB- adrenoceptors. 
However the ratio of subtypes differs from the pig. Cavalli et al (1997) report that only 
42% of the total ai-adrenoceptors aie of the aiA-subtype with the remaining 58% being
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made up of the aiB-subtype, whilst Yang et al (1998) report a proportion of 30%:70%, 
in favour of the aiB-adrenoceptor.
A lack of antagonists, which are both subtype-selective and able to penetrate the blood 
brain barrier, makes it virtually impossible to allocate a particular central effect to a 
specific subtype. However, transgenic mice which either overexpress the WT aiB- 
adrenoceptor or a constitutively active aiB-adrenoceptor have provided a means of 
characterising the central effects mediated by aiB-adrenoceptors. At 3 months of age 
these mice showed hindlimb dysfunction which manifested itself in abnormal gait, 
sprawling and dragging of hindlimbs, a lack of spontaneous locomotion and a 
prevalence of tremor at rest (Zuscik et al, 2000). This locomotor phenotype was 
reported to resemble Parkinsonism, which is in agreement with Cash et al (1984) who 
found that the density of ai-adrenoceptors was increased in Parkinson patients who also 
had dementia. In addition to the locomotor impairment, 12 month old transgenic mice 
were found to suffer from grand mal-type seizures characterised by behavioural arrest, 
facial twitching, loss of balance, forelimb automatism, whole-body jerking and 
hypersalivation (Zuscik et al, 2000). The percentage of mice showing seizures 
correlated with the level of aiB-adrenoceptor overstimulation i.e. constitutively active 
mice had a higher percentage of seizures than overexpressed mice. Both the impaired 
locomotor function and the seizures could be reversed by terazosin, an ai-adrenoceptor 
antagonist. These mice also showed signs of neurodegeneration which began in areas 
that express a high density of aiB-adrenoceptors such as the cortex, hypothalamus and 
cerebellum, progressing with age to encompass all brain areas (Zuscik et al, 2000). The 
central effects of deleting the aiB-adrenoceptor from the KO mouse created by Cavalli 
et al (1997) has not been studied. However, in the light of these findings by Zuscik et al
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(2 0 0 0 ) it would be of interest to determine if the central effects in this mouse are the 
opposite of what Zuscik et al (2000) observed in mice with overstimulation of the aiB- 
adrenoceptor.
2.1.2. ai-Adrenoceptors in the liver
The presence of ai -adrenoceptors in the liver is a well-documented phenomenon and is 
hardly surprising given that ai-adrenoceptors are found throughout the body. What is 
unusual is that the liver is one of the few organs that has been found to contain a 
relatively pure population of one ai-adrenoceptor subtype, in practically every species 
investigated. The specific subtype differs between species but the overall homogeneity 
appears to be a characteristic of hepatic ai-adrenoceptors.
Garcia-Sainz and colleagues (1992-1996) have contributed substantially to our 
knowledge of a%-adrenoceptors in the liver, identifying and characterising the ai- 
adrenoceptor subtype in the liver of no fewer than ten species, ranging from the mouse 
and hamster to the rhesus monkey and human. The methodology used was similar for 
each species with slight differences in the antagonists used depending on the popular 
subtype-selective antagonists at the time. CEC was used to determine the percentage of 
receptors susceptible to inactivation and binding was earned out using agonists and 
antagonists in a bid to determine orders of potency. The agonists used throughout were 
adrenaline, noradrenaline, methoxamine and oxymetazoline. Surprisingly, the order of 
potency for the agonists was the same, regardless of the subtype concluded to be 
expressed. The order of potency was:- 
Oxymetazoline > adrenaline > noradrenaline > methoxamine
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The only difference between species was in the absolute affinity values. For example, in 
livers which were subtyped as aiA (cat, dog and human (Garcia-Sainz et al, 1996b; 
1995a; 1995b)) oxymetazoline produced nanomolar affinity values, whereas in am- 
expressing livers (mouse, rat and hamster (Garcia-Sainz et al, 1992; 1994)) it had 
micromolar affinity values.
The antagonists used for the earlier competitive binding studies (Garcia-Sainz et al, 
1992; 1994; 1995a; 1995b) were as follows: prazosin, WB4101, phentolamine, 
benoxathian, 5-methylurapidil and (+)-niguldipine. Prazosin and phentolamine were 
relatively unselective, whilst the remaining antagonists showed select!vities expected of 
aiA-selective antagonists. The later studies on rhesus monkey and cat liver utilised 
additional antagonists, which had not been available for the other studies, i.e. 
tamsulosin (aiA-selective) and BMY7378 (aio-selective) for the rhesus monkey 
(Garcia-Sainz et al, 1996a) and spiperone (am-selective) and BMY7378 for the cat liver 
(Garcia-Sainz etal, 1996b).
The conclusions reached regarding the ai-adrenoceptor subtype expressed in the liver of 
each species are summarised in tabular form in Figure 2.1
An interesting pattern is revealed when the results are presented like this. When species 
such as human, rhesus monkey, cat and dog are used in experiments they tend to be 
further on in their life cycle than animals such as mice, rats and hamsters. These are also 
the species which express aiA-adrenoceptor’s whereas the mice, rats and hamsters all 
express the am-adrenoceptor. An age-related change in the ai-adrenoceptors of the rat 
aorta has been documented by Gurdal et al (1995). 1 Month old rats were shown to
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SPECIES CONCLUSION
Mouse IB^
Hamster IB^
Rat lB'-2
Guinea-pig lA^
Rabbit lA"
Cat lA '
Dog 1A<
Rhesus monkey lA/lB^
Human lA®
Figure 2.1:- Conclusions reached regarding the identity of the a^-adrenoceptor 
subtype in the livers of these species. ^Garcia-Sainz et al, 1994; ^Garcia-Sainz 
et al, 1992; ^Garcia-Sainz et al, 1996; "^Garcia-Sainz et al, 1995; ^Garcia-Sainz 
et al, 1996; ^Garcia-Sainz et al, 1995
express a mixture of am- and am-adrenoceptors. However by 6  months of age the level 
of expression of am - adrenoceptors had decreased whilst the level of expression of aiA- 
adrenoceptors had increased. The rat liver is also well known for changing the balance 
of its adrenoceptor populations with age (Rossby and Cornett, 1991). Therefore the 
variation seen between species could be due to an age-related difference in the ai- 
adrenoceptor expressed rather than a definitive species difference in receptor.
Although Garcia-Sainz and colleagues have made a major contribution to subtyping 
hepatic ai-adrenoceptors a number of other groups have also characterised ai- 
adrenoceptors in the livers of various species. Whether it be for purely pharmacological 
desires to subtype the a%-adrenoceptors (Taddei et al, 1993; Yang et al, 1998) or to test 
the selectivity of an ai-adrenoceptor antagonist (Gross et al, 1988; Hanft and Gross, 
1989; Deng et al, 1996), there is a seemingly endless supply of papers looking at 
various aspects of hepatic ai-adrenoceptors. The reason the liver is such a popular 
choice is due to its perceived homogeneity of ai-adrenoceptors, which provides an 
environment in which to study native ai-adrenoceptors without the complications 
associated with heterogeneity of subtypes. Much of the work has been carried out in 
rats. In fact, the first evidence that the a%-adrenoceptors of rat liver were am- 
adrenoceptors eame, not from Garcia-Sainz, but from Minneman et al (1988). They 
showed that WB4101 bound with low affinity to hepatic ai-adrenoceptors and that CEC 
inactivated these receptors, providing preliminary evidence for a homogeneous 
population of aiB-adrenoceptors. It is now universally agreed that am-adrenoceptors are 
the only ai-adrenoceptor subtype present in the rat liver, many papers attesting to this
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(Terman et al, 1990; Han and Minneman, 1991; Taddei et al, 1993; Ohmura and 
Muramatsu, 1995; Buscher et al, 1996; Yang et al 1997; Shen et al, 2000).
The a i-adrenoceptor subtype in pig liver has been characterised to be a homogeneous 
population of ai A-adrenoceptors (Wikberg-Matsson et al, 1998), which is in agreement 
with the observation that larger/older mammals contain hepatic ai-adrenoceptors of the 
aiA-adrenoceptor subtype.
Ohmura and Muramatsu identified two a%-adrenoceptor subtypes in rabbit liver when 
they used 0.3|iM prazosin to define non-specific binding, whilst they could identify 
only one subtype when they used 10p,M phentolamine (traditionally used to define non­
specific binding). Their basis for using prazosin was that phentolamine at a 
concentration of 10p,M was insufficient to completely inhibit the binding of [^H]- 
prazosin to ai-adrenoceptors (Ohmura and Muramatsu, 1995). The two sites which they 
had identified appeared to represent the a% A-adrenoceptor (high affinity for antagonists 
used) and the aiL-adrenoceptor (low affinity for antagonists used, in particular prazosin, 
pKi = 8 ). The low affinity site appeared to dominate, representing approximately 70- 
80% of the total binding sites. This was in direct contrast to Garcia-Sainz et al (1992) 
who also used prazosin to define the non-specific binding, but could identify only one 
subtype, the aiA. This was the same group who identified three binding sites in the rat 
cerebral cortex where all other groups had identified only two (Oshita et al, 1991).
The ai-adrenoceptor subtype in the mouse liver was characterised as being the am- 
subtype by Garcia-Sainz et al as far back as 1992 (prior to the nomenclature devised by
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lUPHAR in 1995) and it has been only in recent years that any further characterisation, 
with more subtype specific drugs has occurred. Targeted disruption of the am- 
adrenoceptor gene resulted in a mouse that failed to express the am-adrenoceptor 
protein (Cavalli et al, 1997). Binding studies revealed that there was a 98% loss of a i- 
adrenoceptors in the liver of this KO mouse compared to the WT mouse, indicating a 
homogeneous population of am-adrenoceptor in mouse liver. Confiimation of this was 
provided by Yang et al (1998) who reported that a series of ai-adrenoceptor ligands, 
including 5-methylurapidil and BMY7378, bound monophasieally and with low affinity 
to the hepatic ai-adrenoceptors of mice, indicative of an am-adrenoceptor population.
The initial aim of this study was to use radioligand binding to confirm the previously 
published reports detailing the presence of a mixed population of aiA- and am- 
adrenoceptors in the WT murine brain and a homogeneous population of am- 
adrenoceptors in the WT murine liver. Using the am-adrenoceptor KO mouse, a further 
aim was to demonstrate the loss of the native am-adrenoceptor in the KO mouse brain 
and liver. The results from this preliminary investigation were surprising with regard to 
the KO liver and so a more detailed pharmacological analysis was earned out in both 
WT and KO brain and liver tissue, in an attempt to characterise changes present in the 
KO tissue, which had not been previously identified for this particular mouse. This may 
provide an insight into the role of the am-adrenoceptor subtype.
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2.2 METHODS
2.2.1 Solutions and drugs used
All binding experiments were carried out in assay buffer of the following composition 
(mM):- NaCl (150), Tris-HCl (50), EDTA (5), MgCh (10) and 10% glycerol -  pH 7.4. 
When preparing plasma membranes lOOmls of this assay buffer was used to which 
protease inhibitors were added in the following concentrations (|iig/ml);- soybean 
trypsin inhibitor (500), leupeptin (1), bacitracin (1), pepstatin A (1), antipain (1) and 
lOmM benzamidine. The wash buffer used to terminate the binding reaction and wash 
the filters was a 50mM Tris-HCl solution -  pH 7.4
The following compounds were used:-
(R)-A-61603 (N-[5-(4,5-dihydro-lH-imidazol-2yl)-2-hydroxy-5,6,7,8- 
tetrahydronaphthalen-1 -yl] methanesulphonamide hydrobromide, a gift from Dr. 
Hancock, Abbott Laboratories, USA), antipain (Sigma), BMY7378 (dihydrochloride 
8-[2-[4-(2-methoxyphenyl)-l-piperozynl]ethyl]-8-azaspiro(4,5}decone-7,9-dione, 
Research Biochemicals International), bacitracin (Sigma), benzamidine (Sigma), 
GTP-y-S (Guanosine 5'-0-(3-thiotriphosphate) tetralithium salt. Sigma), L765,314 (4- 
amino-2-[4-[l-(benzyloxycarbonyl)-2-(S)-[[(l,l dimethylethyl)amino]carbonyl]- 
piperazinyl]-6,7-dimethoxyquinazoline, a gift from Dr. Patane, Merck and Company, 
USA), leupeptin (Sigma), pepstatin A (Sigma), phentolamine hydrochloride 
(Sigma), polyethylenimine (Sigma), [^H]-prazosin hydrochloride (Amersham), 
prazosin hydrochloride (Sigma) RS100329 (a gift from Dr Michelson, Roche 
Bioscience, USA) and soybean trypsin inhibitor (Sigma).
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2.2.2 Animals used/tissue preparation
Unless otherwise stated the mice tissues used in the age studies were treated in an 
identical fashion to those used for the subtyping studies.
Wildtype and knockout male C57-Black mice were obtained from the Central Research 
Facility at the University of Glasgow. Mice were killed by cervical dislocation (or by 
overdose of carbon dioxide if carotid arteries were being removed). All mice used were 
~4 months old, weighing 30-40g with the exception of mice used in the age studies 
which were only 3 months old (20-30g). The brain and liver tissues were rapidly 
removed (only liver tissue was collected from 3 month old mice), washed in assay 
buffer and then snap frozen in liquid nitrogen. The tissues were stored at -80°C until 
required for analysis.
2.2.3 Isolation of plasma membranes
Brain and liver tissues were pulverised under liquid nitrogen using a stainless steel 
percusson mortar, followed by a pestle and mortar. Tissues were suspended in assay 
buffer containing protease inhibitors. The volume in which the tissues were suspended 
was dependent on the number of brains and livers used in each assay (generally 5- 
lOmls). The tissue suspensions were homogenised in a pre-cooled polytron, on ice, for 
3/4, 15s bursts at setting 6 . The homogenate was filtered through two layers of muslin 
and centrifuged at 1200 x g for 5 minutes at 4°C. The supernatant was removed and kept 
on ice and the pellet was resuspended in approximately 5mls of buffer. When isolating 
plasma membranes using liver tissue this first supernatant was discarded due to the high
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concentration of red blood cells present in this tissue which, if not removed, would 
produce high amounts of non-specific binding when the radioligand binding assay was 
performed. The resuspended pellet was homogenised using the polytron (setting 6 ) and 
then centrifuged as before. This homogenisation/centrifugation step (which endeavours 
to wash away endogenous agonists and mediators (e.g. guanine nucleotides) which may 
interfere with the radioligand binding assay) was repeated 3 times in total (4 for the 
liver) and the supernatants pooled together. The pooled supernatants were centrifuged at 
high speed (56,000 x g for 30 minutes at 4°C) in an ultracentrifuge. The supernatant was 
discarded and the pellet was washed and resuspended in assay buffer and 
ultracentrifuged again at the same settings. The resultant pellet was resuspended in 1-2 
mis of assay buffer and homogenised in a glass homogeniser until smooth and then 
aliquoted into eppendorfs and stored at -80°C until needed. Plasma membranes were 
usually used within a week of isolation and were never kept for longer than 4 weeks.
2.2.4 Determination of protein concentration
A Pearce Bicinchoninic Acid (BCA) Protein Assay kit was used to determine the 
concentration of plasma membrane protein that had been isolated. The protein standard 
used was bovine serum albumin (BSA) which came in a stock solution of 2mg/ml. This 
was diluted using deionised water to give working concentrations of 1, 0.5, 0.25, 0.125 
and 0.0625mg/ml from which the protein content of the plasma membranes could be 
calculated. 25jLil of either the BSA dilutions or the membrane samples (diluted to a 1:10 
solution in order to minimise the amount of membranes used) were pipetted into a 96- 
well plate. The BSA samples were incubated in duplicate and the membrane samples in 
quadruplicate. 200)11 of the BCA working reagent was added to each sample. The BCA
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working reagent was made up with 50 parts of Reagent A (a solution of sodium 
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartarate in 0.2M sodium 
hydroxide) and 1 part of reagent B (a solution containing 4% cupric sulphate). The 
reaction was allowed to proceed for 30 minutes at 37°C after which the reaction was 
terminated when the samples were removed from the incubator and left to stand for 5-10 
minutes at room temperature (22°C). The protein present in the samples reduces Cu^ "*" to 
Cu^\ which then goes on to react with the BCA to produce a colour change. This water 
soluble complex exhibits a strong absorbance at 562nm that is linear with increasing 
protein concentrations and so after termination of the reaction the absorbance of the 
samples was measured at 562nm using a Dynatech plate reader to quantify the colour 
change. A graph was plotted using the values obtained for the BSA standards, which 
was then used to calculate the actual concentration of membranes. The membranes were 
diluted using assay buffer to give a working concentration of 2i5mg/ml.
2.2.5 Saturation experiments
The affinities (K d) and maximal receptor densities (Bmax) of expressed ai-adrenoceptors 
in WT and KO brains and livers were determined using saturation binding assays. Brain 
and liver membranes (0.5mg/ml) were incubated in duplicate with -prazosin (0.025- 
5nM, 75Ci/mmol) made up to a total volume of 0.5mls with assay buffer. Non specific 
binding was determined in the presence of lOjiM phentolamine at each concentration of 
[^H]-prazosin. After equilibrium (30 minutes at 22°C) bound ligand was separated from 
free by vacuum filtration over GF/C filters (pre-soaked in assay buffer containing 0,3% 
aqueous polyethylenimine to reduce non specific binding) which were washed three 
times with ice cold wash buffer using a Branded cell harvester. Each filter was placed in
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3mls of scintillant and left overnight after which time the filter had dissolved and the 
radioactivity could be measured in a Beckman LS5000TD liquid scintillation counter,
2.2.6 Competition experiments
To determine the ai-adrenoceptor subtypes present in the brains and livers of WT and 
KO mice competition binding assays were performed using various subtype selective 
ligands. The ligands used and their subtype selectivities are as follows:- Prazosin (non- 
selective oti-adrenoceptor antagonist), (R)-A-61603 (aiA-selective agonist), RS 100329 
(ociA“Selective antagonist), L765, 314 (aiB-selective antagonist) and BMY7378 (am- 
selective antagonist).
Competition binding assays were performed by incubating WT and KO brain and liver 
membranes with 0.5nM [^H]-prazosin in the presence or absence of the competing 
ligands. When deciding on the concentration of [^H]-prazosin to use 2 factors are taken 
into consideration. In general a concentration of [^H]-prazosin approximately equal to 
its Kd is preferred. However the concentration used has to be sufficient that the counts 
per minute are large enough to be measurable, and so a further factor in deciding the 
concentration to be used is whether or not the counts per minute will be detected 
reliably by the scintillation counter. A concentration of [^H]-prazosin that produces total 
counts of approximately 1000 is deemed to be sufficient. In KO livers this was found to 
occur at a concentration of 0.5nM. However 0.2nM was found to be adequate to 
produce counts of 1000 in the other tissues used (WT and KO brains and WT livers). It 
was decided that 0.5nM would be used throughout the study for all tissues examined in
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order to provide accurate counts for all tissues used and to enable a valid comparison to 
be made between tissues.
The concentrations of the competing ligands used in the assay were dependent on the 
specific ligand’s affinity range for the three subtypes of ai-adrenoceptor. Preliminary 
experiments were carried out for each of the competitors over a wide range of 
concentrations increasing in log increments in order to determine the affinity range of 
each ligand. This allowed for the determination of a suitable range of concentrations for 
each competing ligand, which had to include a plateau at the top and bottom of the 
concentration range in order to perform non-linear curve fitting analysis. From this data 
17 concentrations were chosen which increased in half-log increments. The 
concentrations for each ligand were:- Prazosin:-IpM -  0.1 mM, RS 100329:- O.lpM -  
10i4M,L765,314:- IpM -O .lm M , BMY7378:- lO pM - Im M and (R)-A61603:- lOpM 
-  ImM. Non specific binding was determined in the presence of lOjLiM phentolamine as 
for saturation assays. The incubations were allowed to proceed for 30 minutes at 22°C 
until equilibrium was reached whereupon the reaction was terminated and counted by 
the same method employed for the saturation assays.
All experiments using (R)-A-61603 were carried out both in the presence and absence 
of 1 0 0 |4 M GTPyS (a non-hydrolysable analogue of GTP). The reason for this is that in 
the hands of this laboratory (R)-A-61603 exhibits a biphasic curve due to its interaction 
as an agonist with G proteins. This occurs because the binding of (R)-A-61603 to ai- 
adrenoceptors will result in a proportion of the receptors interacting with G proteins, 
while the rest of the receptors do not. When an agonist-receptor complex interacts with 
the a-subunit of a G protein there is a decrease in the affinity of the nucleotide binding
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site for GDP and a ternary complex forms where the a  subunit is bound to the receptor 
and the |3 and y subunits are empty. If GTP is absent the activated receptor is unable to 
dissociate from the a  subunit. When this happens it increases the stability of the 
agonist-receptor complex which increases the affinity of the agonist for the receptor 
(Bockaert et al, 1997). When the G protein concentration is limiting (as is the case when 
using isolated plasma membranes) there will be a percentage of the receptors which 
have a higher than normal affinity for the agonist.
In a study such as this, that relies on fitting data to one-site or two-site binding 
isotheiTns, it is imperative that any heterogeneity that was observed was as a result of 
there being two binding sites, and not due to experimental conditions which would not 
be present physiologically. Experiments were carried out in the presence and absence of 
a non-hydrolysable analogue of GTP, GTPyS, to allow the biphasic nature of (R)-A- 
61603 to be demonstrated and to show that the presence of GTP could abolish this.
2.2.7 Analysis of results
The average counts per minute (cpm) for each antagonist in WT and KO tissues is 
presented in tabular form in appendix A1-A12. All data was analysed using GraphPad 
Prism 3.01 (Institute for Scientific Information, San Diego, California, USA). All 
equations and nomenclature used in the text are taken from GraphPad Prism 3.01. 
Statistical comparison of WT and KO data was performed using an unpaired t test. A p 
value of less than 0.05 was considered to be significant.
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2.2.7.1 Data analysis for saturation curves
Specific binding in saturation experiments was calculated by subtracting non-specific 
binding from total binding for each concentration of [^H]-prazosin. Non-specific 
binding was analysed using linear regression. Total and specific binding were analysed 
using non-linear regression, comparing the data to a one-site or a two-site model. For 
saturation experiments the data was consistently found to fit more accurately to a one- 
site model. All saturation assays were carried out in duplicate, each experiment was 
repeated a minimum of three times and the results from each pooled and expressed as 
mean ± s.e.m. The Kd (which is the equilibrium dissociation constant i.e. the 
concentration of ligand which occupies half of the receptors at equilibrium) and the 
Bmax (the maximal receptor density) are calculated using the following equation:-
Specific binding = Bmax.[RL]
Kd + [RL]
This equation describes a rectangular hyperbola where [RL] is the concentration of free 
radioligand.
2.2.7.2 Data analysis for competition curves
As with saturation curves, experiments were carried out in duplicate, repeated a 
minimum of three times and the results from each pooled and expressed as mean ± 
s.e.m. For competition curves specific binding was determined by a different method 
from that used with saturation curves. Non-specific binding (determined in the presence
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of 10|iM phentolamine) was defined as 0% and total binding (in the absence of any 
competitor) was defined as 100%. Specific binding is then calculated accordingly and 
expressed as % specific binding of maximum.
In the simplest case competitive binding can be described by the equation
Y = NSB + rTotal-NSBI
Y = binding in the presence if the competitor
Log[D] = logarithm of the concentration of the competitor
NSB = non-specific binding in the presence of a saturating concentration of D
Total = binding in the absence of a competitor
[loglCso] = logarithm to the base 1 0  of the concentration of the competitor which 
inhibits the binding of the radioligand by 50%
This equation describes a situation in which the radiolabel and the competing ligand 
compete for only 1 receptor type. However in many tissues there are 2 classes of 
binding sites, which may represent 2 subtypes of receptor. This situation can also be 
described by an equation, albeit a more complicated one:-
Y = NSB + (Total-NSB). + 1-F
1 +  1 Qlog[D]-Iog(IC5o) ^  Qlog[D]-log(IC5o),
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Where Y, NSB, Total and [D] are as for the previous equation and F = fraction of 
binding to receptors of the first type of receptor.
Data from competition experiments were analysed using both the one-site and two-site 
models. Results of these were compared to determine which gave the more accurate fit. 
This was done in a number of ways. Firstly the graphs were compared visually to assess 
which equation looked to be fitting the data better, after which a number of statistical 
parameters were looked at, which are provided by Graph Pad when performing 
nonlinear regression. (All definitions are taken from the GraphPad guide to Nonlinear 
Regression by Harvey Motulsky, 1996).
95% Confidence Intervals:- if all the assumptions of non-linear regression are true 
then there is a 95% chance that the true value of the variable lies within the interval. 
Therefore the naiTower the confidence interval, the better the fit.
Sum of Squares (SS):- the sum of squares is defined as the sum of the square of the 
vertical distances of the points from the curve. So the smaller the value of SS then the 
closer the points are to the curve and the more accurate the fit.
r^i- a measure of the goodness of the fit. It is a fraction between 0 and I and has no 
units. When r  ^= 0 the best-fit curve fits the data no better than a horizontal line going 
through the mean of all the y values, i.e. knowing x does not help you predict y. When 
r  ^= 1 all points lie exactly on the curve with no scatter i.e. if you know x you can 
predict y.
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Prism also performs a test called the F test which directly compares the fits of 2
equations and reports which is statistically better suited to the data. The results are
presented in the form of an F ratio which is calculated as shown below
F =  rSSl-SS2VSS2 
(DF1-DF2)/DF2
SS = sum of squares 
DF = degrees of freedom
If the simpler equation (i.e. the one-site model) is cotrect then F ~ 1 because the relative 
increase in the sum of squares is approximately equal to the relative increase in the 
degrees of freedom. However if F is  much greater than 1 then the more complicated 
equation is correct because the relative increase in the sum of squares (going from the 
complicated to the simpler model) is greater than the relative increase in the degrees of 
freedom.
For the purposes of this study a two-site model was accepted only when the F ratio was 
found to be much greater than 1 and produced a p value of < 0.05.
The Ki or inhibition constant is defined as the concentration of the unlabelled drug that 
will bind half the receptors at equilibrium, in the absence of radioligand or any other 
competitors and can be calculated using the Cheng-Prusoff equation (Cheng and 
Prusoff, 1973):-
Ki= IC50
l+ FRLI
Kd
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For each competition experiment a Ki was calculated and then converted to a pKi value, 
which is the negative logarithm to the base 1 0  of the Ki.
However, these three equations are based on assumptions, which if not met, deem the 
equations no longer accurate. One of these assumptions is that only a small fraction of 
the added ligand actually binds. Therefore the assumption being made is that the 
concentration of free ligand in solution is the same as the concentration of ligand added. 
This can only be upheld when less than 10% of the ligand binds. In cases where more 
than 1 0 % binds any data analysis carried out would have to take account of this ligand 
depletion. To determine if ligand depletion had taken place in any of the competition 
experiments carried out for this study the percentage of ligand bound was calculated:-
% Bound = Total Binding x 100% 
Total RL added
This phenomenon was only found to occur in WT tissues. In the WT liver it occurred 
when using RS100329 and BMY7378 and in the WT brain it occurred with BMY7378. 
This meant that the equations describing competitive binding to one or two sites could 
not be used to fit the data, nor could the Cheng Prusoff equation be used to calculate the 
Ki’s. Fortunately Graph Pad has an equation that can be used in a more complicated 
situation such as this:-
Y=(-l.b + V(b.b-4.a.c))
2 a
KdCPM = KdnM.SpAct.V.1000 
R=NSB+1
S=[ 1 , i QCPM+Hot  
a=-l.R
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b=R.S+NSB.Hot + Bmax 
C= -1.Hot.(S.NSB 4 - Bmax) 
where:-
SpAct = specific activity of radioligand 
V = volume
Hot = amount of labelled ligand added to each tube
This equation accounts for the fact that the free concentration of radioligand is less than 
the concentration added and was used to fit data in any situation where bound ligand 
was found to account for more than 10% of ligand added.
Non linear regression was also carried out using the Hill equation in order to determine 
the Hill slope, which allows for the quantification of the steepness of the slope.
Y = NSB + (Total-NSB)
I +  J Q(loglC50-log[RL]).slope factor
A one-site competitive binding curve that follows the law of mass action will have a 
slope of -1 (it is negative because the curve goes downhill). If the slope differs 
significantly from -1 then the binding does not follow the law of mass action. One of the 
possible explanations for such an event would be that there is a heterogeneous 
population of receptors for which the competing drug has different affinities or it could 
be due to heterogeneity in the receptor coupling to other molecules such as G proteins.
A Hill slope was calculated for each competition experiment in order to provide further 
infoimation about the nature of the binding.
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2.3 RESULTS
2.3.1 Binding studies in brains from WT and KQ mice
2.3.1.1 Saturation studies
-prazosin demonstrated specific, saturable binding of high affinity in brains from 
both WT and KO mice and was found to fit to a one-site binding isotherm (Figure 2.2). 
Kd’s were calculated as being 0.6 ± O.OSnM for WT brain and 0.8 ± 0.2nM for KO 
brain, confirming the presence of ai-adrenoceptors in the murine brain. The difference 
in the affinity of [^H]-prazosin between WT and KO was not significant. However, 
when the total receptor number was calculated there was found to be a smaller number 
of receptors in KO brains (60.33 ±5.0 fmol/mg), when compaied with brains from WT 
mice (87.5 ± 3.8fmol/mg) (p< 0.05).
2.3.1.2. Competition studies
With the presence of ai-adrenoceptors in the murine brain confiimed, the subtype(s) 
that made up this population were investigated. A number of selective and non-selective 
antagonists and a selective agonist were utilised in order to determine the ai- 
adrenoceptor subtype(s) present in the murine brain. The antagonists used were prazosin 
(non-selective ai-antagonist), RS 100329 (an aiA-selective antagonist), L765,314 (an 
aiB-selective antagonist), BMY7378 (an «lo-selective antagonist) and (R)-A-61603 (an 
aiA-selective agonist).
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Figure 2.2:-Saturation curves showing [% ]-prazosin binding 
(0.025-5nM) in WT (top) and KO (bottom) brain membranes. 
WT brain produced a of 0.6±0.08nM and a of 
87.5±3.8fmol/mg, whilst KG brain produced a of 0.8+0.2nM 
and a of 60.33+5.Ofmol/mg Total (■), specific (□) and
non-specific (O) binding. Each data point is expressed as 
mean ± s.e.m (n=4).
The competition curves for the ligands used are shown in Figures 2.3 -  2.7 and a table 
with their pKi values and Hill slopes is given in Figure 2.8.
Prazosin inhibited [^H]-prazosin binding in WT and KO brain (Figure 2.3) resulting in 
pKi values of 9.3+0.05 and 9.2+0.06 respectively, which correlate well with values 
expected at ai-adrenoceptors (Bylund et al, 1994). In addition to this high affinity 
binding site (which accounted for 89+4% of the total number of binding sites) the KO 
brain also had a low affinity site with a pK, of 7.4+0.45. The Hill slope in the KO brain 
reflects the biphasic nature of prazosin’s binding in that it is significantly different from 
negative unity (-0.85: 95% Cl = -0.99 to -0.72). However the graph in Figure 2.3 does 
not necessarily reflect this biphasic nature as a result of the data plotted being the mean 
data rather than single experiments. When single experiments were analysed the graph 
was more obviously biphasic than when plotted as mean data. The Hill slope in the WT 
brain is indicative of competitive binding to a single site, in that it is not significantly 
different to negative unity (-1.1: 95% Cl = -1.4 to -0.9).
RS 100329, an a,A/a-selective antagonist with approximately 120 fold selectivity over 
the aib“adrenoceptor and 50 fold selectivity over the aid-adrenoceptor (Williams et al, 
1999), demonstrated a one-site binding curve in the KO brain, with a pKi of 9.3+0.03 
and a Hill slope not significantly different from negative unity of -1.0 (95% Cl = -1.2 to 
-0.8). However, in the WT brain the situation was not suggestive of one-site binding but 
showed instead that RS 100329 was binding with two separate affinities. The high 
affinity site of 9.5+0.1 is comparable to the value of 9.3+0.03 in the KO brain and 
makes up 36+2.5% of the binding sites. However, there is an additional second site 
found to be present in the WT which is not present in the KO brain. This second site in
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Figure 2.3:-Displacement of 0.5nM [^H]-prazosin from WT 
(top) and KO (bottom) brain membranes by increasing 
concentrations of prazosin (IpM-O.lmM). Data points are 
expressed as mean ± s.e.m. (n>3)
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Figure 2.4:-Displacement of 0.5nM [^H]-prazosin from WT (top) 
and KO (bottom) brain membranes by increasing concentrations 
of RSI 00329 (O.lpM-lOjxM). Data points are expressed as 
mean ± s.e.m.(n=3)
the WT brain has 100 fold lower affinity than the first site with a pKj value of 7.4±0.07, 
The shallow Hill slope (-0.46: 95% Cl = -0.53 to -0.38) confirms the biphasic nature of 
the binding of RS 100329 in WT brain (Figure 2.4).
The selective agonist used in this study, (R)-A-61603, demonstrated two-site binding 
both in the presence and absence of GTPÀS when used in the WT brain. The pKi values 
were identical under both conditions (6.7±0.16 and 5.2+0.13) and the Hill slopes were 
both shallow and significantly different from negative unity (-0.64 (95% Cl = -0.78 to - 
0,47) without GTPÀS and -0.66 (95% Cl = -0.77 to -0.55) in the presence of GTPXS). 
(R)-A-61603 behaved in a similar manner in the KO brain, in that it exhibited two-site 
binding both in the presence and absence of GTPyS, with similar affinities to the WT 
brain. When GTPyS was absent the pKj values were 7.010.07 and 5.510.2 with a Hill 
slope which was significantly different from negative unity (0.73: 95% Cl = -0.81 to -  
0.65). The presence of GTPyS doesn’t appear to affect the binding curve, resulting in 
pKi’s which are almost identical to those without GTPyS: 6.810.06 and 5.310.4. There 
is a slight steepening of the Hill slope going from 0.73 in the absence of GTPyS to 0.84 
when GTPyS is present. However the Hill slope is still significantly different from 
negative unity with 95% Cl = -0.95 to -0.73. Although the pK  values for WT and KO 
brain are virtually identical there is a significant difference (p<0.05) in the fraction of 
high affinity sites present in the WT compared with the KO brain. In the WT brain the 
high affinity site corresponds to 4516,3% of the total binding sites whereas in the KO 
brain the high affinity site accounts for 8615.3% of the total (Figure 2.5).
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Figure 2.5:- Displacem ent o f 0.5nM[^H]-prazosin from 
W T (top) and KO (bottom) brain membranes by 
increasing concentrations o f (R)-A -61603 
(lO pM -lm M ) in the presence (□ ) and absence (■ ) 
o f GTPy S. D ata points are expressed as m ean ± s.e.m. 
(n^3)
L765,314 inhibited -prazosin binding in WT brain with a pK, value of low affinity 
(6.4+0.07) and a Hill slope of -1.0, (95% Cl = -1.3 to -0.66) suggestive of monophasic 
binding. The KO brain was found to produce a similar pKi value of 6.3±0.09 with a 
steep Hill slope which was not significantly different from negative unity (-0.96; 95%
Cl = “1.3 to -0.65) (Figure 2.6).
BMY7378, which is the only antagonist to date with significant selectivity for the aio- 
adrenoceptor over the other two subtypes (Saussy et al, 1994) was found to bind in a 
monophasic manner and with low affinity in the WT brain resulting in a pK, of 6.0±0.03 
and producing a Hill slope of -1.0 (95% Cl = -1.4 to -0.84). The KO brain was also 
found to bind BMY7378 with low affinity (pK = 6.1±0.06) which resulted in a steep 
Hill slope which was not significantly different from negative unity (-0.87: 95% Cl = -
1.1 to -0.65) (Figure 2.7).
2.3.1.3 Correlations
Figures 2.9 and 2.10 show binding correlations for the ligands used in WT and KO 
brain respectively, plotted against the published binding affinities for these ligands at 
the three cloned ai-adi*enoceptors. For WT brain the values plotted for RS 100329 and 
(R)-A-61603 are the high affinity pK /s when plotted against the aia-adrenoceptor 
values but the low affinity pK, values were used when plotted against the aib- 
adrenoceptor values. For KO brain the high affinity prazosin site was used throughout. 
All (R)-A-61603 data was plotted as the pKj values in the presence of GTPyS. The 
published pKi values used for A-61603 are the affinities of the racemic mixture at the 
cloned subtypes, whereas the experiments carried out here used the R-enantiomer of A-
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Figure 2.8:- Inhibition affinities in W T and KO brain mem branes expressed 
as pKj values ± s.e.m. Hill slopes (nH) are expressed as the negative o f 
the hill slope ± s.e.m.(H) = high affinity site and (L) = low affinity site, 
indicates a Hill slope w hich is significantly different from  negative unity.
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Figure 2.9:- Correlation o f potencies o f ligands used on W T brain 
membranes with published potencies o f the same ligands at cloned 
a  1-adrenoceptor subtypes. (1):- prazosin, (2):- RS 100329,
(3):- (R)-A61603, (4):- L765,314 and (5);- BM Y7378.
(W illiams et al, 1999, Knepper et al, 1995,Patane et al, 1998 and 
Yang et al, 1997). The dotted line shows the line o f unity.
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Figure 2.10:- Correlation of potencies of ligands used on KO brain 
membranes with published potencies of the same ligands at cloned 
a  ^ -adrenoceptor subtypes. (1):- prazosin, (2):- RSI 00329,
(3):- (R)-A61603, (4):- L765,314 and (5):- BMY7378.
(Williams et al, 1999, Knepper et al, 1995, Patane et al, 1998 and 
Yang et al, 1997). The dotted line shows the line of unity.
61603. However, only data at otiA-adrenoceptors has been published for the R- 
enantiomer so to enable correlations to be carried out it was decided to use the values 
quoted for the racemic mixture.
There appears to be a weak conelation between the affinities for the ligands in the WT 
brain and for cloned aid-adrenoceptors (r = 0.55). However the correlation is much 
stronger when the affinities in the WT brains are plotted against the affinities in either 
aia-adrenoceptors or aib-adrenoceptors. Both correlations give very similar 
r values of 0.86 at aia-adrenoceptors and 0.85 at aib-adrenoceptors but the plot with 
a  I a-adrenoceptors most closely followed the line of unity. In KO brain there is a very 
good linear correlation with aia-adrenoceptors (r = 0.88) which closely resembles the 
line of unity. The conelations with aib-adrenoceptors and aia-adrenoceptors are poor 
with r values of 0.31 and 0.14 respectively.
2.3.2 Binding studies in livers from wildtvpe and knockout mice
2.3.2.1 Saturation studies
As was the case with the murine brain, the liver was found to display specific, saturable 
binding of high affinity to [^H]-prazosin (Figure 2.11) and as with the brain was found 
to fit consistently to a one-site binding isotherm. The WT liver was found to have an 
affinity of 0.3 ± 0.08nM whilst KO liver had an affinity of 0.15 ± 0.04nM, indicating a 
population of ai-adrenoceptors present in both WT and KO liver. The Bmax was found 
to be significantly lower in the KO (30.0 ± 2.0fmol/mg) when compared to the WT liver 
(50.0 ± 3.1fmol/mg), which mirrors the findings in the brain. Murine liver has been 
proposed to contain a pure population of aia-adrenoceptors (Yang et al, 1998). We
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Figure 2.11:- Saturation curves showing [%]- 
prazosin binding (0.025-5nM) in WT (top) and 
KO (bottom) liver membranes. WT liver 
produced a Kj-, of 0.3±0.08nM and a of 
50±3.1fmol/mg, whilst KG liver produced a K ,^ of 
0.15±0.04nM and a of 30±2.0fmol/mg. Total 
(■), specific (□) and non-specific (o) binding. 
Each data point is expressed as mean ± s.e.m. 
(n>3).
therefore expected to find no specific binding with [^H]-prazosin in the KO liver as a 
direct consequence of the deleted ais-adrenoceptor. Not only is there specific binding 
but this binding is of high affinity and well within the range of pK; values that prazosin 
has been shown to exhibit at ai-adrenoceptors (Bylund et al, 1994 and Garcia Sainz et 
al, 1994).
2.3.2.2 Competition studies
The competition curves for the ligands used in this set of experiments are shown in 
Figures 2.12 -  2.16 with the table of their respective pKj values given in Figure 2.17.
When prazosin was used as the competing ligand, as well as for the radioligand, the KO 
liver was found to produce a two-site binding curve with a Hill slope significantly 
different from negative unity (-0.5: 95% Cl = -0.8 to -0.2), despite saturation studies 
with [^H]-prazosin displaying one-site binding in KO liver. The pKi values were 
calculated to be 9.0 ± 0.5 and 7.0 ± 0.23 with the high affinity site being present in 
much greater numbers than the low affinity site, making up almost 60% of the total 
binding sites (57+6.3%). This is a similar situation to that seen in the KO brain where 
prazosin also demonstrated two-site binding. Conversely, in WT liver prazosin binds 
monophasically producing a Hill slope of exactly -1.0 (95% Cl = -1.1 to -0.9) and a pKi 
of 9.7 ±0.11 indicating binding to a homogeneous population of ai-adrenoceptors 
(Figure 2.12).
Although the use of prazosin as a competing ligand confirms that -adrenoceptors are 
present in the WT and KO liver it does not confirm the identity of the subtype(s)
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Figure 2.12:- Displacement of 0.5nM pH]-prazosin 
from WT (top) and KO (bottom) liver membranes by 
increasing concentrations of prazosin (IpM-O.lmM). 
Data points are expressed as mean ± s.e.m. (n^3)
present. In order to determine this we used the same subtype selective ligands as those 
used in the brain.
In the WT liver RS 100329 bound with low affinity, producing a pKj value of 7.8+0.02 
with a Hill slope which was not significantly different from negative unity 
(-1.0: 95% Cl = “1.1 to -0.9), indicative of competitive binding to a homogeneous 
population of receptors. The KO liver on the other hand was found to bind RS 100329 
with greater affinity producing a pKi value of 9.3+0.07 and this binding appeared to be 
to only one-site due to the Hill slope of the curve being not significantly different from 
negative unity (-0.82: 95% Cl = -1.03 to -0.61) (Figure 2.13).
In WT liver tissue (R)-A-61603 produced a biphasic curve with affinities of 7.4 + 0.4 
and 4 ± 0.06 and a shallow Hill slope of -0.7 (95% Cl = -0.9 to -0.5) when no 
GTPyS was present. This high affinity site was only 7±2% of the total number of 
binding sites and upon addition of GTPyS this site disappeared producing a monophasic 
curve of low affinity (pK = 4.2 ± 0.08) with a Hill slope not different from negative 
unity (-1.1 : 95% Cl = -1.3 to -0.8). The binding of (R)-A-61603 in the KG liver was 
unaffected by the presence of GTPyS. When GTPyS was absent, (R)-A-61603 bound 
with a high affinity (7.9+0.15) which appeared to be competitive due to the steep Hill 
slope which was not significantly different from negative unity (-1.3: 95% Cl = -2.2 to -  
0.5). In the presence of GTPyS the same was found to be true: (R)-A-61603 bound with 
high affinity producing a pK, of 8.2+0.13 with a steep Hill slope (-0.75: 95% Cl = -1.1 
to -0.4) (Figure 2.14).
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Figure 2.14:- Displacement of 0.5nM pH]-prazosin 
from WT (top) and KO (bottom) liver membranes 
by increasing concentrations of (R)-A-61603 
(lOpM-lmM) in the presence (□) and absence (■)of 
GTPy S. Data points are expressed as mean ± s.e.m. 
(n^3)
L765,314, which has been reported in the literature to be selective for aiB- 
adrenoceptors (Patane et al, 1998) bound monophasically and with relatively low 
affinity in both WT and KO liver membranes resulting in pKi values of 7.6±0.03 and 
7.8±0.1, respectively. The Hill slopes for both curves were not significantly different 
from negative unity with the WT liver producing a slope of -1.1 (95% Cl = -1.3 to 
-0.9) and the KG liver a slope of -0.8 (95% Cl = -1.1 to -0.5) (Figure 2.15).
In WT and KG liver, BMY7378 inhibited [^H]-prazosin binding with low affinity to 
produce virtually identical pKi values of 6.3+0.02 and 6.2+0.09 respectively, with 
similar Hill slopes of -1.0 (95% Cl = -1.16 to -0.94) and-0.9 (95% Cl = -1.19 to-0.54) 
respectively, which were not significantly different from negative unity, indicating 
competitive one-site binding (Figure 2.16).
2.3.2.3. Correlations
The correlations for the ligand’s affinities in WT and KG liver and their affinities at 
cloned ai-adrenoceptors are shown in Figures 2.18 and 2.19 respectively. For KG liver 
the high affinity pKi for prazosin was used throughout. All (R)-A-61603 data was 
plotted as pKi values in the presence of GTPyS. As with correlations in brain the 
affinities for A-61603 are for the racemic mixture at the three recombinant subtypes.
In the WT liver the strongest correlation is evident with cloned aib-adrenoceptors, 
which produced an r value of 0.90, whereas there was only a weak correlation with otw- 
adrenoceptors (r = 0.58) and virtually no correlation with aia-adrenoceptors
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Figure 2.16:- Displacem ent o f 0.5nM [^H]-prazosin from 
W T (top)and KO (bottom) liver membranes by increasing 
concentrations o f BMY7378 (lO pM -lm M ). Data points are 
expressed as mean ± s.e.m. (n^3)
WT LIVER
pKi - nH
KO LIVER
pKi - nH
Prazosin (H)
(L)
9.7+0.11 1.0+0.25 9.010.5,
7.010.23
0.5010.08^
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7.410.4,
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(R)-A-61603 +GTPyS 4.2+0.08, 1.1+0.2 8.210.14 0.7510.17
RS100329 7.8+0.02 1.0+0.04 9.310.07 0.8210.1
L765,314 7.6+0.03 1.1+0.07 7.810.1 0.810.14
BMY7378 6.3+0.02 1.010.05 6.210.09 0.910.15
Figure 2.17:- Inhibition affinities in WT and KO liver membranes expressed 
as pKj values ± s.e.m. Hill slopes (nH) are expressed as the negative of 
the hill slope ± s.e.m. (H) = high affinity site and (L) = low affinity site.
* indicates a Hill slope which is significantly different from negative unity.
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Figure 2.18:- Correlation of potencies of ligands used on WT 
liver with published potencies of the same ligands at cloned 
otj-adrenoceptor subtypes. (1):- prazosin, (2):- RS 100329, 
(3):- (R)-A61603, (4):- L765,314 and (5):- BMY7378. 
(Williams et al, 1999, Knepper et al, 1995, Patane et al, 1998 
and Yang et al, 1997). The dotted line shows the line of 
unity.
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Figure 2.19:- Correlation of potencies of ligands used on KO liver 
with published potencies of the same ligands at cloned a^-adrenoceptor 
subtypes. (1):- prazosin, (2):- RS 100329, (3):- (R)-A61603,
(4):- L765,314 and(5):- BMY7378. (Williams et al, 1999,
Knepper et al, 1995, Patane et al, 1998 and Yang et al, 1997).
The dotted line shows the line of unity.
(r = 0.12). The KO liver displayed a different correlation to that of the WT liver by 
showing its strongest correlation with aia-adrenoceptors (r = 0.73) with no correlation 
evident with either aib-adrenoceptors (r = 0.18) or aid-adrenoceptors (r = 0.005).
2.3.3. Preliminary age studies
A chance observation in 3 month old KO mice showed that there are negligible 
ai-adrenoceptors present in KO liver at this age. Saturation studies revealed a B^ax of 
7.4±0.73fmol/mg and a Kd of 1.0±0.27nM (Figure 2.20), compared with livers from 4 
month old KO livers (Figure 2.11) (which were used for the subtyping experiments): as 
previously reported, these had a Bmax of 30±2.0fmol/mg and a Kd of 0.15±0.04nM. The 
Bmax and Kd in 3 month old KO livers was significantly different compared with 4 
month old KO livers. Initially it was thought that this discrepancy in the density of ai- 
adrenoceptors in this tissue was a result of using immature mice. However, when 
saturation studies were performed on livers from 3 month old WT mice the ai- 
adrenoceptor population was found to be present in densities similar to that seen in 
livers from 4month old WT mice. 3 month old WT mice had a Bmax of 76+3.3fmol/mg 
and a Kd of 0.3±0.05nM (Figure 2.20), whilst 4 month old WT mice had a Bmax of 
50±3.1fmol/mg and a Kd 0.3±0.08nM (Figure 2.11). In fact the Bmax from 3 month old 
WT mice is significantly greater (p<0.05) than that from 4 month old WT mice, with the 
Kd remaining the same. Therefore it would appear that this phenomenon seen in the 
liver is unique to the KO mouse.
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Figure 2.20:- Saturation curves showing [^H]-prazosin binding 
(0.025-5nM) in 3 month old WT (top) and KO (bottom) liver 
membranes. WT liver produced a K^ of 0.3±0.05nM and a 
Bmax 76±3.3fmol/mg, whilst KG liver produced a Kj  ^of 
1.0±0.27nM and a Bmax 7.4±0.73fmol/mg Total (■), specific (□) 
and non-specific (O) binding. Each data point is expressed as 
mean ± s.e.m. (n=3 for WT and KO).
2.4. DISCUSSION
Radioligand binding is a popular technique with which to characterise ai-adrenoceptor 
subtypes because it can provide direct measurements of drug-receptor dissociation 
constants that are independent of the character of the drug. Radioligand binding studies, 
using purified plasma membranes, avoid the problems associated when obtaining drug 
affinities in tissues e.g. transport of the drug to its site of action, neuronal or 
extraneuronal uptake of the drug, the drug’s metabolism and desensitisation of the 
response. Therefore radioligand binding may provide the most accurate measurement of 
a drug’s true binding affinity. If an antagonist binds to two groups with different 
affinities this constitutes strong evidence that the receptor populations are different, 
hence radioligand binding becomes a valuable tool with which to identify and 
characterise ai-adrenoceptor subtypes.
Radioligand binding studies were undertaken on plasma membranes isolated from the 
brains and livers of WT and KO mice in order to confirm previous findings that the WT 
brain has a mixture of aiA- and aiB-adrenoceptors (Cavalli et al, 1991 \ Yang et al, 
1998), whilst the WT liver contains aiB-adrenoceptors (Cavalli et al, 1997; Yang et al, 
1998). A further aim was to ascertain if there was a reduced number of receptors in the 
KO tissues as a result of deleting the oci e-adrenoceptor.
2.4.1. Brain
The presence of ai-adrenoceptors in WT and K O  brain was confirmed by saturation 
studies using [^H ]-prazosin. The calculated K d ’s of 0.6nM (WT) and 0.8nM (K O ) are
within the range of Kd values which have been quoted for -prazosin binding to a i- 
adrenoceptors in the brains of rats, mice, pigs and humans (50pM -  2nM) (Han et al, 
1987b; Palacios et al, 1987; Minneman et al, 1988; Oshita et al, 1991; Cavalli et al,
1997 and Wikberg-Matsson et al, 1998). The number of receptors in the KO brain was 
significantly decreased compared with the WT brain (30% reduction). If the WT brain 
does indeed contain a mixed a population of ocia- and aie-adrenoceptors then a 
reduction in ai-adrenoceptor density in the KO brain is to be expected.
When unlabelled prazosin was used to compete with [^H]-prazosin, both WT and KO 
brains exhibited a high affinity site with a pKi greater than 9.0, characteristic of prazosin 
binding to ai-adrenoceptors (Bylund et al, 1994). In addition to this high affinity site 
the KO brain had a second low affinity site, with a pK, of 7.4. The putative aiL- 
adrenoceptor has been defined as having a low affinity for prazosin (Drew, 1985; 
Flavahan and Vanhoutte, 1986; Muramatsu et al, 1990) and although, to date, it has not 
been identified genetically there is an increasing amount of evidence which points to its 
existence functionally (Muramatsu et al 1990; Ford et al, 1997; Van der Graaf et al, 
1997; Daniels et al, 1999), whether it be as a subtype in its own right or as an isoform of 
the aiA-adrenoceptor. Although the affinities obtained for prazosin at the aiL- 
adrenoceptor can sometimes be as low as -8.0 (Kohno et al, 1994; Van der Graaf et al,
1997) it is very rare to see affinities of less than 8.0. Therefore it is unlikely that the low 
affinity site for prazosin observed in the KO brain can be attributed to the aiL- 
adrenoceptor. It seems more likely that the second site represents prazosin binding to 
a 2-adrenoceptors. The initial identification of a 2-adrenoceptor subtypes was based on 
differential affinity for prazosin. The aie- and a 2c-adrenoceptors have relatively high 
affinities for prazosin, whilst the (%2 A- and a 2o-adrenoceptors have relatively low
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affinities for prazosin (Bylund et al, 1994). The affinity of prazosin at the 0 C2B- or a 2c- 
adrenoceptor is approximately 7-7.5 (Bylund et al, 1994), which coiTclates well with the 
second site prazosin identified in the brain.
The aiA-selective antagonist, RS 100329, bound consistently to two sites in the WT 
brain, of high and low affinity. The pKf values of 9.5 and 7,4 are consistent with binding 
to aiA“ and am-adrenoceptors respectively (Williams et al, 1999). The ratio for the two 
sites as a percentage of the total binding was 36%:64% in favour of the lower affinity 
site (aiB). This is similar to the ratios of aia:ocib-adrenoceptors reported by Cavalli et al 
(1997) and Yang et al (1998) (58% and 70% respectively of the total binding was 
attributed to the aiB-adrenoceptor). In the KO brain, where this second low affinity site 
is absent, RS 100329 demonstrates competitive binding to a single high affinity site 
comparable to the high affinity site in the WT brain, representative of the otiA- 
adrenoceptor.
The agonist used in this study, (R)-A-61603, is regarded in the literature as being aiA- 
selective (Knepper et al, 1995; Ford et al, 1997). Experiments were conducted in the 
presence and absence of GTPyS (a non-hydrolysable analogue of GTP). When plasma 
membranes are used the concentration of GTP is limiting. Therefore if an agonist is 
used as a competing ligand without the addition of GTP or a non-hydrolysable analogue 
(such as that used here), two-site binding is more likely to occur. A more detailed 
explanation of this phenomenon is given in the methods section of this chapter. If two- 
site binding is a result of a limiting concentration of GTP, then addition of GTPyS 
should abolish this and only one-site will be detected.
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The WT and KO brain both exhibit two-site binding to (R)-A-61603 of similar affinities 
regardless of whether GTPyS is present. This would suggest that the two-site binding is 
due to the presence of two receptor populations rather than a deficiency of GTP. The 
low affinity site in the WT brain seems likely to be the aiB-adrenoceptor as this 
correlates with the affinity quoted for the racemic mixture of A-61603 at aie/b- 
adrenoceptors (Knepper et al, 1995). The high affinity site of 6.7 although too low to be 
an a i A-adrenoceptor is too high to be an aio-adrenoceptor, if the published pKi values 
are used as a guideline (Knepper et al, 1995). It should be noted here that the present 
study used the R-enantiomer of A-61603, which appears to confer potency at otiA- 
adrenoceptors (Knepper et al, 1995). However its potency at aiB- and aio- 
adrenoceptors has not been determined.
The pKi values in KO brain are also confusing. The low affinity site could be either an 
aiB- or an am-adrenoceptor. However, the a ie -adrenoceptor cannot be present in the 
KO brain because its deletion has been confirmed both by the group who created the 
mouse (Cavalli et al, 1997) and also by our own laboratory (unpublished observations). 
The affinity of A-61603 (the racemic mixture) at aib- and aid-adrenoceptors is similar, 
whilst in tissues it is 10 times more potent at aiB-adrenoceptors than at a ^ -  
adrenoceptors (Knepper et al, 1995). Therefore, the low affinity site is more likely to be 
the aiD-adrenoceptor, whilst the high affinity site is most probably the aiA- 
adrenoceptor, despite its relatively low affinity at this subtype. If this is the case then 
logically the high affinity site in the WT brain is also an ai A-adrenoceptor, due to the 
similar affinity values of these two sites. In WT brain the proportion of the two sites is 
similar to the proportions found with RS 100329, with the low affinity site, likely to be 
the aiB-adrenoceptor, constituting 55% of the total ai-adrenoceptor population. In the
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KO brain this proportion has shifted in favour of the high affinity site, likely to be the 
aiA-adrenoceptor, accounting for 86% of ai-adrenoceptors in the brain. The remaining 
14% could be otiD-adrenoceptors (but see discussion of BMY7378 data). Alternatively it 
could be an experimental observation, for which there is no explanation at this point.
From work in our own laboratory, this unexpected behaviour of (R)-A-61603 does not 
seem to be limited to native ai-adrenoceptors. In cell lines expressing recombinant aia- 
adrenoceptors, (R)-A-61603 has been shown to be unaffected by GTPyS, producing 
biphasic curves whether GTPyS is present or not. However, when phenylephrine was 
used in binding studies, using the same cell line, biphasic curves were produced in the 
absence of GTPyS, becoming monophasic in the presence of GTPyS. It is possible that 
(R)-A-61603 is resistant to the effects of GTPyS or may respond in a different manner 
to that of other agonists, such as phenylephrine, when it is present. This may be related 
to its selectivity at aiA/a-adrenoceptors. (R)-A-61603 has an affinity at aia- 
adrenoceptors that is approximately 30 fold higher than phenylephrine’s affinity at this 
receptor and in tissues expressing aiA-adrenoceptors this selectivity is increased; (R)-A- 
61603 is 160-330 times more potent than phenylephrine. Could the higher affinity and 
selectivity of (R)-A-61603 at aiA/a-adrenoceptors be responsible for its unusual 
behaviour when GTPyS is present?
During my project a new ai-adrenoceptor antagonist, L765, 314, became available to 
me (a kind gift from Dr. Patane at Merck) which had been proposed to be selective for 
the aiB-adrenoceptor (Patane et al, 1998). Binding studies at cloned receptors had 
shown that L765,314 possessed a 10-fold selectivity at the aib-adrenoceptor over the
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aid-adrenoceptor and 100-fold selectivity over the aia-adrenoceptor (Patane et al,
1998). Binding in native tissues expressing either a homogeneous population of aiA- or 
aiB-adrenoceptors i.e. rat prostate and rat spleen showed that L765,314 had 
approximately 50 fold selectivity at aiB-adrenoceptors over aiA-adrenoceptors. 
L765,314’s affinity in tissues expressing ociD-adrenoceptors was not determined (Patane 
et al, 1998). The possibility that a drug had been developed which showed selectivity 
for the aiB-adrenoceptor was exciting because to date there have been no examples of a 
convincingly selective aiB-adrenoceptor antagonist. I hoped that L765,314 would 
highlight a clear distinction between the -adrenoceptor subtypes of WT and KO 
tissues.
In WT and KO brain L765,314 bound competitively to one site. Having only the 
affinity values quoted by Patane et al (1998) for comparison the data would suggest that 
in both WT and KO brain L765,314 is binding to aiA-adrenoceptors. This is not only 
unexpected but is inconsistent with my data using other competitors and with the 
literature. If the WT brain contains a mixture of a,A-and «is-adrenoceptors as has been 
previously proposed (Cavalli et al, 1997; Yang et al, 1998) and if L765,314 is selective 
for the aiB-adrenoceptor then I would have expected L765,314 to either exhibit two-site 
binding in WT brain or to bind selectively to oci B-adrenoceptors producing a pKi similar 
to that reported by Patane et al (1998). However, two-site binding is not apparent in the 
WT brain and the pK, is lower than expected for L765,314 to be acting at Uib- 
adrenoceptors. This could be accounted for if the otiB-adrenoceptor was present in a 
proportionately smaller amount than the ai A-adrenoceptor resulting in the aiA- 
adrenoceptor masking the presence of the aiB-adrenoceptor. However, the results with
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RS100329 and (R)-A-61603 contradict this by showing that the otis-adrenoceptor 
makes up a substantial portion of the ai-adrenoceptors in the WT brain, enough to 
demonstrate two-site binding with aiA-selective ligands. An alternative explanation 
may be that L765,314 is not as selective at the aiB-adrenoceptor as has been proposed 
by Patane et al (1998). When we carried out radioligand binding on all three cloned ai- 
adrenoceptor subtypes using L765,314 as a competitor, no selectivity was observed 
amongst any of the subtypes (Mackenzie, unpublished observations).
The final antagonist used was BMY7378, an am-adrenoceptor antagonist which 
displays nanomolar affinity at the am-adrenoceptor (Kenny et al, 1995; Saussy et al, 
1994; Goetz et al, 1995). BMY7378 bound competitively with low affinity to a single 
site in both WT and KO brains. This low affinity suggests that the aio-adrenoceptor is 
not present in either the WT or KO brain. Although the low affinity site for (R)-A- 
61603 seemed to suggest an aiD-adrenoceptor population, the results with BMY7378 
overrule this because BMY7378 has been more widely characterised with regard its 
affinity values at the three -adrenoceptor subtypes. In addition to this, being an 
antagonist it provides more accurate affinity values without the complications 
associated with using an agonist. With this in mind I was confident that the data 
obtained with BMY7378 provided evidence against the presence of an aio- 
adrenoceptor in either the WT or KO brain. This is consistent with the results of Cavalli 
et al (1997) and Yang et al (1998) who found no evidence for the functional presence of 
the aiD-adrenoceptor in any of the tissues they examined despite the presence of the 
aiD-adrenoceptor mRNA (Cavalli et al, 1997). The low affinity ‘single site’ binding of 
BMY7378 in both WT and KO brains is likely a reflection of BMY7378’s inability to
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distinguish between aiA- and ai B-adrenoceptors and is consistent with its known 
affinity at these receptors (Saussy et al, 1994; Goetz et al, 1995). Thus it binds to otiA- 
adrenoceptors in the KO brain and aiA- and aiB-adrenoceptors in the WT brain with 
similar affinity.
The con'elations for the WT and KO brain show that the WT brain correlates to the 
same extent with aia- and aib-adrenoceptors, indicative of a mixed population whereas 
the KO brain clearly correlates better with the aia-adrenoceptors. The saturation and 
competition studies suggest that there has been an upregulation of the ai A-adrenoceptor 
in the KO brain. The saturation studies reveal that approximately a third of the binding 
appears to be due to aiB-adrenoceptors, whereas the competition studies with RS 100329 
and (R)-A“61603 suggest that approximately 60% of the binding can be attributed to 
aiB-adrenoceptors. Therefore it appears that the brain attempts to compensate for the 
reduction in ai-adrenoceptor density.
Defining the role of ai-adrenoceptors in the central nervous system and in particular the 
brain is problematic due to the problems associated with drugs crossing the blood brain 
barrier and a lack of subtype selective antagonists. The activation of central ai- 
adrenoceptors has been shown to enhance locomotor activity and arousal (Sirvio and 
MacDonald, 1999). However, results obtained from transgenic mice, which either 
overexpress the a%B-adrenoceptor or express a constitutively active form of the receptor, 
contradict the view that central ai-adrenoceptors have a stimulatory effect. Zuscik et al 
(2 0 0 0 ) reported that these mice had a locomotor dysfunction, suffered grand mal-type 
seizures and were subject to neurodegeneration that worsened with age. In the light of
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these findings it would be of interest to examine the central effects of deleting the am- 
adrenoceptor using the KO mice used in this study.
To summarise, these binding studies confirm the presence of a mixed population of aiA- 
and aiB-adrenoceptors in the WT brain with a ratio of 36%:64% respectively and the 
absence of the B-adrenoceptor from the KO brain, which now contains a pure 
population of otia-adrenoceptors. In addition, deletion of the aiB-adrenoceptor from the 
KO brain appears to have unmasked a population of a 2 -adrenoceptors that is not evident 
from binding studies in the WT brain. The possible reasons for this will be discussed in 
more detail in the discussion for the liver results.
2.4.2. Liver
The radioligand binding studies in the brain produced results that were, on the whole, 
anticipated. However results from the liver studies were unexpected. It was predicted 
that the KO liver would not possess an ai-adrenoceptor population and therefore would 
display no specific binding, as a consequence of deleting the aiB-adrenoceptor, the sole 
receptor subtype reported to be present in the murine liver (Cavalli et al, 1997; Yang et 
al, 1998). Cavalli et al (1997) found there to be a 98% decrease in (%i-adrenoceptor 
density in KO livers when compared to WT livers. In contrast to this I discovered that at 
4 months old there was only a 40% decrease in ai-adrenoceptor numbers in KO livers. 
The WT liver had a Bmax of 50fmol/mg, which is identical to that described by Yang et 
al (1998). Cavalli et al reported a Bmax of only 20fmol/mg in WT liver, which decreased 
to a negligible amount of protein in the KO liver. However, in the present study the Bmax 
in the KO liver remained as high as 30fmol/mg. The calculated Kd values in WT and
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KO liver were similar and comparable to those of Cavalli et al (1997) and Yang et al 
(1998). I believe the discrepancy between the results presented here and those published 
by Cavalli et al (1997) are due to methodological differences in the isolation of the 
plasma membranes used for these experiments. Cavalli et al used a centrifugation speed 
of 1 0 , 0 0 0  X g, which is not a sufficiently high enough speed to isolate plasma 
membranes, but will isolate only mitochondrial membranes (Evans, 1990). To isolate 
plasma membranes a centrifugal speed of at least 30,000 x g is required and a speed in 
excess of this was used for the isolation of plasma membranes in my experiments.
Although the presence of ai-adrenoceptors in the KO liver was unexpected, a 
mechanism to compensate for the absence of the aiB-adrenoceptor was not surprising. 
As well as determining the subtype present in the WT liver, an interesting aim of this 
study became the determination of the OC]-adrenoceptor subtype which had ‘replaced’ 
the oci B-adrenoceptor in the KO liver.
When prazosin was used as the unlabelled competitor the WT liver displayed one-site 
binding and the KO liver displayed two-site binding, a similar scenario to that observed 
in the brains of WT and KO mice. The site in the WT liver and the high affinity site in 
the KO liver display pK /s typical of prazosin binding to ai-adrenoceptors (Bylund et 
al, 1994) with similar affinity values to the high affinity sites in the WT and KO brain.
A further analogy with the KO brain and KO liver can be found in the low affinity site 
to prazosin, which appears to represent a 2~adrenoceptors. As was the case in the KO 
brain, a contribution from the putative aiL-adrenoceptor in the KO liver can be ruled out 
as the pKi is too low to be attributed to the aiL-adrenoceptor. However, prazosin has 
been shown to have an affinity of 7-7.5 at the a 2B- and (%2c-adrenoceptor subtypes
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(Bylund et al, 1994) similar to the affinity observed in the KO liver. Saturation studies 
would not identify this lower affinity site found in the KO brain and liver because the 
concentrations of -prazosin used are not high enough to label this population. It is 
possible that this second site is observed only in KO tissues because there is a reduction 
in the density of ai-adrenoceptors which alters the ratio of ai/ocz-adrenoceptors to an 
extent that the a^-adrenoceptor population is uncovered. Alternatively there could be an 
upregulation of oc2 -adrenoceptors in the KO tissues to compensate for the loss of ai- 
adrenoceptors as a result of deletion of the ai B-adrenoceptor.
From the subtype selective antagonists used, the two aiA-selective ligands, RS 100329 
and (R)-A-61603 showed the clearest distinction in affinity values between the WT and 
KO liver, providing evidence that the ai-adrenoceptor population in the KO liver had 
altered. RS 100329 had a low binding affinity in the WT liver, consistent with an ocm- 
adrenoceptor, whilst the [^H]-prazosin binding sites in the KO liver had a 100-fold 
greater affinity for RS 100329 than those in the WT, with a pK; value similar to its 
published pKi values at aiA/a-adrenoceptors (Williams et al, 1999). This 100-fold 
difference in affinity provides good evidence that the ai-adrenoceptor population in the 
KO liver is different from that of the WT liver and suggests that it is the aiA- 
adrenoceptor.
The results with (R)-A-61603, the aiA-selective agonist, appear to consolidate these 
findings. In the presence of GTPyS, (R)-A-61603 is 10,000 times more potent at the ai- 
adrenoceptors in the KO liver than those in the WT liver. The pKi value calculated for 
(R)-A-61603 in the KO liver correlates well with previous reports of its affinity at ociA/a-
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adrenoceptors (Knepper et al, 1995; Ford et al, 1997; Hrometz et al, 1999; Argyle and 
McGrath, 2000; Mackenzie et al, 2000). When GTPyS is not present, (R)-A-61603 still 
displays one-site binding in KO liver to a high affinity site with a similar pKi to that 
when GTPyS is present. A biphasic curve in the absence of GTPyS is not evident. The 
reasons for this are not clear. A possible explanation may be that the ai-adrenoceptor 
subtype in the KO liver is continually in a high affinity state; therefore, the addition of 
GTPyS would make no difference to the binding affinity. Alternatively this may be an 
effect that is related to (R)-A-61603’s selectivity for aiA/a-adrenoceptors (mentioned in 
discussion of brain results). The only situation in which (R)-A-61603, with and without 
GTPyS, behaves as expected is in the WT liver. When GTPyS is absent, high and low 
affinity sites are observed. The high affinity site only accounts for 1% of the total 
binding and is found to disappear when GTPyS is present, suggesting this site is a result 
of a limiting concentration of GTP. The low affinity site in WT liver suggests an am- or 
aiD-adrenoceptor population.
Neither L765,314 nor BMY7378 differentiate between the ai-adrenoceptors of WT and 
KO livers. BMY7378 binds with low affinity to both WT and KO hepatic ai- 
adrenoceptors, the WT pK; being comparable to that reported by Yang et al (1998). The 
calculated pK;’s are similar to the affinity values published for BMY7378 at aiA- and 
aiB-adrenoceptors (Saussy et al, 1994; Goetz et al, 1995). Although it is not possible to 
determine which of these two subtypes BMY7378 is binding to, it is possible to exclude 
aiD-adrenoceptors from being present in either the WT or KO liver. However, there is 
some evidence from experiments carried out by a fellow colleague on isolated 
hepatocytes, that after 24 hours in culture both WT and KO hepatocytes express a%A- 
and aiD-adrenoceptors (Woollhead, PhD thesis, 2001). Therefore, it would seem that
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the liver is capable of expressing all three ai-adrenoceptor subtypes, although the 
triggers which switch each subtype on, remains to be determined. L765,314 produces 
very similar pKi values in both WT and KO liver which are almost identical to the 
affinity values published for L765,314 at aiB-adrenoceptors (Patane et al, 1998). For the 
WT liver this corresponds with the low affinities observed for RS 100329, (R)-A-61603 
and BMY7378 which overall seem to point to a pure population of aiB-adrenoceptors. 
However, the KO liver does not contain oti B-adrenoceptors and the binding data reveals 
that the ai-adrenoceptor pharmacology is more like that of the aiA-adrenoceptor. Again, 
these results call into question the selectivity and validity of L765,314 as an am- 
adrenoceptor antagonist.
When the binding data from all the ligands used in WT and KO livers is analysed, the 
pharmacology confirms previous reports that the WT murine liver contains a pure 
population of ctiB-adrenoceptors, whereas the KO liver appears to contain a pure 
population of aiA-adrenoceptors. The coiTelations in Figures 2.18 and 2.19 show this 
convincingly.
Not only does the oti-adrenoceptor pharmacology of the KO liver point to this 
conclusion, but in theory it seems one of the subtypes would have to ‘replace’ the am- 
adrenoceptor if the liver requires an oti-adrenergic component to function correctly, oti- 
Adrenoceptors are required in the liver for essential functions such as glycogenolysis 
(Schwarz et al, 1984; Ishac et al, 1992; Thai et al, 1996) so if the naturally expressed 
a i-adrenoceptor subtype fails to function then a replacement mechanism must be 
present or these mice would not be viable. The KO mice appear healthy and 
demonstrate no outward signs of abnormalities.
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The ai A-adrenoceptor would be the likely replacement bearing in mind that only a 
handful of native tissues have been shown to functionally express the am-adrenoceptor 
in either mice (Cavalli et al, 1997; Yang et al, 1998) or rats (Yang et al, 1997) despite 
its presence (at least in rats) at the mRNA (Faure et al, 1994; Price et al, 1994a; Rokosh 
et al, 1994; Scofield et al, 1995) and protein (Shen et al, 2000) level. The tissues in 
which the aio-adrenoceptor appears to be functional is mainly blood vessels, namely 
the rat aorta (Kenny et al, 1995; Piascik et al, 1995; Testa et al, 1995b; Piascik et al, 
1997), mouse aorta (Daly et al, unpublished), rat iliac and femoral artery (Piascik et al, 
1995; Piascik et al, 1997), rat carotid artery (Nagadeh, 1996, University of Glasgow, 
PhD thesis) and the mouse carotid artery (see Chapter 3). There is no evidence of the 
aiD-adrenoceptor being functional in liver tissue, not only in mice and rats, but also in 
hamsters, guinea-pigs, rabbits, cats, dogs and humans. Although there is evidence that 
cultured hepatocytes express a% o-adrenoceptors (Woollhead, 2001, University of 
Glasgow, PhD thesis) there is as yet no evidence to show that these receptors are 
functional.
In mice, rats and hamsters the am-subtype is the functional ai-adrenoceptor in the 
livers of these animals, whereas the remaining animals all functionally express the aiA- 
adrenoceptor. This species difference in the subtype of a%-adrenoceptor expressed in the 
liver may be age-related, a suggestion which was alluded to in the introduction to this 
chapter. With the exception of the guinea-pig and rabbit, the animals studied early on in 
their life span i.e. mice, rats and hamsters, all appear to express the am-adrenoceptor. In 
contrast, those species that are studied experimentally at a later point in their life cycle 
i.e. cat, dog and human express the aiA-adrenoceptor.
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The ai B-adrenoceptor has been implicated as being important in the regulation of 
growth. Chen et al (1995) found that stimulation of an am-like adrenoceptor mediated a 
growth-promoting effect, characterised by an increase in cell protein and total RNA. 
Overexpression of the aiB-adrenoceptor has also been shown to cause cardiac 
hypertrophy (Zuscik et al, 2001). In addition, Faber et al (2001) found that 
noradrenaline-stimulated a%-adrenoceptors in cultured adventitial fibroblasts promoted 
proliferation and protein synthesis. Although it was not determined which subtype 
mediated this effect, the ai A-adrenoceptor was not considered to be responsible because 
aiA-adrenoceptor mRNA declined to almost undetectable levels when adventitial 
fibroblasts were cultured. The same group working on balloon injured rat aorta 
discovered that the trophic effects which this insult had on the adventitia could be 
inhibited by an aiB-adrenoceptor antagonist (Zhang and Faber, 2001). If the am- 
adrenoceptor is responsible for growth regulation it seems highly probable that the am- 
adrenoceptor would be functionally present at a young age with its importance 
decreasing over time.
As well as having the capacity to regenerate, the liver is also one of the few organs 
which has been well documented as being capable of altering its balance of ai- and P- 
adrenoceptors with age. In the liver of newborn rats the density of a%-adrenoceptors is 
low and that of P-adrenoceptors high (Rossby and Cornett, 1991). Over a period of 6  
days, from postnatal day 21 to postnatal day 27 the density of a;-adrenoceptors 
increased until they reached a steady state, which was maintained over the 
developmental period studied (birth-90 days). In contrast the number of P-adrenoceptor 
binding sites decreased at postnatal day 6  and remained low throughout the 90 day 
period studied (Rossby and Cornett, 1991). If the rat liver is capable of altering its ai-
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and P~adrenoceptor populations then it is possible that it may also be capable of 
changing the subtype of «i-adrenoceptor expressed. To my knowledge this phenomenon 
has not been reported in the mouse liver. However, I plan to carry out experiments to 
investigate this phenomenon to determine if this change does indeed occur in the murine 
liver.
Preliminary experiments earned out on 3 month old WT and KO livers reveal that the 
Bmax of the WT liver is significantly greater, compared with 4 month old WT livers, 
being respectively, 76fmol/mg and 50fmol/mg. The Kd was unaltered. Interestingly, the 
KO liver at 3 months was found to have virtually no ai-adrenoceptors with a Bmax of 
only 8 fmol/mg compared with the 4 month old livers which had a Bmax of 30fmol/mg 
(p<0.05). In addition to this altered Bmax, the Kd was approximately 10 times higher at 3 
months (Kd = l.OnM) compared with the Kd at 4 months (Kd = 0.15nM) (p<0.05). The 
reasons for this are unclear. These preliminary studies of 3 month old livers demonstrate 
that upregulation of ai-adrenoceptors in the KO liver does not occur prior to birth or 
even in the first few weeks of life (when the switch from p- to cq-adrenoceptors takes 
place in the rat) but it would seem that the majority of this upregulation takes place 
between 3 and 4 months. It is also clear that the ai-adrenoceptors of murine liver are 
capable of changing not only the subtype that is expressed, but also the density of (%r 
adrenoceptors. It is possible that the aie-adrenoceptor is expressed early on in the life of 
WT mice but as these mice age the oci e-adrenoceptor population decreases to be 
replaced with the aiA-adrenoceptor. In the KO liver the a ie -adrenoceptor is already 
absent and so the oti A-adrenoceptor is evident at an earlier age. This may also explain 
why there is a reduced ai-adrenoceptor density in 4 month old WT livers when 
compared with 3 month old WT livers. In order to prove or disprove this hypothesis the
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a i -adrenoceptors in the WT liver at 3 months would have to be characterised and 
subtyped. A further age point at a later stage in the mouse life cycle, e.g. 1 year, would 
also need to be studied, carrying out the same experiments with the same ligands as at 3 
and 4 months.
In conclusion, the binding studies on WT murine brains and livers reveal that they 
express a mixed population of aiA- and aiB-adrenoceptors and a pure population of a ^ -  
adrenoceptors, respectively, confirming previous reports (Cavalli et al, 1997; Yang et 
al, 1998). Binding in KO brain displays the characteristics of a pure population of ctiA- 
adrenoceptors, as does the KO liver. Deletion of the aie-adrenoceptor from the brain 
and liver tissues of KO mice uncovered a putative ag-adrenoceptor population that was 
not detected in the WT tissues examined. The aia-adrenoceptors of the KO liver may 
result from upregulation of this receptor subtype to compensate for the deletion of the 
aiB-adrenoceptor. This upregulation takes place between 3 and 4 months of age because 
at 3 months of age there are virtually no hepatic ai-adrenoceptors present in KO mice. 
Although the purpose of this study was purely to confirm the subtypes present in WT 
brains and livers and to verify the absence of the aiB-adrenoceptor from the equivalent 
KO tissues, some interesting issues have been raised with regard to the regulation of ai- 
adrenoceptor subtypes in the liver. Further study will be necessary to characterise the 
exact nature of this regulation.
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CHAPTER 3 -FUNCTIONAL CHARACTERISATION 
OF THE MURINE CAROTID ARTERY AND 
CLASSIFICATION OF THE ai-ADRENOCEPTOR 
SUBTYPE MEDIATING CONTRACTION TO 
PHENYLEPHRINE IN WTAND KO MURINE 
CAROTID ARTERIES.
3.1. INTRODUCTION
3.1.1. Models using the carotid artery
The carotid artery is commonly used in models of atherosclerosis, angioplasty-induced 
restenosis and vascular injury, as well as being the artery most commonly used for gene 
transfer into blood vessels. The carotid artery lends itself well to studies such as these 
because it can be manipulated with relative ease in an in vivo situation. These models 
have been heavily studied in rats, rabbits and pigs (Wilcox et al, 1996; Shi et al, 1996; 
Ooboshi et al, 1998; Faggin et al, 1999; Gutterman et al, 1999; Oparil et al, 1999). But 
it is only in recent years, with the continuing advances of transgenic technologies, that 
mouse models of these pathological conditions have begun to emerge, as the ability to 
introduce transgenes or to disrupt endogenous gene expression has made the mouse an 
attractive species with which to study the function of specific genes in vascular biology. 
Mice have been developed that are deficient in apolipoprotein E leading to the 
development of a severe form of atherosclerosis, similar to humans (Plump et al, 1992). 
A carotid artery ligation model has been designed in the mouse which results in the 
development of a neointima similar to that seen with restenosis and many other injuries 
to the vasculature (Kumar and Lindner, 1997). The development of these models makes 
it easier to manipulate these pathological conditions at a genetic level and work already 
carried out in rats and rabbits means that the gene targets have already been identified.
Models of atherosclerosis or restenosis have highlighted the complexities of these 
disease processes. Studies have shown that these are multifactorial diseases, and no one 
factor has been implicated as being wholly responsible for their pathogenesis. For
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example, there is indirect evidence to suggest that stimulation of ai-adrenoceptors 
increases smooth muscle cell growth in the growing and adult artery and worsens 
atherosclerosis and restenosis after balloon injury (Xin et al, 1999). Angiotensin IV has 
been demonstrated to have trophic effects, whereby it has been shown to increase DNA 
synthesis and is capable of modulating cellular proliferation and hypertrophy in 
cardiovascular tissues. Following balloon injury in rabbit carotid arteries, AT4 receptors, 
which bind angiotensin IV, were found to increase to 230% of control arteries, 20 
weeks after the balloon injury (Moeller et al, 1999). Atherosclerotic arteries have been 
shown to have impaired relaxant properties, which can be rescued by transfecting nitric 
oxide synthase into the adventitia (Ooboshi et al, 1998).
3.1.2. Pharmacology of the carotid artery
Despite the carotid artery being widely used to study atherosclerosis, restenosis etc. 
very little effort has been focused on its ‘normal’ pharmacology. Any knowledge we 
have has generally been obtained from comparison of control arteries with carotid 
arteries from models such as those described above. This section will concentrate on 
some of the literature that is available about the pharmacology of the carotid artery, with 
the following section concentrating on what is known about the ai-adrenoceptor 
pharmacology of the carotid artery.
Phenylephrine and UK14304 have been shown to contract the rat carotid artery through 
stimulation of (%i- and ctz-adrenoceptors respectively (Nagadeh, 1996, University of 
Glasgow, PhD thesis; Fujimoto and Itoh, 1995). 5-Hydroxytryptamine (5-HT) is also 
capable of producing a contraction, which in rats, has been shown to be inhibited by
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tyrosine kinase inhibitors, suggesting that tyrosine kinase activation may partially 
mediate contractility to 5-HT in arterial smooth muscle (Watts et al, 1996). Angiotensin 
II contracts the rat carotid via the ATi receptor (Caputo et al, 1995; Boulanger et al, 
1995), but it is also capable of relaxing this artery through the same receptor, causing 
the release of nitric oxide, which, in turn, inhibits the contraction mediated by 
angiotensin II (Boulanger et al, 1995). In an in vitro system designed to mimic the in 
situ carotid artery, the rat carotid artery has been shown to release endothelin from 
endothelial cells, in response to stretch. The released endothelin exerts a tonic stiffening 
effect, mediated via ETa receptors (Marano et al, 1999). Vasopressin is capable of 
relaxing the rat carotid artery through Vi receptors as is isoprenaline through a mixture 
of classical (P1/P2 ) and atypical (P3) -adrenoceptors respectively (Rutschmann et al, 
1998; MacDonald et al, 1999).
The rabbit carotid artery can be contracted by endothelin via ETa receptors (Maurice et 
al, 1997) and by 5-HT mediated through 5 -HT2 a receptors (Black et al, 1981). 
Bradykinin is capable of relaxing the rabbit carotid artery but pre-incubation with 
bradykinin is required before the relaxation is evident. Its actions appear to be mediated 
through BKi receptors, which are coupled to the release of endothelium-derived nitric 
oxide (Pruneau and Belichard, 1993).
3.1.3. ai-Adrenoceptor pharmacology of the carotid artery
The subtyping of ai-adrenoceptors in the carotid artery, in comparison with other 
arteries such as the aorta and mesenteric arteries, has not been extensively studied.
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However, a handful of publications have investigated the ai-adrenoceptor subtypes 
mediating vasoconstriction in this artery.
The rabbit carotid artery was initially proposed to contain an aiL-adrenoceptor 
population, based on a low affinity for prazosin (Muramatsu et al, 1990). However, 
when the same group repeated their experiments a year later the rabbit carotid artery 
was found to be biphasically inhibited by prazosin, producing two distinct pKg values 
of high and low affinity, in addition to having low affinity for the aiN-adrenoceptor 
antagonist, HV723. Based on these findings, it appeared that the rabbit carotid artery 
mediated contraction through am- and aiL-adrenoceptors (Muramatsu et al, 1991b).
The aiH-subtype was later characterised to be the aiB-adrenoceptor (Muramatsu et al,
1995).
The dog carotid artery was proposed to contain am-adrenoceptors when it was 
discovered to have high affinity for prazosin (Muramatsu et al, 1990; Muramatsu et al, 
1991b). This am-subtype was later characterised as the am-adrenoceptor, when it was 
shown to have low affinity for the aiA-antagonists, WB4101 and 5-methylurapidil as 
well as having low affinity for HV723, ruling out a contribution from the am-subtype 
(Muramatsu et al, 1991a; Kohno et al, 1994).
The ai-adrenoceptors of the rat carotid artery have been characterised by a number of 
groups as being of the am-subtype. Villalobos-Molina and Ibarra (1996) used WB4101, 
5-methylurapidil and BMY7378 to determine the subtype of ai-adrenoceptor mediating 
contraction in the rat carotid artery. However, they discovered that 5-methylurapidil and 
WB4101 showed similar affinities in all the arteries they looked at (in addition to the
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carotid artery they also studied the aorta, mesenteric and caudal arteries). As a result of 
this they did not use these antagonists to make their conclusions but based them solely 
on the affinity of BMY7378. In the carotid artery BMY7378 produced a pA% of 8.7 
which they concluded was evidence that the ai-adrenoceptors of the rat carotid artery 
were of the otm-subtype (Villalobos-Molina and Ibarra, 1996). Nagadeh (1996) used a 
variety of subtype selective antagonists including BMY7378, WB4101, 5- 
methylurapidil, tamsulosin, prazosin and HV723. 5-Methylurapidil and WB4101 
produced high affinities in the rat carotid artery but the slopes of the Schild plots were 
shallow, indicating possible heterogeneity of receptors. However, the pA] values 
correlated better with affinities for the cloned aid- compared with aia- or aib- 
adrenoceptor clones, which in conjunction with a high affinity for BMY7378 was 
consistent with a functional am-adrenoceptor population. Both Nagadeh (1996) and 
Villalobos-Molina and Ibarro placed a lot of faith in BMY7378 as being a selective 
aiD/d-adrenoceptor antagonist. This is often necessary if any conclusions are to be made 
about which subtype is present in the tissue because more often than not one or two of 
the antagonists will be contradictory to the general trend of the other antagonists used. 
The experimenter then has to make a decision about which antagonists he/she has the 
most faith in.
A study by de Oliveira et al (1998) which was investigating the effects of maturation 
and ageing on the responsiveness of the carotid artery to ai-adrenoceptor stimulation 
reported a high affinity for WB4101 in all ages examined (3, 8 , 17 and 29 weeks) and 
inhibition of the phenylephrine induced contraction by CEC. From this data they 
concluded that the rat carotid artery contained a population of aio-adrenoceptors in 
agreement with Villalobos-Molina and Ibarro (1996) and Nagadeh (1996).
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The a i -adrenoceptor subtype(s) mediating contraction in the mouse carotid artery had 
yet to be discovered and indeed there is still much to be learnt about the pharmacology 
of the mouse. The identification of functional a%-adrenoceptor subtypes can be a 
difficult process due to the limited number of subtype-selective drugs (see Introduction, 
Section 1.3). The am-adrenoceptor KO mouse described by Cavalli et al (1997) 
provides a new approach to tackling this problem. There are no well established am/b- 
adrenoceptor selective drugs that make it possible to definitively identify or rule out the 
am-adrenoceptor from a particular tissue and much of the confusion of subtyping ai- 
adrenoceptors arises from this problem. The am-adrenoceptor KO mouse has the 
advantage in that the am-adrenoceptor can be immediately excluded as a possible 
contributor to the functional response. This simplifies the situation to two subtypes for 
which there are well established selective antagonists and in theory should make the ai- 
adrenoceptor subtyping of tissues a less daunting task.
The aim of this study was to use the am-adrenoceptor KO mouse along with its WT 
counterpart to subtype the ai-adrenoceptors mediating phenylephrine-induced 
contraction in the carotid arteries of these mice. As mentioned at the start of this 
introduction, the carotid artery is commonly used in models of atherosclerosis, 
angioplasty-induced restenosis and vascular injury, ai-Adrenoceptors have been 
implicated in these pathophysiological conditions. Therefore, it is of interest to know 
which a;-adrenoceptor subtypes are functional in this artery and contributing to 
contraction. Cavalli et al (1997) have suggested a role for the am-adrenoceptor in the 
maintenance of vascular tone using the am-adrenoceptor KO mouse. They 
demonstrated a decreased response to phenylephrine in the isolated aorta of KO mice, as
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well as a decreased pressor response in vivo. By using the KO mouse this should allow 
the contribution of the otie-adrenoceptor to vasoconstriction in the murine carotid artery 
(and its contribution to the regulation of blood pressure) to be elucidated.
In addition to determining the identity of the ai-adrenoceptor population responsible for 
vasoconstriction of the murine carotid artery, this study will also undertake a 
preliminary investigation of the general pharmacology of the WT carotid artery, similar 
to that which was published during the course of my project for the mouse aorta 
(Russell and Watts, 2000). This will enhance our knowledge and understanding of 
murine pharmacology, which is imperative if we are to understand the consequences of 
their genetic manipulation.
Towards the end of my project, two additional strains of mice became available to me, 
which overexpressed either the WT or a constitutively active form of the am- 
adrenoceptor. Preliminary cardiovascular studies on these mice revealed that they were 
hypotensive (Zuscik et al, 2001). A final aim of this section of my thesis was to 
investigate the sensitivity of the carotid and mesenteric arteries of these mice to 
phenylephrine. The carotid artery was chosen to follow up on my work in WT and KO 
carotid arteries. The mesenteric artery was chosen, because, being a resistance vessel, it 
was hoped that if the am-adrenoceptor had a role in the control of blood pressure, this 
would be evident in differing sensitivities to phenylephrine in the mesenteric arteries 
from the different strains of mice. The results from the mesenteric artery have been 
published in Journal of Biological Chemistry; Zuscik et al, 2001; 276(17): 13738-13743.
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3.2 METHODS
3.2.1 Solutions and drugs used
The Krebs-Hensleit solution used as the physiological salt solution in which all 
experiments were carried out was of the following composition (mM): NaCl (112), KCl 
(5.9), MgCl2 (1.2), CaCl2 (2), NaHCOa (25), NaHP0 4  (1.2), glucose (11.5) and 
Na2EDTA (0.023).
The following compounds were used:-
(R)-A-61603 (Abbott laboratories, gift of Dr. Hancock), L-arterenol (noradrenaline. 
Sigma), acetylcholine hydrochloride (Sigma), angiotensin II (Sigma), BMY7378 
(dihydrochloride 8-[2-[4-(2-methoxyphenyl)-l-piperozynl]ethyl]-8- 
azaspiro(4,5}decone-7,9-dione, Research Biochemicals International) endothelin 
(Scientific Marketing Association), histamine (Sigma), 5-hydroxytryptamine (Sigma), 
isoprenaline (Sigma), L765,314 (4-amino-2-[4-[l-(benzyloxycarbonyl)-2-(S)-[[(l,l 
dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline, Merck and 
Company, a gift of Dr. Patane), L-NAME (N^-nitro-L-arginine methyl ester 
hydrochloride. Sigma) 5-methylurapidil (Research Biochemicals International), 
phenylephrine hydrochloride (Sigma), Prazosin hydrochloride (Sigma), UK14304 
(Research Biochemicals International), vasopressin (Blood Pressure Unit, University of 
Glasgow).
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3.2.2 Animals used and set-up procedure
Wildtype and knockout male C57-Black mice were obtained from the Central Research 
Facility at the University of Glasgow. Control, over-expressed and constitutively active 
CBA mice were obtained from the Royal Infirmary. All mice were killed by lethal 
overdose of carbon dioxide. The common carotid arteries were removed from all mice 
and dissected free of connective tissue with the aid of a dissecting microscope. The 
mesentery was removed from control, over-expressed and constitutively active mice 
only. First order mesenteric arteries were isolated and dissected using a microscope to 
ensure as little connective tissue remained attached to the vessel as possible. All WT 
and KO mice were used at a similar age (-16 weeks) and weight (30-40g). Control, 
over-expressed and constitutively active mice were -  60 weeks of age and -  40-50g in 
weight.
Experiments were carried out in a four chamber Mulvany Halpem wire myograph (J.P. 
Trading. Aarhus, Denmark.) (Mulvany and Halpem, 1976). Arteries were cut into 
approximately 2mm lengths and mounted on two 40p,m wires. One wire was attached to 
a fixed head while the other was attached to a head connected to a force transducer. The 
force transducer was in turn connected to a Linseis 4 channel pen recorder to allow 
recordings of the force achieved.
3.2.3 Determination of optimal resting tension
In order to determine the optimal resting tension for the murine carotid artery, arterial 
strips were placed under a tension of 83mg (equivalent to 5 small boxes on a Linseis 4
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channel pen recorder) and allowed to equilibrate for 30 minutes. After this equilibration 
period the tissues were challenged with a near maximal concentration of phenylephrine 
(lOpM) and the active force generated was recorded. This was repeated until 
reproducible responses of similar magnitude were achieved with 10 minute rest 
intervals between challenges with phenylephrine. This usually required 3 challenges 
with phenylephrine at each tension. Once a reproducible response had been obtained the 
passive tension was increased. This process was repeated several times over a tension 
range of 83-500mg in order to allow for the generation of a passive-active tension 
curve. This type of experiment has previously been carried out in rat carotid artery 
where a resting tension of 2500-3000mg was found to be optimal (Nagadeh, PhD thesis,
1996). For the mouse carotid artery the optimal tension was deemed to be 250mg 
(Figure 3.1). Chataigneau et al (1999) found the optimal tension to be approximately the 
same in their studies using the murine carotid artery. For all subsequent experiments the 
vessels were stretched to a resting tension of 250mg.
The optimal resting tension of the mesenteric arteries of the mouse has been previously 
shown by our laboratory to be 170mg (internal diameter -200|Lim) (M^Gee, unpublished 
observations) and all mesenteric arteries were placed under this tension for all 
experiments.
3.2.4 Start-up procedure
Vessels were allowed to equilibrate in Krebs (37°C and gassed with 95% O2 , 5% CO2) 
for 15 minutes after which 250mg (carotid) or 170mg (mesenteric) of tension was 
placed on each artery. Arteries were allowed to equilibrate at this tension for 30-45
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Figure 3.1:- Tension development curves of the effect of passive 
tension on the active contractile force of the mouse isolated common 
carotid artery in response to lOpM PE. Only WT vessels were used 
to determine the optimum tension under which to place the vessels for 
all subsequent experiments, which was determined to be 250mg. It was 
deemed that this tension produced a near maximum response without 
putting the arteries under any undue stress (n = 11).
minutes and were washed with Krebs every 15 minutes. Prior to the start of each 
experiment vessels were challenged with a sensitising concentration of phenylephrine 
(3xlO'^M). This concentration was chosen because it is approximately equal to the EC50  
of phenylephrine in carotid arteries (see Results, Section 3.3.1). When the contraction 
had reached a plateau (usually after 3-5minutes) the vessels were washed until the tone 
had returned to baseline. This sensitising procedure was repeated until a reproducible 
response was maintained, with 10-15 minute rest intervals between concentrations. This 
served to confiiTn that vessels were functional and it was found that following this there 
was good reproducibility of up to 4 concentration response curves. On occasions when 
this was not carried out there was a tendency for the tension developed in the vessels to 
increase in magnitude with each curve and so this procedure was always performed at 
the start of each experiment.
3.2.5. Agonist profiles
To ascertain the contribution of a i- and a 2-adrenoceptors to vasoconstriction in the 
murine carotid artery, agonist profiles were performed using a selection of adrenoceptor 
agonists with varying selectivities. Noradrenaline (InM - 100|LiM) was used since it is 
the endogenous agonist and will act via ai- and ai-adrenoceptors, phenylephrine (InM 
-  ImM) was used in its capacity as a selective ai-agonist, UK14304 (InM - 30pM) as a 
selective (%2 -agonist and (R)-A-61603 (InM - 100p,M) as an aiA-selective agonist. In 
addition, agonists were used which act on several important vasoactive systems to 
determine not just the a-adrenergic properties of this artery but also to investigate its 
general phaimacological properties. It should be noted that this was not meant to be an 
exhaustive study, in terms of investigating substances that can alter the tone of the
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carotid artery, but rather was to serve as a starting point from which further studies 
could be undertaken, dependent on the results presented here. The agonists used for this 
purpose and the concentration range in which they were tested were as follows. 
Isoprenaline (InM - 30qM), acetylcholine (InM - 30pM), vasopressin (O.lpM -  
300nM), endothelin (O.lpM -  300nM), histamine (InM - 30qM), adenosine tris 
phosphate (ATP) (InM - 30qM), bradykinin (InM - 30qM), angiotensin II (lOpM - 
IqM) and 5-HT (InM -  30qM). The ability of each of these agonists to produce a 
contraction in murine carotid arteries was tested and in addition to this several of the 
agonists were tested for relaxant properties in carotid arteries. These were UK14304, 
acetylcholine, isoprenaline, histamine, bradykinin and ATP. The concentrations used 
were the same as when testing these agonists for their contractile properties.
4-8 vessels were set up in parallel, as described previously and after the start-up 
procedure were allowed a 30 minute recovery period before the experiment started and 
between subsequent concentration response curves. Cumulative CRC were constructed 
using half-log increments. The CRC were repeated a total of 3 times in each vessel with 
a different agonist being used each time.
For relaxant agents the arteries were initially contracted with lOqM phenylephrine and 
the contraction was allowed to reach a plateau for approximately 10 minutes before the 
concentration response curve (CRC) was carried out to ensure that the contraction 
would be maintained throughout the experiment and that any relaxation was purely as a 
result of the compounds being tested. If relaxation was produced by any of the agonists 
the concentration response curve was repeated in the presence of lOOqM L-NAME.
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3.2.6. Antagonist profiles
As for agonist profiles, 4-8 vessels were set up in parallel and each vessel was randomly 
assigned to a competitive antagonist or designated as the time control. The time control 
serves to demonstrate the effect of time (if there is any) on the response from the blood 
vessels. An initial cumulative CRC was carried out to phenylephrine (InM -  ImM) 
increasing in half-log increments, after which the vessels were washed and allowed to 
return to the baseline. Only when the vessels were at their resting tension were 
antagonists added to the bath and left for 30 minutes, after which time it was deemed 
that the antagonist would have reached equilibrium. A total of 4 CRC were carried out 
in each vessel:- a control CRC followed by three CRC carried out in the presence of 
increasing concentrations of antagonist. The antagonists, their ai-adrenoceptor subtype 
selectivity and the concentrations used were as follows:- Prazosin (non-selective, InM, 
lOnM and lOOnM), 5-methylurapidil (aiA-selective, 0.1 qM, 0.3qM and IqM), L- 
765,314 (aiB-selective, lOnM, lOOnM and l|iM ) and BMY7378 (am-selective, InM, 
lOnM and lOOnM).
3.2.7. Control, over-expressed and constitutively active mice -  carotid and 
mesenteric artery - Sensitivity to PE
A single CRC to phenylephrine was carried out (InM -  lOOqM) in carotid and 
mesenteric arteries of control, over-expressed and constitutively active mice, to 
determine the effect, if any, of the genetic manipulation of the aiB-adrenoceptor.
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3.2.8. Data Analysis
3.2.8.1 Agonist studies
3.2.8.1.1 Contractile agents
All agonist data obtained from WT and KO mice as well as from CB A control, 
overexpressed and constitutively active mice was analysed by the same method. 
Responses to agonists were expressed as developed tension in grams and were either 
plotted as such, as a percentage of their own maximum response or as a percentage of 
the maximum phenylephrine contraction. All data from CRC was curve fitted using 
GraphPad Prism 3.01 (San Diego, California, USA) using an equation which describes a 
one-site sigmoidal dose response curve of variable slope, with the exception of data 
from noradrenaline CRC (see below). This equation calculates the maximum response, 
pECso and the Hill slope of the curve as determined by the following equation:-
[Also"” + [A]"”
where: - E = response, a  = maximum response, [A] = concentration of agonist, [A] 50 = 
concentration of agonist which produces an effect that is 50% of the maximum response 
(a) and nH = Hill coefficient.
The mean data from noradrenaline CRC did not fit satisfactorily to the equation used for 
all other CRC but instead non-linear regression was carried out using a 2-site model 
described by the following equation:-
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Where:- E, [A] 50 and nH are as before and X = logarithm to the base 10 of the agonist 
concentration. Numbers 1 and 2 denote the two sites. This equation was first described 
by Furchgott (1981) and further developed by Lemoine and Kaumann (1983) and 
Kenakin (1992) and has been previously used by a colleague in this laboratory, Dr.
Sally Argyle. It was with her assistance that the equation was programmed into 
GraphPad Prism for use in this section of my thesis, for which I am very grateful.
The mean of the raw data was calculated and data expressed as mean ± s.e.m. This data 
was plotted in logarithmic space and the best fit curve superimposed onto the data. 
Statistical analysis in the form of an unpaired t test was performed on the pECso’s, Hill 
slopes and the maximum response to determine significant differences between the 
responses of WT and KO carotid arteries to agonists. A p value of less than 0.05 was 
considered to be significant.
3.2.8.1.2 Relaxant agents
Data from relaxant agents was analysed in the same way as for the contractile agents but 
was expressed differently, as a percentage relaxation.
3.2.8.2 Antagonist studies
The data from the antagonist studies was expressed as a percentage of the maximum 
response of the first CRC. As with agonist studies the data was curve fitted using 
GraphPad Prism 3.01 using an equation describing a sigmoidal dose response curve of 
variable slope. The pEC^o value and the Hill slope (as calculated by GraphPad Prism
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3.01) and the maximum response of each CRC in both WT and KO tissue was analysed 
using a two-way ANOVA. This method of statistical analysis allows for the effect of the 
antagonist on the response and the effect of the mouse type (i.e. either WT or KO) on 
the response to be analysed. If the antagonist was shown to produce a significant effect 
on the response then a one-way ANOVA followed by a Bonferroni post test was also 
carried out which allows for analysis of the CRC at each concentration of antagonist. It 
was necessary to perform one-way ANOVA on WT and KO data separately because, 
although two-way ANOVA will determine if the effect of the antagonist on the response 
is significant, it doesn’t provide any information on the individual CRC at each 
concentration of antagonist. Therefore performing a one-way ANOVA allows for a 
direct comparison of the CRC in the presence of the antagonist with the control CRC, 
thus enabling identification of the concentration(s) of antagonist at which the effect was 
significant.
The aim of the antagonist studies was to determine the affinities of the various 
antagonists in WT and KO carotid arteries. This was determined by Schild regression 
(Arunlakshana and Schild, 1959). From this regression a pA% or pKs value can be 
derived which allows the potency of a given antagonist to be quantified. The definitions 
and circumstances of use for these values will be described shortly.
In order to carry out Schild regression, a range of 3 concentrations was employed for 
each antagonist studied. Dose ratios (DR) were calculated for each concentration of 
antagonist. The dose ratio is the ratio of the EC50 in the presence and absence of the 
antagonist. The E C 5 0  values were derived from the curve fitting procedure for individual 
experiments.
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A Schild plot was constructed using these DR values, by plotting log (DR-1) against the 
log of the antagonist concentration and linear regression was performed through the 
points. The X-intercept of this linear regression line is equal to the pA2 value. In order 
for Schild regression to be an accurate measure of antagonist potency certain criteria 
have to be met. Firstly equilibrium conditions must be met before any measurements are 
made, if not then an underestimation of the antagonist potency would result. A range of 
antagonist concentrations must be used and finally increasing concentrations of the 
antagonist must produce parallel dextral displacement of the control curve without a 
decrease in the maximal response (Kenakin, 1982; Arunlakshana and Schild, 1959). 
Therefore all CRCs were expressed as a percentage of the maximum response of the 
control curve before Schild regression was carried out.
The pA2 value, as calculated by linear regression, is defined as the negative logarithm to 
the base 10 of the molar concentration of antagonist that makes it necessary to double 
the concentration of agonist needed to elicit the original response (Schild, 1947). It is an 
empirical measure of the activity of an antagonist that is not dependent on how the 
antagonist acts (Jenkinson et al, 1995). The pA2 value is calculated from the Schild plot 
where the slope of the line does not have to be constrained to unity. The pKg is the 
negative logarithm to the base 10 of the equilibrium dissociation constant of the 
antagonist. It is calculated from the Schild equation (Arunlakshana and Schild, 1959; 
Jenkinson et al, 1995) which constrains the slope of the line to 1.
pKfi = log (DR-1) - log[B]
1 2 1
[B] = concentration of antagonist and Kb = equilibrium dissociation constant of 
antagonist. The pA2 and pKb values only coincide if the requirements for Schild 
regression are met and if the slope of the line is exactly equal to unity (Jenkinson et al, 
1995). In some instances the slope of the Schild plot was significantly less than one or 
the antagonist produced a depression in the maximum response. Therefore, it was 
decided to calculate pKs values, in addition to pA2 values, for eaeh antagonist using the 
above equation. The primary objective was to shed some light on the affinities of the 
antagonists that produced shallow slopes.
An unpaired t test was performed on all pA2 values to determine significant differences 
between WT and KO carotid arteries. A p value of less than 0.05 was considered 
significant.
1 2 2
3.3. RESULTS
3.3.1. Agonist profiles
3.3.1.1. Contractile agents
Experiments were performed in the absence of any blocking agents. Out of 13 
contractile agents tested for activity in WT and KO murine carotid arteries only 4 of 
these had the ability to produce a contraction. These were phenylephrine (Figure 3.2), 
noradrenaline (Figure 3.3), (R)-A-61603 (Figure 3.4) and 5-HT (Figure 3.5). 
Noradrenaline was found to produce a biphasic curve in both WT and KO carotid 
arteries. Figure 3.6 compares the concentration response curves for phenylephrine, 
noradrenaline, (R)-A-61603 and 5-HT expressed as a percentage of the maximum 
phenylephrine contraction. The remaining 9 agonists were shown to be ineffective as 
contractile agents. These were UK14304, isoprenaline, vasopressin, endothelin, 
angiotensin II, acetylcholine, ATP, histamine and bradykinin.
The pECso values produced by the agonists that elicited a response were - 
Noradrenaline:-?.97±0.04 and 5.12+0.04 (n=10). Phenylephrine:- 6.31 ± 0.06 (n=26), 
(R)-A61603:- 6.90 ± 0.09 (n=10) and 5-HT:- 6.88 ± 0.08 (n=9) in WT carotid arteries 
and the corresponding values in KO carotid arteries were -  Noradrenaline:- 7.80+0.02 
and 5.58+0.05 (n=7). Phenylephrine:- 6.95 ± 0.22 (n=24), (R)-A-61603:- 6.71 ± 0.08 
(n= ll) and 5-HT:- 6.77 ± 0.04 (n=6). Phenylephrine was the only agonist found to 
produce a significantly different pECso between WT and KO arteries.
The maximum responses obtained by each agonist were - Noradrenaline:- 0.23±0.02g, 
Phenylephrine:- 0.37+0.01g, (R)-A-61603:- 0.27+0.02g and 5-HT:- 0.27±0.04g for WT
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Figure 3.2:- Mean control concentration response data to 
phenylephrine in WT (■) and KO (□) murine carotid arteries 
plotted as tension in grams (top) or as a % of their own maximum 
response (bottom). Mean curves were generated using 
non-linear regression upon which the mean data ± s.e.m. has 
been superimposed. For WT and KG arteries n=26.
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Figure 3.3:- Mean control concentration response data to 
noradrenaline in WT (■) and KO (□) murine carotid arteries 
plotted as tension in grams (top) or as a % of their own maximum 
response (bottom). Mean curves were generated using 
non-linear regression upon which the mean data ± s.e.m. has 
been superimposed. For WT arteries n=8 and for KG arteries 
n=7.
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Figure 3.4:- Mean eontrol eoncentration response data to 
(R)-A-61603 in WT (■) and KO (□) murine carotid arteries 
plotted as tension in grams (top) or as a % of their own 
maximum response (bottom). Mean curves were generated 
using non-linear regression upon which the mean data ± s.e.m. 
has been superimposed. For WT arteries n=10 and for KG 
arteries n= ll.
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Figure 3.5:- Mean control concentration response data to 
5-hydroxytryptamine in WT (■) and KO (□) murine carotid arteries 
plotted as tension in grams (top) or as a % of their own maximum 
response (bottom). Mean curves were generated using 
non-linear regression upon which the mean data ± s.e.m. has 
been superimposed. For WT arteries n=9 and for KG arteries n=6.
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Figure 3.6:- Mean concentration response data for phenylephrine (□), 
noradrenaline (o), (R)-A-61603 (x) and 5-hydroxytryptamine (()) 
in WT (top) and KO (bottom) carotid arteries expressed as a percentage 
of the maximum contraction to phenylephrine. Mean curves were 
generated using non-linear regression upon which the mean data ± s.e.m. 
has been superimposed.
Agonist pECso Maximum 
response(g)
Hill slope
NA 7.97+0.04
5.12+0.05
0.23+0.02 1.27 (0.83-1.7) 
1.47 (0.87-2.1)
PE 6.31+0.06 0.37+0.01 0.50 (0.41-0.59/
(R)-A-61603 6.90+0.09 0.27+0.02 0.66 (0.43-0.88/
5-HT 6.88+0.08 0.27+0.04 1.2 (0.6-1.7)
Agonist pECgo Maximum 
response(g)
Hill slope
NA 7.80+0.02
5.58+0.05
0.33+0.05 1.7(1.3-2.0/ 
1.25(0.69-1.80)
PE 6.95+0.22 0.34+0.01 0.41 (0.24-0.59/
(R)-A-61603 6.71+0.08 0.28+0.02 0.59 (0.43-0.74/
5-HT 6.77+0.04 0.27+0.05 1.35 (0.94-1.70)
Figure 3.7:- Comparison of pEC^g values, maximum responses and Hill slopes for 
agonists producing contractions in WT (top) and KO (bottom) mouse carotid arteries.
The pECjo values and maximum responses are given as mean ± s.e.m. and the hill 
slopes are given along with their 95% confidence intervals. * indicates p<0.05 compared to 
WT and  ^indicates a Hill slope significantly different from unity.
carotid arteries and in KO carotid arteries the maximum responses achieved were -  
Noradrenaline:-0.33±0.05g, Phenylephrine:- 0.34±0.01g, (R)-A-61603:- 0.28±0.02g and 
5-HT:- 0.27±0.05g. There was no significant difference in the maximum response 
between WT and KO carotid arteries for any of the agonists tested.
In both WT and KO carotid arteries only 5-HT exhibited binding to a single site of 
receptors producing Hill slopes of 1.2 (95% Cl = 0.6-1.7) and 1.35 (95% Cl = 0.94-1.7) 
respectively, which were not significantly different from unity. The adrenergic agonist, 
phenylephrine, demonstrated shallow Hill slopes of 0.50 (95% Cl = 0.41-0.59) and 0.41 
(95% Cl = 0.24-0.59) in WT and KO carotid arteries respectively which were 
significantly different from unity. (R)-A-61603 was found to produce Hill slopes of 
0.66 (95% Cl = 0.43-0.88) and 0.59 (95% Cl = 0.43-0.74) in WT and KO carotid 
arteries respectively. As with phenylephrine these Hill slopes were significantly 
different from unity.
The pECso’s, maximum responses and Hill slopes are presented in tabular form, see 
figure 3.7.
3.3.1.2 Relaxant agents
Of the 6 agonists tested for their ability to relax the mouse isolated carotid artery, only 3 
were found to be able to produce a relaxation. These were acetylcholine, isoprenaline 
and UK14304 (Figure 3.8). Acetylcholine was capable of relaxing the contraction to 
phenylephrine by 76.5+0.99% with a pECgo of 7.6+0.1. Isoprenaline was able to relax 
the tissue to a similar extent to acetylcholine (74.0+7.7%) but with a lower affinity of
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Figure 3.8:- Mean relaxation curves in the isolated mouse 
carotid artery to acetylcholine (□), isoprenaline (O) and 
UK14304 (^). Mean curves were generated using non linear 
regression upon which the mean data ± s.e.m has been superimposed. 
Acetylcholine (n=6), UK14304 (n=10) and isoprenaline (n=7). 
Relaxation curves were only performed in WT carotid arteries.
Agonist Pre contraction 
to lOpM PE (g)
pECso Maximum 
relaxation (%)
Hill slope
Acetylcholine 0.63+0.11 7.6+0.04 76.5+0.99 1.2(0.88-1.5)
UK14304 0.55+0.08 6.0±0.1 51.5+9.3 0.87 (0.51-1.23)
Isoprenaline 0.52+0.06 6.5±0.07 72.7±13.7 0.99(0.63-1.34)
Figure 3.9:- Comparison of pEC^Q values, maximum % relaxation and Hill slopes for 
agonists producing relaxation in WT mouse carotid arteries. The levels of pre contraction 
to PE ± s.e.m. are also given. The pEC^Q values and maximum % relaxations are given as mean 
± s.e.m. and the Hill slopes are given along with their 95% confidence intervals.
 ^indicates a Hill slope significantly different from unity.
6.9+0.1 and UK14304 produced a maximum relaxation of 63.6+7.7% with less potency 
than that of acetylcholine or isoprenaline (pECso = 6.1+0.1). Again these results are 
presented in tabular form, see figure 3.9. The relaxation produced by these agents was 
blocked by the nitric oxide synthase inhibitor, L-NAME.
3.3.2 Antagonist profiles
Time control CRC were carried out to ascertain that the CRC to phenylephrine was 
unaffected by time and that the observed effects were a consequence of the antagonist 
and not due to a deterioration in the vessel’s functionality over time. All parameters i.e. 
maximum response, pECso and Hill slope remained the same throughout each 
experiment with no significant differences observed (Figure 3.10).
In the presence of increasing concentrations of prazosin the phenylephrine CRC of both 
WT and KO carotid arteries (Figure 3.11) were displaced to the right with a significant 
decrease in the maximum response but from the Bonferroni post test carried out after 
the one-way ANOVA this decreased maximum was found to occur at only the highest 
concentrations of prazosin used (lOOnM). One-way ANOVA (followed by a BonfeiToni 
post test) of the pECso values in the presence of prazosin were significantly different 
from control values at lOnM and lOOnM prazosin in WT arteries, whereas in KO 
arteries there was a significant difference in the pECso values at all concentrations of 
prazosin used when compared with the control CRC. Two-way ANOVA of the pECso’s 
obtained in WT and KO arteries revealed that there was a significant difference in the 
pECso values between the strains of mice. The Hill slopes from the WT carotid arteries 
in the presence of prazosin were found to be significantly different from control Hill
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Figure 3.10:- M ean concentration response data for time 
controls to phenylephrine in W T (top) and KO (bottom) 
m urine carotid arteries, curve (□ ), 2 "  ^curve (x ),
3 rd cijrve (^) and 4^ *^  curve (o). M ean curves were generated using 
non-linear regression upon which the mean data ± s.e.m. has 
been superimposed. For W T arteries n^7 and for KO arteries n=9.
slopes. A post test revealed that this was due to a steepening of the curve at lOOnM 
which was not observed at any other concentration. In KO carotid arteries the situation 
was slightly different. The Hill slopes were again found to be significantly different 
from control values. In this case it was due to a steepening of the CRC at lOnM and 
lOOnM and as a result of this two-way ANOVA revealed that the WT and KO Hill 
slopes when compared directly were significantly different. Schild regression of the WT 
data produced a pA% value of 9.6 for prazosin with a slope of 0.93 (95% Cl = 0.77-1.08) 
whilst the KO data produced a significantly higher pA2 of 10.3 (p<0,05) but with a 
similar slope factor of 0.92 (95% Cl = 0.68-1.2) (Figure 3.15). The calculated pKe’s in 
the WT were 9.6±0.1 (InM), 9.5+0.1 (lOnM) and 9.4+0.1 (lOOnM) and in the KO were 
10.1+0.2 (InM), 10.2+0.2 (lOnM) and 10.0+0.1 (lOOnM) (Figure 3.20). These values 
are similar to the pA% values calculated for prazosin in WT and KO carotid arteries and 
as such the KO pKs values were found to be significantly different from WT values at 
all concentrations of prazosin.
5-Methylurapidil in increasing concentrations produced a rightward shift of the 
phenylephrine CRC with no decrease in the maximum response for either WT or KO 
carotid arteries (Figure 3.12). When the pECso values were analysed, using one-way 
ANOVA, significant differences were revealed for all concentrations of 5- 
methylurapidil, when compared with control values. This was true for both WT and KO 
arteries. However when WT and KO pECso values were compared using a two-way 
ANOVA no significant difference was observed. The Hill slopes for WT and KO 
carotid arteries when analysed separately revealed a significant difference to control 
values, which a post test revealed was due to an increased Hill slope at concentrations of 
0.3pM and IjuM in WT arteries but only an increased Hill slope at IpM 5-
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methylurapidil in KO arteries. This difference in Hill slopes did not caiTy over into a 
direct difference between WT and KO carotid arteries because when a two-way 
ANOVA was carried out no significance was observed. Overall there were no 
significant differences in the maximum responses, pECso’s or Hill slopes in WT and KO 
arteries with 5-methylurapidil. This is reflected in the similar pA% values calculated for 
5-methylurapidil in WT and KO arteries. The WT yielded a value of 7.5 and the KO a 
value of 7.6. The slopes for both were found to be identical and were not significantly 
different from unity (a slope of 1.1 for both WT and KO with 95% Cl of 0.73 -  1.5 for 
WT and 0.77 -  1.5 for KO) (Figure 3.16). The pKg values calculated for 5- 
methylurapidil in the WT carotid artery were 7.6+0.1 (0.1 pM), 7.7+0.1 (0.3pM) and 
7.7+0.2 (IpM ) and in the KO carotid artery were 7.8+0.1 (0.1 pM), 8.0+0.1 (0.3pM) and 
7.9+0.1 (IpM) (Figure 3.20). These values are similar to the pAg values calculated for 
5-methylurapidil in WT and KO carotid arteries and no significant differences were 
observed in these values between WT and KO.
L765,314 produced a rightward displacement of the phenylephrine CRC in both WT 
and KO carotid arteries without a decrease in the maximum response (Figure 3.13). 
Following one-way ANOVA the pECso values in the presence of L765,314 were found 
to be significantly different from control pECso’s, in both WT and KO carotid arteries, 
which a post test revealed was due to the highest concentration of antagonist used 
(IpM). The Hill slopes for both arteries were not found to change significantly from 
control values at any of the L765,314 concentrations used. Two-way ANOVA of the 
maximum response, pECso and Hill slope data from WT and KO arteries was not found 
to be significantly different indicating that there is no difference in these parameters 
between WT and KO mice. However, this was not reflected in the pA2 values and slope
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parameters calculated, which were quite different. The WT carotid artery had a pA% of 
9.0 and a slope which was significantly different from unity (0.65, 95% Cl = 0.4-0.9), 
whereas KO arteries were found to produce a pAg of 8.3 and a slope of 0.79 (95% Cl = 
0.46-1.1) which was not significantly different from unity (Figure 3.17). As a result of 
the shallow Schild slope calculated for L765,314 in the WT, pKs values were calculated 
for WT and KO carotid arteries at the three concentrations of L765,314, in the hope that 
this would provide a further insight into its affinity in these arteries. For the WT carotid 
artery the pKe’s calculated were 8.6+0.09 (lOnM), 8.4+0.15 (lOOnM) and 7.9+0.17 
(IpM) and for the KO carotid artery were 8.3+0.12 (lOnM), 7.9+0.15 (lOOnM) and 
7.9+0.26 (IpM) (Figure 3.20). The pKb’s calculated at lOOnM L765,314 were found to 
be significantly different between WT and KO carotid arteries (p<0.05).
As with all other antagonists, BMY7378 shifted the CRC to phenylephrine to the right 
in a concentration-dependent manner (Figure 3.14). One-way ANOVA revealed that the 
maximum response achieved at all concentrations of BMY7378 in both WT and KO 
vessels was unchanged from the maximum response of the control CRC. However, the 
pECso values were significantly altered from control values in WT and KO arteries. In 
WT carotid arteries this was due to a significant difference between the control pECso 
and the pECso at lOOnM BMY7378. This was also the case in KO carotid arteries. In 
addition, there was a significant difference between the pECso from the control CRC 
and the pECso at lOnM BMY7378. When a direct comparison of the pECgo values for 
WT and KO arteries was made using a two-way ANOVA there was found to be a 
significant difference between mice. The Hill slopes in the presence of BMY7378 were 
significantly different from the control Hill slope when analysed separately using a one­
way ANOVA and significantly different between mice, when directly compared using a
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two-way ANOVA. When Schild regression was carried out, WT carotid arteries 
produced a pA% value of 9.7 with a shallow slope of 0.44, which was significantly 
different from unity (95% Cl -  0.27-0.6). KO arteries produced a similar pA% of 9.6. 
However the slope calculated was 0.9, which was not significantly different from unity 
(95% Cl = 0.66-1.1) (Figure 3.18). pKs’s were calculated for WT and KO carotid 
arteries at the three concentrations of BMY7378 for the same reasons as L765,314. For 
the WT carotid artery the calculated pKs’s were 9.5+0.12 (InM), 8.5+0.07 (lOnM) and 
8.3+0.07 (lOOnM) and for the KO were 9.4+0.07 (InM), 9.7+0.16 (lOnM) and 9.2+0.18 
(lOOnM) (Figure 3.20). Statistically significant differences were observed in the pKg 
values calculated at lOnM and lOOnM BMY7378 between WT and KO carotid arteries.
The pA% values and slope parameters calculated by linear regression are presented in 
tabular form in figure 3.19.
3.3.3. Correlations
Figures 3.21 and 3.22 show correlations between the antagonist pA2 values in WT and 
KO carotid arteries with published values of the same antagonists in cloned ai- 
adrenoceptors. The WT carotid artery (Figure 3.21) does not display great correlation 
with any of the subtypes but the best correlation is with aid-adrenoceptors 
(r = 0.6), whereas in the KO carotid artery this weak correlation in the WT with aid- 
adrenoceptors becomes much stronger, producing an r value of 0.94.
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Figure 3.11:- Mean concentration response data to phenylephrine 
in the presence of increasing concentrations of prazosin in WT (top) 
and KO (bottom) murine carotid arteries. Control (□), 1 x lO'^M (x), 
1 X lO'^M (^) andl x lO'^M (O). Mean curves were generated using 
non-linear regression upon which the mean data ± s.e.m. has 
been superimposed. For WT arteries n=12 and for KG arteries n=14.
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Figure 3.12:- Mean concentration response data to 
phenylephrine in the presence of increasing concentrations 
of 5-methylurapidil in WT (top) and KO (bottom) murine 
carotid arteries. Control (□), 1 x lO'^M (x), 3 x lO'^M {()) and 
1 X 10"^M (O). Mean curves were generated using non-linear 
regression upon which the mean data ± s.e.m. has been superimposed. 
For WT arteries n=13 and for KG arteries n=12.
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Figure 3.13:- Mean concentration response data to 
phenylephrine in the presence of increasing concentrations 
of L765,314 in WT (top) and KO (bottom) murine 
carotid arteries. Control (□), 1 x 10"^M (x), 1 x lO'^M (^) and 
1 X lO'^M (O). Mean curves were generated using 
non-linear regression upon which the mean data ± s.e.m. has 
been superimposed. For WT arteries n=14 and for KO arteries 
n=12.
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Figure 3.14:- Mean coneentration response data to 
phenylephrine in the presenee of increasing concentrations 
of BMY7378 in WT (top) and KO (bottom) murine 
carotid arteries. Control (□), 1 x 10‘^ M (x), 1 x lO'^M ((}) and 
1 X lO'^M (O). Mean curves were generated using 
non-linear regression upon which the mean data ± s.e.m. has 
been superimposed. For WT arteries n=14 and for KG arteries 
n=14.
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Figure 3.15:- Schild plots for prazosin in WT (top) and KO 
(bottom). Each point represents an individual experiment and linear 
regression was used to determine the line of best fit, the slope of this 
line and its x-intercept.
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Figure 3.16:- Schild plots for 5-methylurapidil in WT (top) 
and KO (bottom) murine carotid arteries. Each point represents 
an individual experiment and linear regression was used to 
determine the line of best fit, the slope of this line and its 
x-intercept.
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Figure 3.17:- Schild plots for L765,314 in WT (top) and 
KO (bottom) murine carotid arteries. Each point represents 
an individual experiment and linear regression was used to 
determine the line of best fit, the slope of this line and its 
x-intercept.
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Figure 3.18:-Schild plots for BMY7378 in WT (top) and 
KO (bottom) murine carotid arteries. Each point represents 
an individual experiment and linear regression was used to 
determine the line of best fit, the slope of this line and its 
x-intercept.
WT CAROTID 
ARTERY
pÀ2 Slope
KG CAROTID 
ARTERY
pAs Slope
Prazosin 9.6 0.93
(0.77-1.08)
10.3 0.92
(0.68-1.2)
5 -Methylurapidil 7.5 1.1
(0.73-1.5)
7.6 1.1
(0.77-1.5)
L765,314 9.0 0.65*
(0.4-0.9)
8.3 0.79
(0.46-1.1)
BMY7378 9.7 0.44*
(0.27-0.60)
9.6 0.90
(0.66-1.1)
Figure 3.19:- pA^ values and slope parameters calculated from Schild regression 
of antagonists with phenylephrine in WT and KO carotid arteries. The slope value 
is given along with its 95% confidence intervals and an * indicates where the 
slope factor is significantly different from unity.
[PRAZOSIN] WT CAROTID KO CAROTID
ARTERY (pKb) ARTERY (pKe)
InM 9.6±0.1 10.1±0.2*
lOnM 9.5±0.1 10.2+0.2'
lOOnM 9.4±0.1 i o . o ± o . r
pAz 9.6 10.3
Slope 0.93 0.92
[5-MEU] WT CAROTID KO CAROTID
ARTERY (pKb) ARTERY (pKb)
lOOnM 7.6±0.1 7.8±0.1
300nM 7.7±0.1 8.0±0.1
IfjiM 7.7±0.2 7.9±0.1
pAz 7.5 7.6
Slope 1.1 1.1
Figure 3.20:- Mean pKg values ±s.e.m calculated for each concentration 
of prazosin (top) and 5-methylurapidil (5-MEU) (bottom) in WT and 
KO carotid arteries. The pA2  value and slope as calculated by Schild 
regression are also given. * indicates p<0.05.
[L765,314] WT CAROTID KO CAROTID
ARTERY (pKe) ARTERY (pKs)
lOnM 8.6±0.1 8.3±0.1
lOOnM 8.4±0.2 7.9±0.r
lp,M 7.9±0.2 7.9+0.3
pAz 9.0 8.3
Slope 0.65 0.79
[BMY7378] WT CAROTID KO CAROTID
ARTERY (pKb) ARTERY (pKb)
InM 9.5±0.1 9.4±0.1
lOnM 8.5+0.1 9.7±0.2'
lOOnM 8.3±0.1 9.2+0.2*
pAz 9.7 9.6
Slope 0.44 0.90
Figure 3.20 continued:- Mean pKg values ±s.e.m calculated for each 
concentration of L765,314 (top) and BMY7378 (bottom) in WT and 
KO carotid arteries. The pA2  value and slope as calculated by Schild 
regression are also given. * indicates p<0.05.
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Figure 3.21:- Corrélation of the potencies of antagonists used in 
WT carotid artery with their published potencies in cloned 
a  1 -adrenoceptors. (1):- prazosin, (2):- 5-methylurapidil,
(3):- L765,314 and (4):- BMY7378. (Williams et al, 1999,
Burt et al, 1995, Patane et al, 1998, Yang et al, 1997). The 
dotted line shows the line of unity.
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Figure 3.22:- Correlation of the potencies of antagonists used in 
KO carotid artery with their published potencies in cloned 
0 2^ -adrenoceptors. (1):-prazosin, (2):- 5-methylurapidil,
(3):- L765,314 and (4):- BMY7378. (Williams et al, 1999,
Burt et al, 1995, Patane et al, 1998, Yang et al, 1997). The 
dotted line shows the line of unity.
3.3.4. Control, over-expressed and constitutivelv active mice -  carotid and 
mesenteric arteries - Sensitivity to PE
Figure 3.23 shows the CRC to phenylephrine obtained in the carotid arteries of the three 
strains of mice. The pECso values were 6.2+0.11 in control arteries (n=2), 6.0+0.12 in 
over-expressed arteries (n=2) and 6.8+0.15 in constitutively active arteries (n=2). The 
maximum responses produced were 0.24g+0.075 in control arteries, 0.165g in over­
expressed arteries and 0.183g±0.017 in constitutively active arteries. The Hill slopes 
were found to be shallow and significantly different from unity in all arteries. Control 
arteries had a Hill slope of 0.59 (95% Cl = 0.37-0.8), over-expressed arteries had a Hill 
slope of 0.58 (95% Cl = 0.36-0.8) and constitutively active arteries had a Hill slope of 
0.52 (95% Cl = 0.26-0.77). Due to the low n number for these experiments meaningful 
statistical tests could not be carried out.
Figure 3.24 shows the CRC to phenylephrine obtained in the mesenterie arteries of the 
three strains of mice. The pECso values were 5.9+0.05 in control arteries (n=5),
6.2±0.03 in over-expressed arteries (n=5) and 5.9+0.04 in constitutively active arteries 
(n=4). The maximum responses produced were 0.44g+0.07 in control arteries, 
0.27g+0.04 in over-expressed arteries and 0.31g±0.04 in constitutively active arteries. 
The Hill slopes for all arteries were similar and not significantly different from unity. 
These were 0.91 (95% Cl = 0.72-1.1) for control arteries, 1.1 (95% Cl = 0.88-1.26) for 
over-expressed arteries and 1.0 (95% Cl = 0.79-1.2). One-way ANOVA revealed no 
significant differences in the pECgo's, maximum responses or Hill slopes.
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Figure 3.23:- Mean concentration response data to phenylephrine 
in control (□), over-expressed (x)and constitutively active (o)
0 1 2 Q-adrenoceptor carotid arteries expressed as tension in grams 
(top) or as a percentage of their own maximum response (bottom). 
Mean curves were generated using non-linear regression upon 
which the mean data ± s.e.m. has been superimposed, n-2 for 
control, overexpressed and constitutively active.
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Figure 3.24:- Mean concentration response curves to 
phenylephrine in control (□), over-expressed (x) and 
constitutively active (O) oc^g-adrenoceptor mesenteric 
arteries expressed as tension in grams (top) or as a 
percentage of their own maximum response (bottom). 
Mean cuiwes were generated using non-linear regression 
upon which the mean data ± s.e.m. has been superimposed. 
Control (n=5), over-expressed (n=5) and constitutively 
active (n=4).
3.4. DISCUSSION
Much of the physiology and pharmacology of vascular ai-adrenoceptors has been 
carried out in rats, rabbits and dogs and until recently the mouse has been virtually 
ignored. However, the mouse is the only mammalian species to date, in which 
techniques to alter the genome of an animal, such as gene targeting have been 
successful. As these genetically engineered mice become a popular choice of laboratory 
animal it has become obvious that there is a gap in our knowledge of their physiology 
and pharmacology compared with our understanding of rats, rabbits and dogs. I 
undertook this study in an attempt to learn more about the ai-adrenoceptor 
pharmacology and normal vascular function of the mouse carotid artery, neither of 
which had been studied.
3.4.1. Agonist profiles
Surprisingly, only a handful of agonists produced contraction in the mouse carotid 
artery. Of the agonists that produced a response (noradrenaline, phenylephrine, (R)-A- 
61603 and 5-HT), phenylephrine was the only agonist which was found to have 
differing sensitivities in WT and KG carotid arteries. There is some evidence from 
binding studies that phenylephrine may bind preferentially to the aio/d-adrenoceptor 
(Minneman et al, 1994; Knepper et al, 1995; Yang et al, 1997). Knepper et al (1995) 
showed that phenylephrine was 15 times more potent in contracting the otm- 
adrenoceptors of the rat aorta than the ai a-adrenoceptors of the rat vas deferens and 80 
times more potent at contracting the aiB-adrenoceptors of the rat spleen. The enhanced
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sensitivity to phenylephrine observed in the KO carotid artery might be an indication of 
the presence of aiD-adrenoceptors.
In both WT and KO carotid arteries, noradrenaline was found to produce a biphasic 
concentration response curve. The first component of the response produces a pECso 
that is typical of noradrenaline acting at an ai-adrenoceptor (Nagadeh, 1996, University 
of Glasgow, PhD thesis; Russell and Watts, 2000). It is 15 times more potent than 
phenylephrine in WT carotid arteries and 10 times more potent than phenylephrine in 
KO carotid arteries. However, the basis for the second component of the response which 
is approximately 100 fold less sensitive to noradrenaline than the first component is not 
known and requires further investigation. Agents that block ag- and p-adrenoceptors as 
well as neuronal and extraneuronal uptake of noradrenaline are normally employed 
when the ai-adrenergic actions of noradrenaline are being investigated. These agents 
were not employed in this study because I was interested in how noradrenaline would 
act in the absence of the traditional blocking agents used. The biphasic response 
produced by noradrenaline may be due to its actions at az~ or P-adrenoceptors. 
Alternatively, the biphasic response may result from the neuronal or extraneuronal 
uptake of noradrenaline or may arise through the release of mediators, such as nitric 
oxide. Further studies employing agents that block these receptors/processes may 
highlight the exact nature of this biphasic response.
(R)-A-61603, an aiA-selective agonist synthesised by Abbot Laboratories, was 
equipotent to phenylephrine in the KO carotid artery whilst in the WT carotid artery it 
was found to be more potent than phenylephrine. This may suggest that the receptor in 
the WT carotid artery, which has a greater potency for (R)-A-6I603 than for
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phenylephrine is different from the receptor in the KO carotid artery where (R)-A- 
61603 is equipotent to phenylephrine. Noradrenaline was more potent than (R)-A-61603 
in both WT and KO carotid arteries. The sensitivity (EC5 0  values) of the Abbott 
compound in native tissues representing each of the ai-adrenoceptor subtypes has been 
published by Knepper et al (1995). The racemic mixture of A-61603 was found to be 
330 times more potent in the rat vas deferens (ttiA) than phenylephrine and 200 times 
more potent than noradrenaline. In the rat spleen (aie) it was 40 times more potent than 
phenylephrine and 30 times more potent than noradrenaline. And in the rat aorta (aio), 
A-61603 was 30 and 510 times less potent than both phenylephrine and noradrenaline 
respectively. In the present study the R-enantiomer of A-61603 was used rather than the 
racemic mixture. The R-enantiomer appears to confer potency to the compound at aiA- 
adrenoceptors. The potency of (R)-A-61603 was tested at the aiA-adrenoceptors of the 
canine prostate by Knepper et al (1995) where it was found to be 590 times more potent 
than phenylephrine and 460 times more potent than noradrenaline. Unfortunately, (R)- 
A-61603's potency was not determined at aiB- or oti^-adrenoceptors but its sensitivity 
at aiA-adrenoceptors is considerably higher than the sensitivity observed in either the 
WT or KO earotid artery, which may indicate that the aiA-adrenoceptor does not 
mediate contraction in these arteries.
The concentration response curves to phenylephrine and (R)-A-61603 were both found 
to have shallow slopes that were significantly less than 1.0 in both the WT and KO 
carotid artery. This may indicate that these agonists are activating more than one 
population of receptors, since a shallow curve can result through the interaction of an 
agonist with more than one receptor.
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The rank order of potency for those adrenergic agonists that elicited a response in the 
carotid artery, was:-
WT - Noradrenaline component) > (R)-A-61603 > Phenylephrine > Noradrenaline 
(2"  ^component)
KO -  Noradrenaline (L ‘ component) > Phenylephrine = (R)-A-61603 > Noradrenaline 
(2*^  ^component)
Interestingly, the rank order of potency of noradrenaline, phenylephrine and (R)-A- 
61603 in the KG carotid artery is similar to the rank order of potency observed by 
Knepper et al (1995) with the racemic mixture of A-61603, phenylephrine and 
noradrenaline at the ocm-adrenoceptors of the rat aorta. The only difference is that in the 
present study phenylephrine was equipotent with (R)-A-61603 whereas Knepper et al 
found that phenylephrine was more potent than A-61603 (30-fold). This difference 
could be a result of this study using the R-enantiomer rather than the racemic mixture 
but the overall similarity might suggest that the KO carotid artery contains a population 
of aiD-adrenoceptors.
A lack of a contractile response with the oc2-adrenoceptor agonist, UK14304 and the 13- 
adrenoceptor agonist, isoprenaline coupled with the contractile response obtained using 
phenylephrine suggests that in mouse carotid artery the dominant adrenergic receptor 
subtype involved in mediating contraction is the ai-adrenoceptor. (However, the dilator 
effects of UK14304 and isoprenaline, which are discussed below, could obscure any 
potential contractile effects.) This is similar to findings in the mouse aorta (Russell and 
Watts, 2000) and the rat carotid artery (Nagadeh, 1996, University of Glasgow, PhD
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thesis). Although these studies reported that isoprenaline and UK14304 were capable of 
producing contractions in the mouse aorta and rat carotid artery respectively, these 
responses were found to be blocked by prazosin, indicating that they were mediated 
through ai-adrenoceptors. The only other agonist found to be capable of contracting the 
mouse carotid artery in the present study was 5-HT whose sensitivity was similar to that 
of the mouse aorta (Russell and Watts, 2000). In addition to adrenergic and serotonergic 
receptors, Russell and Watts (2000) also found evidence for dopaminergic and 
prostaglandin receptors.
(U-46619, which is a thromboxane mimetic that stimulates thromboxane A% receptors 
was found to contract the WT mouse carotid artery, although CRC were not carried out 
to this agent due to time limitations.)
Relaxant agents were tested only on WT carotid arteries. The agents which produced 
relaxation were acetylcholine, UK14304 and isoprenaline with a potency order of 
Acetylcholine > Isoprenaline > UK14304. The relaxations produced by all three agents 
could be blocked by L-NAME indicating that they were mediated by nitric oxide. It is 
well documented that acetylcholine relaxes the mouse carotid artery via the actions of 
nitric oxide as this is often the artery studied when investigating the consequences of 
‘knocking out' the nitric oxide synthase (NOS) genes, such as inducible NOS (iNOS) or 
endothelial NOS (eNOS) (Chataigneau et al, 1999; Didion et al, 2000; Gunnett et al, 
2000). The relaxation produced by isoprenaline has also been attributed to nitric oxide 
in the rat carotid artery (MacDonald et al, 1999; Nagadeh, 1996, University of Glasgow, 
PhD thesis). UK14304 has been shown to act as a partial ai-agonist in the rat carotid 
artery (Nagadeh, 1996, University of Glasgow, PhD thesis). Although there was no 
evidence for this in the mouse carotid artery when the artery was at resting tension, a
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partial agonistic effect may be revealed when the tissue is preconstricted with a non- 
adrenergic agonist such as U-46619. Further experiments are planned to investigate the 
receptors at which UK14304 acts to produce relaxation in the mouse carotid artery. 
Interestingly, UK14304 does not appear to produce relaxation in carotid arteries from 
D79N mice; transgenic mice whose a 2 a/d-adrenoceptor is uncoupled from its potassium 
channels resulting in it acting like a functional knockout. Time controls to relaxant 
curves were not carried out but would be useful to determine the effect of time on the 
contraction produced by phenylephrine.
The agents that did not produce any response, whether it be a contractile or relaxant 
effect, included such important vasoactive compounds as angiotensin II, endothelin, 
ATP, histamine, vasopressin and bradykinin. Receptors for these agents have been 
found previously in rat (Caputo et al, 1995; Marano et al, 1999; Rutschmann et al,
1998) and rabbit carotid artery (Maurice et al, 1997; Pruneau and Belichard, 1993). This 
study highlights the dangers in extrapolating information from one species of animal to 
the next. Although the mouse and rat are similar animals i.e. small rodents, it is clear 
that their vascular phaimacology is quite different. Whether this species difference in 
the expression of receptors is confined to the carotid artery or whether it will be 
observed in all arteries of these mammals remains to be determined.
3.4.2. Antagonist profiles
To determine the ai-adrenoceptor subtype mediating contraction in WT and KO carotid 
arteries, four ai-adrenoceptor antagonists with differing selectivities for the ai- 
adrenoceptor subtypes were used. Prazosin produced a pA2 value of 9.6 in WT carotid
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artery and a significantly higher pA2 of 10.3 in KO carotid artery. These high affinities 
indicate that the aiL~adrenoceptor does not contribute to vasoconstriction in either WT 
or KO carotid arteries. The pA2 in the KO is high for prazosin. However, this can be 
seen to arise as a result of a higher control sensitivity to phenylephrine in the KO. The 
pECso’s for phenylephrine in the control curves are found be significantly more 
sensitive to phenylephrine in the KO than in the WT, yet the subsequent curves in the 
presence of equal concentrations of prazosin are the same for both WT and KO carotid 
arteries. Therefore, the higher pA2 value that was calculated does not appear to be due 
to prazosin having an absolute higher affinity in the KO cai’otid artery compared with 
the WT, but instead appears to be a result of phenylephrine having a higher sensitivity 
in the KO carotid artery (discussed above).
A pA2 value of similar potency to that in the KO carotid artery has also been found in 
the KO mouse aorta (Daly et al, unpublished observations). The KO aorta has been 
shown to have an increased sensitivity to phenylephrine (Daly et al, unpublished 
observations), so it would be of interest to re-examine the pECso’s calculated in this 
artery to see if a similar situation also exists in the KO mouse aorta. This may be a 
characteristic of KO blood vessels or it may be a characteristic of the subtype of ai- 
adrenoceptor expressed in the KO carotid artery and aorta. This latter suggestion seems 
more likely because results from the mesenteric and tail arteries of KO mice show that 
the sensitivity to phenylephrine is unchanged when compared with the equivalent WT 
vessels (Daly et al, unpublished observations). This is reflected in the pA2 value for 
prazosin, which is identical in the WT and KO mesenteric artery (pA2 values for 
prazosin have still to be calculated for tail arteries). Both the mesenteric and tail arteries 
are believed to mediate contraction through a mixture of aiA- and oq B-adrenoceptors in
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the WT and through the aiA-adrenoceptor in the KO (Daly et al, unpublished 
observations). The pharmacology of these vessels does not resemble the pharmacology 
of the mouse aorta or the mouse carotid artery (discussed in more detail below) 
suggesting that the ai-adrenoceptor subtype mediating contraction in the mesenteric and 
tail arteries is different from that in the aorta or carotid artery. Therefore, the increased 
sensitivity to phenylephrine which results in an increased pA2 for prazosin is more 
likely to be due to a characteristic of the oti-adrenoceptor subtype found in the aorta and 
carotid artery or it may be a characteristic of large conducting arteries.
The aiA-adrenoceptor antagonist, 5-methylurapidil, acted competitively in both WT and 
KO carotid arteries producing similar pA2 values of low potency. At aiA/a- 
adrenoceptors, 5-methylurapidil has been shown to have pA2 values of between 8.5 and 
9.5 (Hanft and Gross, 1989; Kong et al, 1994; Schwinn et al, 1995; Vargas and 
Gorman, 1995; Daniel et al, 1999) whilst at aiB/b- and am/d-adrenoceptors its affinity is 
approximately 10-100 fold less (Hanft and Gross, 1989; Schwinn et al, 1995;
Mackenzie et al, 2000). Therefore the pA2 values calculated for WT and KO carotid 
arteries indicate that there is unlikely to be an aiA-adrenoceptor component to the 
contraction in these arteries. It is more probable that the response involves am- and/or 
am-adrenoceptors. The am-adrenoceptor cannot be a contributor to the contraction in 
the KO carotid artery and so it would seem likely that in both the WT and KO carotid 
artery, where similar pA2 values were obtained, the am-adrenoceptor is mediating 
contraction. However, the am-adrenoceptor may be involved in the WT contraction 
because 5-methylurapidil does not distinguish between am/b“ and am/d-adrenoceptors.
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The results using L765,314 suggest that there is a contribution from the am- 
adrenoceptor in the contraction of the WT carotid artery. The pA2 for L765,314 is high 
but L765,314 is not acting competitively, producing a shallow Schild slope of 0.65 that 
was found to be significantly less than 1.0. This would be consistent with the presence 
of more than one receptor subtype distinguished by different sensitivities to L765,314. 
The shallow Schild slope would also result in a pA2 that is artificially high. The high 
pA2 value coupled with the shallow slope of the Schild plot may imply that there is a 
component of the contraction that is mediated by the am-adrenoceptor and a component 
which is mediated by another a%-adrenoceptor subtype. In the KO carotid artery, 
L765,314 is less potent than in the WT artery, although it appears to be acting 
competitively, producing a slope which is not significantly different from unity.
As a result of L765,314 producing a shallow Schild slope in the WT carotid artery 
pKe’s were calculated for each concentration of L765,314 used in the WT and KO 
carotid artery to deteimine whether these might shed some light on the affinity of this 
drug in the WT carotid artery. The pKg's for L765,314 in the WT carotid artery were 
found to be smaller than the pA2 value, whereas the KO pKe’s were similar to the pA2 
value (as expected given that L765,314 appears to be acting competitively in the KO). 
These pKe values correlate better with L765,314’s affinity at native and recombinant 
aiB-adrenoceptors, than the pA2 value in the WT carotid artery, which was about 10 
times more potent than its published affinity at a%B-adrenoceptors (Patane et al, 1998). 
The pKb values and the pA2 calculated for the KO are also similar to the affinity of 
L765,314 at am/b-adrenoceptors. The fidelity of the am-adrenoceptor KO mouse has 
been proved by the receptor’s absence in all of the major organs of the KO mouse 
(Cavalli et al, 1997; our own unpublished observations), so despite L765,314 displaying
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an affinity in the KO carotid artery which is comparable to its affinity at a m /b -  
adrenoceptors, this cannot be the subtype mediating contraction in this artery. The 
similarity of the pKe values in the WT and KO carotid artery also imply that the am/b- 
adrenoceptor does not mediate contraction in the WT carotid artery either. However, the 
shallow Schild slope in the WT suggests heterogeneity of receptors and the presence of 
the aiA-adrenoceptor has already been excluded because of the low pAg value for 5- 
methylurapidil. These results seem to place some doubt over the effectiveness of 
L765,314 as an am-adrenoceptor antagonist.
The calculated pAz values for the am/d-adrenoceptor antagonist, BMY7378, were 
similar in WT and KO carotid arteries and were of high potency. However, the Schild 
plot in the WT carotid artery resulted in a shallow slope which was significantly 
different from unity, whilst the slope of the Schild plot in the KO carotid artery 
indicated competitive antagonism. This is similar to the circumstances presented with 
L765,314 where a shallow slope is evident in the WT carotid artery which is not 
observed in the KO carotid artery. As with L765,314, pKg values were calculated for 
WT and KO arteries to gain a more accurate reflection of BMY7378’s affinity in the 
WT carotid artery. The affinity of BMY7378 was reduced in the WT carotid artery 
when pKfi values were calculated, demonstrating that the pAg value was indeed 
artificially high, whilst the pKs’s in the KO carotid artery were similar to the pAz. The 
affinity of BMY7378 was found to be significantly higher in KO arteries compared with 
WT arteries at concentrations of lOnM and lOOnM. In the light of the findings with 
prazosin, the pECso values used in the Schild analysis for BMY7378 were examined. 
The trend was found to be the same as for prazosin. The control pECjo’s were 
significantly different whereas the pECso’s in the presence of BMY7378 were the same
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between WT and KO carotid arteries. Again this indicates that BMY7378 has a similar 
affinity at the ai-adrenoceptors of WT and KO carotid arteries. The KO appears to have 
a higher affinity because it has an increased sensitivity to phenylephrine, which results 
in lower dose ratios being calculated for the KO, therefore higher pKe’s. This apparent 
difference in affinity is not observed in the pA% values because of the shallow Schild 
slope in the WT, producing a deceptively high affinity value. The affinities calculated 
for BMY7378 in WT and KO carotid artery indicate the presence of an am- 
adrenoceptor population in both WT and KO carotid arteries, with the possibility of 
there being a second receptor subtype in the WT resulting in the shallow slope. 
BMY7378 does not discriminate between aiA- and aiB-adrenoceptors and its affinity at 
these receptors is approximately 100 fold less than its affinity at am-adrenoceptors 
(Saussy et al, 1994; Goetz et al, 1995). There is no evidence for the presence of the aiA- 
adrenoceptor from the agonist and antagonist studies, therefore the second subtype in 
the WT would appear to be the am - adrenoceptor.
When correlations were performed, comparing the pA% values calculated here with 
published pKj values for the same antagonists at cloned receptors, the WT carotid artery 
did not correlate particularly well with any of the subtypes but produced the best 
conelation with the aw-adrenoceptor (r = 0.6). In the KO carotid artery this correlation 
with the aid-adrenoceptor was improved (r = 0.94). These conelations confirm the 
involvement of the am-adrenoceptor in the contractions of the WT and KO carotid 
arteries.
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3.4.3. Control, over-expressed and constitutively active mice
The sensitivities of the control, over-expressed and constitutively active mice to 
phenylephrine were found to be unchanged in mesenteric arteries suggesting that the 
aiB-adrenoceptor does not play a major role in contraction of this vessel. Interestingly, 
the carotid arteries of the constitutively active mice were found to have a pECso which 
was comparable to the KO carotid artery, whilst the control and over-expressed had 
similar values to the WT carotid artery. Due to the low n number for these experiments 
statistical analysis was not carried out. However, if these pECso values were found to 
remain at these values when the n number was increased it seems likely that there would 
be a significant difference between the constitutively active carotid arteries and the 
control and over-expressed arteries. This is an interesting point to note because after 
discovering an increased potency to phenylephrine in the KO carotid artery, it was 
anticipated that the opposite would be true in the constitutively active carotid arteries. 
Agonists have been shown to demonstrate increased affinity for constitutively active 
receptors (Cotecchia et al, 1990; Lefkowitz et al, 1993) which may explain the 
increased sensitivity observed in the constitutively active carotid arteries. The similarity 
in the pECgo values in the KO and in these constitutively active arteries may not be 
related to an involvement of the am-adrenoceptor in contraction but may result from 
both receptors being constitutively active. The first functional evidence for 
constitutively active receptors was presented last year when Gisbert et al (2000) 
proposed that the am-adrenoceptors of the rat aorta were constitutively active. This 
would explain the increased sensitivity to phenylephrine observed in the KO carotid 
artery (which I am proposing to express the am-adrenoceptor) and also observed in the 
KO aorta (also proposed to express the am-adrenoceptor) (Daly et al, unpublished
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observations). Another possible explanation could be if the aio-adrenoceptor of the KO 
carotid artery is upregulated in some way, which may manifest itself in an increased 
number of receptors or an increased efficiency of coupling of agonist and receptor. 
Either of these would result in an increased sensitivity to phenylephrine. However it 
should be noted that the WT and KO mice and the control, overexpressed and 
constitutively active mice are different strains of mice. The WT and KO mice are C57 
Black 6J mice whereas the control, overexpressed and constitutively active mice are 
CBA mice. Different strains of mice may have differing sensitivities to agonists.
In conclusion, the data from this study provides evidence that the am-adrenoceptor 
mediates contraction in both WT and KO murine carotid arteries. There is also evidence 
that a component of the contraction in the WT carotid artery is mediated through the 
aiB-adrenoceptor, producing the shallow Schild slopes observed with L765,314 and 
BMY7378. The rat carotid artery has previously been characterised as having an am- 
adrenoceptor population by two separate groups (Nagadeh, 1996, University of 
Glasgow, PhD thesis; Villalobos-Molina and Ibarra, 1996) based on high affinity for 
BMY7378. The rabbit carotid artery was found to have a low affinity for prazosin, 
prompting the suggestion that it contained the am-adrenoceptor (Muramatsu et al, 
1990), whilst the dog carotid artery has been claimed to mediate vasoconstriction 
through the am-adrenoceptor on the basis of low affinities for 5-methylurapidil and 
WB4101 (Kohno et al, 1994). This species difference again highlights the pitfalls that 
exist if assumptions are made about the ai-adrenoceptor expressed in different animals.
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CHAPTER 4 -  INVESTIGATION INTO THE 
STRUCTURAL DIFFERENCES IN WT AND KO 
MURINE CAROTID ARTERIES USING CONFOCAL 
LASER SCANNING MICROSCOPY
4.1. INTRODUCTION 
4.1.1 Structure of blood vessels
All blood vessels, with the exception of the capillaries, share the same basic structural 
features. They are composed of three layers, or ‘tunics’. The tunica intima consists of a 
layer of endothelial cells, which line the lumen of the vessel and which rest on a basal 
lamina. Beneath the endothelium is the subendothelial layer, consisting of loose 
connective tissue, which, in larger arteries, may contain occasional smooth muscle cells. 
The tunica media is primarily composed of concentric layers of smooth muscle cells 
oriented in a helix at an angle of 20°-40° to the longitudinal axis (Williams, 1998). 
Interspersed among these smooth muscle cells can be found elastic fibres and lamellae, 
collagen fibres and proteoglycans. In arteries, the media is separated from the intima by 
an internal elastic lamina which contains gaps (fenestrae) through which substances can 
diffuse in order to nourish cells deep in the vessel wall. The outermost layer of a blood 
vessel is the tunica adventitia which consists of an external elastic lamina, nerve fibres 
and surrounding connective tissue which contains collagen and elastic fibres, adventitial 
fibroblasts and macrophages (Gutterman, 1999).
4.1.2. Arteries
Arteries are classified according to their size:-
Arterioles;- Less than 500jim in diameter in humans and have relatively naiTOw lumens 
Muscular arteries:- Medium-large diameters, most of the named arteries are of this type.
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Large elastic arteries:- Includes aorta and its branches e.g. carotid. Have a yellowish 
colour due to the accumulation of elastin in the media.
These elastic arteries are also known as conducting arteries because their major function 
is to transport blood away from the heart. They also serve to smooth out the large 
fluctuations in pressure created by the heartbeat. The intima of these elastic arteries 
tends to be thicker than that of a muscular artery. The media consists of a series of 
concentrically ananged perforated elastic laminae whose number increase with age and 
whose thickness increase due to deposition of elastin. Interspersed between these elastic 
laminae are smooth muscle cells, collagen fibres and chondroitin sulphate. The tunica 
adventitia does not show an external lamina and is relatively underdeveloped.
4.1.3. Adventitia
Before 1980, study of the vasculature was primarily concerned with the tunica media of 
arteries, using pharmacological agents to examine vascular smooth muscle reactivity. 
With the discovery by Furchgott and Zawadzki (1980) that nitric oxide could be 
released from the endothelium, the emphasis shifted towards the study of the 
endothelium. 20 years on from this discovery, we now accept, that instead of simply 
acting as a semi-permeable barrier between the blood and the artery, the endothelium is 
capable of releasing a host of vasoactive substances through which it regulates vascular 
tone. Throughout this period the tunica adventitia received minor attention. Its 
importance was believed to be only that of a structural role. However, it is now 
becoming apparent that there is more to the adventitia than would first appear.
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In recent years, the adventitia has become a popular target for gene transfer using 
adenovirus’ which have met with varying success. In 1997, Chen et al introduced the 
endothelial nitric oxide synthase (eNOS) gene into adventitial fibroblasts of the canine 
basilar artery. Endothelial nitric oxide synthase (eNOS) is one of three isoforms of nitric 
oxide synthase, the enzyme which catalyses the formation of nitric oxide from L- 
arginine. Transfection of eNOS into canine basilar arteries resulted in an augmented 
relaxation response to bradykinin (Chen et al, 1997). Tsutsui et al (1998) also reported 
an enhanced relaxation response in basilar arteries transfected with eNOS which they 
discovered was unaffected by removal of the endothelium. A follow up paper revealed 
that the relaxation in these vessels could be inhibited by chemical (ethanol) or 
mechanical (rubbing) disruption of the adventitia indicating that the transfected 
adventitial fibroblasts were responsible for the increased relaxant response (Tsutsui et 
al, 1999).
The functional consequences of eNOS transfection do not seem to be limited to the 
basilar artery. The rabbit carotid artery was also found to produce an augmented 
relaxation to acetylcholine in both normal and atherosclerotic vessels transfected with 
eNOS (Ooboshi et al, 1998). The relaxation of atherosclerotic vessels is impaired, yet 
gene transfer of eNOS was able to restore a ‘normal’ relaxant response (Ooboshi et al, 
1998). These studies suggest that adventitial fibroblasts are capable of releasing nitric 
oxide and acting as surrogate endothelial cells.
Data has also been presented to show that the adventitia of the rat aorta is capable of 
releasing nitric oxide when exposed to endotoxin. In fact, the adventitia was found to 
generate more nitric oxide than either the endothelium or the media (Zhang et al, 1999;
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Kleschyov et al, 2000) demonstrating that the adventitia is capable of releasing nitric 
oxide without the need for gene transfer. These findings may impact on treatments in 
the future for vascular and inflammatory diseases.
There is mounting data to suggest that the adventitia may play an important role in the 
pathogenesis of atherosclerosis. Removal of the adventitia from large arteries of the 
rabbit was found to result in intimai and medial hyperplasia, characteristic of early 
atherosclerotic lesions (Barker et al, 1994). In the coronary circulation, adventitial mast 
cells were found to be present in higher concentrations in infarct-related coronary 
arteries, associated with coronary atherosclerosis, when compared with control arteries 
(Gutterman, 1999).
A role for the adventitia in postangioplasty restenosis has also been suggested. As with 
atherosclerosis the main focus of study for restenosis has been the medial and intimai 
layers of blood vessels, since this is the site of the lesion. However, there is now 
evidence to suggest that the adventitia is involved in the early proliferative phase prior 
to formation of the neointima. Wilcox et al (1996) found that 2-3 days after angioplasty, 
proliferation was primarily observed in the adventitia. A week after angioplasty the 
proliferation in the adventitia was reduced and was now concentrated in the neointima. 
These proliferating cells were found to include adventitial fibroblasts that had migrated 
from the adventitial layer to the site of the neointima. Intravascular irradiation was 
found to inhibit the growth of adventitial cells resulting in a decrease in the cellular 
proliferation in the neointima (Wilcox et al, 1996).
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Laser scanning confocal microscopy revealed that the adventitia may contribute to the 
vascular remodelling observed in hypertension. The number of adventitial cells in 
mesenteric arteries was found to have almost doubled in SHRSP rats when compared 
with WKY controls (Arribas et al, 1997). Adventitial-like cells were also observed in 
the medial layer of SHRSP rats, implying migration of adventitial cells from the 
outermost part of the vessel into the media (Arribas et al, 1997). This is similar to the 
phenomenon observed in balloon injured arteries which may suggest that migration of 
adventitial cells is common to vascular remodelling.
This year the role of the adventitia was further questioned by the discovery that 
adventitial fibroblasts, isolated from the rat aorta, express a i- and adrenoceptors and 
that the density of ai-adrenoceptors was similar to that observed in the media (Faber et 
al, 2001). Using a combination of competitive RT-PCR and radioligand binding, 
adventitial fibroblasts were shown to express all three a,-adrenoceptor subtypes and the 
Gt2D-adrenoceptor. RT-PCR revealed that mRNA for the ai-adrenoceptor subtypes was 
most abundant for the aio-adrenoceptor, followed by the aiA- and then the aiB- 
adrenoceptor. Radioligand binding contradicted these findings by revealing that the Œia- 
adrenoceptor was present in the greatest density, followed by the (%iB- and am- 
adrenoceptors. These experiments were also earned out on the medial layer of the rat 
aorta, where in contrast to the adventitia, results from RT-PCR and radioligand binding 
coincided. The am-adrenoceptor was found to be the predominant subtype in terms of 
density, followed by the am- and aia-adrenoceptors. These results are consistent with 
functional studies showing the am-adrenoceptor to be responsible for the contraction of 
the rat aorta (Kenny et al, 1995; Piascik et al, 1995; Testa et al, 1995b; Deng et al,
1996; Hussain and Marshall, 1997; Piascik et al, 1997; Guimaraes and Moura, 2001).
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The media and adventitia of the rat carotid artery were also found to express the same 
four a-adrenoceptor subtypes, (aiA, otm, (%iD and a 2 o) as the rat aorta, in similar 
amounts (Faber et al, 2001). An additional finding in this paper was that noradrenaline 
caused proliferation and protein synthesis in adventitial fibroblasts, a phenomenon 
which has been demonstrated previously in smooth muscle cells (Chen et al, 1995; Xin 
et al, 1997). The finding that adventitial fibroblasts express ai-adrenoceptors is 
surprising, given the traditional view that fibroblasts are normally non-contractile and 
considered to be structural cells. However, this may go some way to explaining the 
discrepancies that surround attempts to conelate mRNA levels of ai-adrenoceptors with 
the functioning subtype in intact arteries. Given the increasing amounts of data 
implicating the adventitia in vascular diseases, some of which has been reviewed here, it 
is possible that one or more of the a-adrenoceptor subtypes discovered on adventitial 
fibroblasts could be capable of signalling a trophic action of catecholamines on vascular 
wall growth and remodelling.
From the data obtained from functional studies in WT and KO murine carotid arteries, 
detailed in chapter 3 of this thesis, the contraction in the WT carotid artery appears to be 
mediated by the am-adrenoceptor with a contribution from the am-adrenoceptor, whilst 
the contraction in the KO carotid artery is mediated by the am-adrenoceptor. With the 
recent discovery that the adventitia of the rat aorta and carotid artery express all three 
ai-adrenoceptor subtypes (Faber et al, 2001) and the growing importance of the 
adventitia in the pathogenesis of vascular diseases, the possible structural and functional 
consequences of deleting the am-adrenoceptor from the KO carotid artery was 
investigated with the focus being on the adventitia. It was hoped that such a study might 
reveal a role for the am-adrenoceptor in the adventitia of these blood vessels. Ideally all
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three layers of the arteries would have been studied in detail but due to technical 
limitations, both in the equipment available and the tissue used, it was only practical to 
study the adventitia in any detail.
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4.2.METHODS
4.2.1. Solutions and drues used
All vessels were fixed using neutral buffer formalin of the following composition:- 10% 
formaldehyde, sodium phosphate, monobasic (NaH2P0 4 ‘H2 0 ) -  135mM, sodium 
hydroxide (NaOH) -  105mM, pH -  7.4. The sodium borohydride solution was of the 
following composition:- sodium phosphate, dibasic (Na2HP0 4 ) -  70mM, sodium 
borohydride (NaBHq) -  13mM. 100ml of this solution was made up fresh on the day of 
the experiment and then discarded after use.
The following compound was used:- 
Propidium iodide (Sigma).
4.2.2. Animals used
Wildtype and knockout male C57-Black mice were obtained from the Central Research 
Facility at the University of Glasgow. Mice were killed by lethal overdose of carbon 
dioxide and the common carotid arteries immediately removed by careful dissection 
using a microscope and placed in cold Krebs. The arteries were further dissected to 
ensure as little connective tissue remained attached to the vessel as possible. Where 
possible mice of a similar age (-16 weeks) and weight (30-40g) were used.
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4.2.3. Pressurisation and fixation procedure
Vessels were mounted in Krebs at 37°C in a pressure myograph system by means of a 
glass cannula. One end of the vessel was secured to the cannula using fine ligatures, 
whilst the other end was left unattached. In order to produce a closed system in which 
pressure could be maintained the unattached end of the vessel was tied off with 
ligatures. The cannula was connected to a pressure-servo unit, which allowed the 
pressure of the system to be precisely controlled and altered at will. Pressure was 
applied to the vessel over a 15 minute period, increasing by 40mmHg every 5 minutes 
until the in vivo pressure of the artery was attained. This has been previously reported to 
be 120mmHg (Cavalli et al, 1997). The pressurised artery was allowed to equilibrate in 
Krebs for 15-20minutes to ensure that pressure was maintained. Towards the end of the 
equilibration period several measurements were taken from the artery, specifically, the 
internal diameter and the right and left wall thickness which allowed the external 
diameter to be calculated. This was achieved by carefully placing the perfusion 
myograph on the stage of a Zeiss light microscope and raising the stage until the tip of 
the objective (XIO) was immersed in the Krebs solution. The artery was then brought 
into focus being careful not to allow the objective to touch either the artery or the 
cannula. A video dimension analyser was used to take the measurements from the 
vessel, which was visualised using a camera and monitor.
Once the equilibration period was over the Krebs solution was removed and replaced 
with neutral buffer formalin and the vessel was fixed overnight (a minimum of 18 hours 
and a maximum of 24 hours).
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Following the fixation procedure the vessel was carefully removed, taken down from 
the cannula, placed in 70% ethanol and stored in the fridge until required. Vessels were 
normally used within a week to a month of being fixed.
4.2.4. Staining procedure
The arteries were removed from ethanol and washed once in distilled water. The end of 
the vessel, which had been tied off during the pressurisation procedure, was cut, 
proximal to where the vessel had been tied, in order to open up the lumen. This allowed 
the staining reagent access to the inside of the vessel resulting in better staining of the 
individual cells.
The arteries were placed in a solution of sodium borohydride prior to staining for 10 
minutes, with gentle agitation every 2 minutes. The sodium borohydride prevents any 
non-specific histochemical reactions and binding of proteins by the free aldehyde 
groups introduced by the fixation procedure. After incubation with sodium borohydride 
the vessels were washed 4 times in distilled water.
The stain used throughout this set of experiments was the nuclear stain, propidium 
iodide (optimum excitation wavelength is 535nm and optimum emission wavelength is 
617nm) (5p,g/ml). All staining procedures were carried out in complete darkness. The 
arteries were stained for 1 hour and then washed 3-4 times in distilled water for 15 
minutes each wash.
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4.2.5. Mounting procedure
The vessels were mounted onto standard glass slides and were placed in a makeshift 
well constructed with thin streaks of a high vacuum silicone grease in the style of a 
noughts and crosses board. A drop of distilled water was placed in the well. This was 
enough to cover the vessel but not enough to allow it to move about on the slide. A 
glass cover slip (No. 1,5) was placed over the vessel and pressed down gently so as not 
to distort the 3-dimensional structure of the artery.
4.2.6. Confocal microscopy
Vessels were visualised with a Noran Odyssey Real Time Confocal Laser Scanning 
Module (CLSM) coupled to an upright Nikon Optiphot-2 microscope. The excitation 
wavelength used was the 5 14nm line of an argon ion laser with an emission wavelength 
bandpass filter of 550nm and a slit width of 15|itm. Metamorph 4.5 (Universal Imaging 
Corporation) was used throughout to acquire images for all image analysis.
Brightfield was used in the first instance to locate the position of the artery on the slide, 
firstly with a xlO objective and then with a x40 water objective. The staining of the 
artery was confirmed using a fluorescence microscope through the use of a mercury 
lamp and only after this were the vessels visualised using the CLSM.
The ‘standard’ protocol in this laboratory when looking at arteries using the CLSM is to 
take a z-series through the artery using a x40 objective in lp,m (or less) steps. This is 
repeated a total of 3 times along the length of the vessel and then from this the number
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of adventitial, smooth muscle and endothelial cell nuclei can be calculated, as well as 
the number of layers of each cell nuclei type in the artery wall and any other 
morphological features of interest to the experimenter. However, the mouse carotid 
artery, although a small artery in relative terms, is a large thick walled vessel 
(~ 50jam) in terms of murine anatomy. In addition to having thick walls, the carotid 
artery contains large amounts of elastin and collagen, which are known to autofluoresce. 
This made visualisation of the individual layers of cell nuclei almost impossible. In fact 
in most cases it proved difficult to see beyond the first layer of smooth muscle cell 
nuclei. Various staining techniques were used, with different stains, different 
concentrations and times of incubations tested to see if this aided in the visualisation of 
the vessel. After many permutations and combinations, none of which made any 
significant difference, it became clear that there were going to be limitations in the 
structural information obtained from the carotid artery using the technique of confocal 
microscopy. In the light of the recent interest in the adventitia as being more than just a 
structural component of the vessel wall, coupled with the fact that this was the only 
layer of artery that I could visualise, I decided to concentrate my efforts on studying the 
adventitial cell nuclei of WT and KO carotid arteries, in an attempt to determine the 
effects (if any) which deletion of the aiB-adrenoceptor had on the adventitia. Two 
protocols were carried out to achieve this aim. The first protocol was devised early on in 
the study as an alternative to the standard protocol used in this laboratory and was 
designed with the sole purpose of providing an estimate of the number of adventitial 
cell nuclei present in WT and KO mouse carotid arteries. The second protocol was a 
shortened version of the standard protocol that I attempted after finishing the study 
using the first protocol because I felt confident that my staining method had improved 
and that I was more skilled at using the CLSM. I restained the vessels used for the first
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protocol and performed z-series of these vessels through the adventitial layer. This 
allowed me to determine the thickness of the adventitial layer and from this I could 
calculate the density of adventitial cell nuclei. Knowing the thickness of the adventitia 
allowed me to calculate the cross sectional area of the adventitia and from this I could 
work out the number of adventitial cell nuclei in a 1mm length of artery.
4.2.7. FIRST PROTOCOL - Procedure for acquiring images of adventitial cell 
nuclei
Using a x40 water-immersion objective a focal plane within the adventitia was chosen 
which was deemed to contain (as near as possible) the first full layer of adventitial cell 
nuclei in the particular artery which was being examined. This was obviously different 
for each vessel examined. The depth at which the adventitia was imaged was 
approximately 5-lOp.m. Once the focal plane had been chosen this was the plane at 
which all subsequent images for that vessel were taken. Working from one end of the 
vessel to the other images were acquired for each section of the artery, being careful not 
to image the same nucleus twice, so that the images collected were representative of the 
number of adventitial cell nuclei present in the carotid artery at a particular focal point. 
Following this the artery was then examined to see if it was possible to visualise any 
smooth muscle or endothelial cell nuclei. If any were visible, images were acquired.
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4.2.8. SECOND PROTOCOL - Procedure for acquiring images of adventitial cell 
nuclei
Using a x40 water-immersion objective, stacks of l|im  thick serial optical slices were 
taken in z-axis starting from the first adventitial cell nuclei until the first layers of 
smooth muscle were visible. This was repeated a total of 4 times along the length of the 
vessel.
4.2.9. Procedure for acquiring images for measurement of external diameter
The artery was imaged using a xlO objective. However, due to the size of the carotid 
artery the whole artery could not be visualised within the screen. To enable the external 
diameter to be calculated 2 images were taken of each section of the artery (top and 
bottom) using an easily recognisable region that was present in both images as a marker. 
This procedure was repeated a total of 3-4 times along the length of the vessel.
4.2.10. FIRST PROTOCOL - Image analysis of adventitial nuclei images
For each individual vessel there were between 20 and 50 frames of images dependent on 
the length of each vessel. In order to carry out image analysis a certain amount of image 
processing was necessary in order to get the images into a binary format from which the 
appropriate morphometric analysis could be carried out. The first stage in the image 
processing was to threshold the individual frames. Thresholding was carried out on 
individual frames because within each set of images and even within single frames there 
were marked differences in the intensity of the fluorescence. Thresholding was set
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manually for each frame in accordance with certain criteria that were deemed to provide 
the most accurate thresholded images possible. These were:-
1. That the threshold identified as many individual objects as possible. In some cases 
when objects were in close proximity to one another the thresholding process would 
merge these objects together as one object. Therefore, a threshold was chosen which 
would minimise this effect.
2. That the threshold identified the correct boundary of as many objects as possible. 
‘Glare’ and out of focus light can distort the true size and shape of an object and so 
the decision had to be made as to what was part of the object and what was an 
artefact of the imaging acquisition.
When a suitable threshold range had been identified i.e. it met either one or the other but 
preferably both the above criteria, the thresholded 8-bit image was converted into a 
binary image. All frames for each vessel were converted into a binary format and then 
subjected to integrated morphometry analysis (a function performed by Metamorph) 
which was used to measure a number of parameters. These were;-
1. Total area:- the total area of the object, including any holes present.
2. Perimeter:- the perimeter of the object as a measurement from the midpoints of each 
pixel around the border.
3. Fibre length:- the maximum length of the object.
4. Fibre breadth:- the maximum width of the object.
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5. Shape factor;- this is a value from 0 to 1 representing how closely the object 
represents a circle. A straight line would have a shape factor of 0 and a perfect circle 
a shape factor of 1.
6. Elliptical form factor:- this is the ratio of the objects breadth to its length.
These measurements were used to determine suitable classifying parameters with which 
to identify and count the number of adventitial cell nuclei. From these measurements it 
was decided that the total area and shape factor would be the best parameters to use.
One vessel was then chosen at random and the area and shape factor of each object was 
measured again along the length of the vessel, this time with a view to determining a 
range of values which appeared to consistently represent single adventitial cell nuclei. 
This was carried out in parallel with the original images, because it is much easier to 
identify an adventitial cell nuclei by sight rather than by a numerical method. On this 
basis, a total area classifier of between 300-4000 pixels and a shape factor classifier of 
0.6-1.0 was used. If an object was smaller than 300 pixels it was assumed that it was (1) 
not an adventitial cell nuclei i.e. it was possibly debris or autofluorescence from 
collagen and elastin fibres or (2) it was a nuclei that was on a different plane from that 
which the image had been taken and only a small fraction of the nuclei was visible.
Any object that was greater than 4000 pixels was generally more than one nucleus and 
so was not counted. The shape factor classifier was chosen because although adventitial 
cell nuclei are generally circular or round they are never a perfect circle and will 
invariably have a shape which is somewhere between that of a circle and an ellipse. In 
addition, the classifier, as it stands, rules out the possibility of including any stray 
smooth muscle cells in the count.
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The data generated by both the measuring and classifying parameters was logged in 
Microsoft Excel 97. The mean and s.e.m. were calculated only for the classifying 
parameters (total area and shape factor) and then transfeiTed into GraphPad Prism 3.01. 
to enable further analysis of the data (e.g. graphical representation of the data, statistical 
tests). The number of adventitial cell nuclei per mm^ was calculated by dividing the 
number of adventitial cell nuclei counted by the area of artery from which the images 
had been taken. The area of vessel was calculated as follows:- each image is 512 x 512 
pixels which, when using a x40 objective is equal to 100.4 x 100.4 pm (1pm = 5.1 
pixels). Therefore the number of images acquired multiplied by 100.4pm is equal to the 
length of the vessel. This value, when multiplied by 100.4pm gives the area of the 
imaged artery. The values calculated from this method were entered into GraphPad 
Prism 3.01. to allow for further analysis.
4.2.11. SECOND PROTOCOL - Image analysis of adventitial cell nuclei images
To deteimine the density of adventitial cell nuclei in each of the vessels analysed the 
thickness of the adventitial layer had to be determined in addition to counting the 
number of adventitial cell nuclei. The adventitia was defined as beginning from the first 
adventitial cell nucleus at its maximum intensity and ending with the first smooth 
muscle cell nucleus at its maximum intensity. Metamorph has a tool which records the 
intensity of the fluorescence of individual cells thus allowing me to identify the 
individual frames which contained the first adventitial cell nucleus and first smooth 
muscle cell nucleus at their maximum intensities. Each image is captured at intervals of 
1pm therefore the thickness of the adventitial layer can be determined. Once this had 
been calculated the adventitial cell nuclei were counted to this depth and the density
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calculated by dividing the number of adventitial cell nuclei by the volume of the 
adventitia (the volume of the adventitia was calculated by area of adventitia imaged 
multiplied by the thickness of the adventitia) and was expressed as number of 
adventitial cell nuclei/mm^ of artery. The cross sectional area (c.s.a.) of the adventitia 
was calculated using the equation:- 
c.s.a. = 7t.((D/2)^  -  (D/2-Xf ) 
which simplifies to:- 
c.s.a. = 7r.T(D-T)
where D = external diameter (pm) and T = thickness of adventitial layer (pm).
The number of adventitial cell nuclei in a 1mm length of artery can then be calculated 
by multiplying the cross sectional area of the adventitia by the density of adventitial cell 
nuclei by 1mm. All data obtained using this protocol was analysed using Graph Pad 
Prism 3.01.
4.2.12. Image analysis for determination of external diameter
Images were analysed in their corresponding pairs, with one image showing the top of 
the vessel and the other the bottom. The marker was identified and using the single line 
tool a horizontal line was drawn through the centre of the marker region on the image 
which represented the top of the artery. 3 vertical lines were then drawn at separate 
intervals along the image, going from the horizontal line to the edge of the vessel, which 
was identified manually. The length of these vertical lines, in pixels, was measured.
This process was repeated on the image representing the bottom of the artery, with the 
vertical lines from this image being drawn as close as possible to the vertical lines from
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the image showing the top of the artery. Adding together the length of the two vertical 
lines from the top and bottom images of the artery gave the external diameter at that 
point. Three measurements of the diameter were taken from each section of artery 
which had been imaged therefore in total there were between 9 and 12 external 
diameters calculated for each vessel. These diameters were averaged and then converted 
from pixels into microns (1 pixel = 0.77pm) after which they were entered into 
GraphPad Prism 3.01.to allow for analysis of the data.
All WT and KO data was analysed for statistical significance using an unpaired t test. A 
p value of less than 0.05 was considered significant.
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4.3. RESULTS
4.3.1. External diameters
The external diameters for WT and KO murine carotid arteries determined using the 
video dimension analyser were not significantly different. The WT carotid artery was 
found to have an external diameter of 541.8+23pm and the KO carotid artery had a 
diameter of 555.5±8.6pm (Figure 4.1). However, the external diameters determined 
from images taken with a xlO objective using a CLSM showed a significant difference 
between WT and KO carotid arteries. The WT had a diameter of 575+7.8pm, whilst the 
KO had a significantly smaller diameter of 513.8+14.3pm (p<0.05) (Figure 4.1). A 
comparison was made of the measurements taken in WT and KO arteries using both the 
video dimension analyser and the CLSM to determine if fixation of the artery affected 
its diameter and also to determine the accuracy of the video dimension analyser. It is 
assumed that images taken with the confocal microscope provide a more accurate 
measurement of the actual diameter of the vessel because the image is viewed in more 
detail than when using the video dimension analyser. Figure 4.2 shows the graphical 
representation of this comparison for WT and KO carotid arteries. For WT arteries there 
is no significant difference between the diameters obtained with the video dimension 
analyser than those obtained with the CLSM. However, the KO arteries were found to 
have a greater diameter when measured using the video dimension analyser than when 
using the CLSM (p<0.05).
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Figure 4.1:- External diameters of WT and KG murine carotid 
arteries, pressurised at 120mmHg and measured using the VDA 
prior to fixation of the arteries (top) and the CLSM after fixation 
(bottom). Data is presented as mean ± s.e.m for the number of 
arteries indicated in brackets. * indicates p<0.05.
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Figure 4.2:- A comparison of the external diameters calculated 
using the CLSM and the VDA in WT (top) and KO (bottom) 
murine carotid arteries. Data is presented as mean ± s.e.m for the 
number of arteries indicated in brackets. * indicates p<0.05.
4.3.2. FIRST PROTOCOL -  Adventitial cell nuclei morphology
The shape factors of the adventitial nuclei from WT and KO mouse carotid arteries were 
virtually identical (Figure 4.3). WT adventitial nuclei were found to have a shape factor 
of 0.77+0.009, whilst KO adventitial nuclei had a shape factor of 0.76+0.004.
No differences were observed concerning the area of each adventitial nuclei. WT 
adventitial nuclei had an average area of 48.2+4.4pm^, whilst KO adventitial nuclei 
averaged an area of 45.7+1.8pm^ (Figure 4.3).
The number of adventitial nuclei occurring in a Imm^ area of adventitial tissue was 
calculated. No significant differences were observed in the number of adventitial nuclei 
in KO carotid arteries when compared with WT. In WT carotid arteries there were 
796+54 adventitial nuclei/mm^ of artery and in the KO carotid artery there was found to 
be 718+42 adventitial nuclei/mm^ (Figure 4.3).
4.3.3. SECOND PROTOCOL -  Adventitial thickness and cell nuclei density
There was no difference in the thickness of the adventitial layer of WT and KO carotid 
arteries. The WT adventitia had a thickness of 19.4+1.5pm, which was virtually 
identical to the thickness of the KO adventitia which was 19.8+1.2pm (Figure 4.4).
The cross sectional area of the adventitia, which is calculated from the external diameter 
and the thickness of the adventitia showed no significant differences between WT and 
KO carotid arteries. This is despite there being a significant difference in the external
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Figure 4.3:- Shape factor (top) and area (middle) of individual adventitial 
cell nuclei from WT and KO murine carotid arteries along with the number of 
adventitial cell nuclei per mm^ of artery (bottom). A shape factor of 0 represents 
a straight line and a shape factor of 1 represents a perfect circle. Data is 
presented as mean ± s.e.m and n=7 for WT and KO. All arteries were 
pressurised and fixed at 120mmHg, stained with propidium iodide and 
imaged using a CLSM.
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Figure 4.4:- Thickness (top) and cross sectional area
of the adventitia (bottom) from WT and KO murine carotid arteries.
All arteries were pressurised and fixed at 120mmHg, stained with 
propidium iodide and imaged using a CLSM. Data is presented as mean 
± s.e.m for the number of arteries indicated in brackets. For WT n=6 
and for KO n=7
diameter of the KO carotid artery compared with the WT, when measured using CLSM. 
The cross sectional area of the WT adventitia was 33,309±2345pm^ while the KO 
adventitia had a cross sectional area of 30,093±2087pm^ (Figure 4.4).
The density of adventitial nuclei in a Imm^ volume of adventitia was calculated. 
Although there was no difference in the thickness or cross sectional area of the 
adventitia between WT and KO carotid arteries there was a significant difference in the 
density of adventitial nuclei (p<0.05). The KO carotid artery was found to have a 
smaller density of adventitial nuclei (1.05+0.05 xlO^ adventitial nuclei/mm^) in 
comparison to the WT carotid artery which was found to havel.24+0.09 xlO^ adventitial 
nuclei/mm^ (Figure 4.5). The density of nuclei in the KO adventitia is 85% of the 
density of nuclei in WT adventitia.
The number of adventitial nuclei in a 1mm length of artery was also found to be 
significantly different between WT and KO arteries following a similar pattern to the 
density. As with the density of adventitial nuclei the actual number of nuclei in the KO 
adventitia was 85% of that in the WT. The number of nuclei was calculated as 
3782+144 in the WT adventitia and 3213+191 in the KO adventitia (p<0.05) (Figure 
4.5).
Figure 4.6 shows the data from both protocols in tabular form and Figures 4.7-4.12 are 
representative images of the adventitia, media and intima taken from WT and KO 
carotid arteries.
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Figure 4.5:-Mean density of adventitial cell nuclei (top) and number of 
cell nuclei in a 1mm length of WT and KO murine carotid arteries (bottom). 
All arteries were pressurised and fixed at 120mmHg, stained with 
propidium iodide and imaged using a CLSM. Data is presented as 
mean ± s.e.m for the number of arteries indicated in brackets. For WT 
n=6 and for KO n=7. * indicates p<0.05.
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Figure 4.6:- Tabular representation of structural data obtained from 
WT and KO carotid arteries using a VDA and a CLSM. Data is presented 
as mean ± s.e.m. Data in bold print was obtained from second protocol, 
all other data was obtained from first protocol. indicates p<0.05 
between WT and KO carotid arteries. # indicates p<0.05 between KO VDA 
external diameter and KO CLSM external diameter. NA = not applicable.
»Figure 4.7:- Adventitial cell nuclei from WT murine carotid artery, 
stained with propidium iodide and imaged using CLSM at x40 
magnification. Each image was captured from a different vessel - 
continued over the page.
Figure 4.7 continued:- Adventitial cell nuclei from WT murine
carotid artery, stained with propidium iodide and imaged using
CLSM at x40 magnification.
Figure 4.8:- Adentitial cell nuclei from KO murine carotid artery, 
stained with propidium iodide and imaged using CLSM at x40 
magnification. Each image was captured from a different vessel - 
continued over the page.
Figure 4.8 continued:- Adventitial cell nuclei from KO murine
carotid artery, stained with propidium iodide and imaged using
CLSM at x40 magnification.
Figure 4.9:- Smooth muscle cell nuclei from W T murine 
carotid artery, stained with propidium iodide and imaged using 
CLSM at x40 magnification. Each image was captured from a 
different vessel - continued over the page.
Figure 4.9 continued:- Smooth muscle cell nuclei from WT murine
carotid artery, stained with propidium iodide and imaged using CLSM
at x40 magnification. Some adventitial cell nuclei are visible.
Figure 4.10:- Smooth muscle cell nuclei from KO murine carotid 
artery, stained with propidium iodide and imaged using CLSM 
at x40 magnification. Some adventitial cell nuclei are visible. 
Each image was captured from a different vessel - continued 
over the page.
Figure 4.10 continued:- Smooth muscle cell nuclei from KO murine
carotid artery, stained with propidium iodide and imaged using
CLSM at x40 magnification.
Figure 4.11:- Endothelial cell nuclei from WT murine carotid 
artery, stained with propidium iodide and imaged using 
CLSM at x40 magnification. Each image was captured 
from a different vessel.
Figure 4.12:- Endothelial cell nuclei from KO murine carotid 
artery, stained with propidium iodide and imaged using 
CLSM at x40 magnification. Each image was captured 
from a different vessel.
4.4. DISCUSSION
The carotid artery of the mouse, despite being a major conduit vessel and one of the 
largest vessels found in the mouse vasculature, is relatively small compared to its 
equivalent in the rat. The external diameter of the rat carotid artery is approximately 
950pm in WKY rats (Marano et al, 1999) whereas in the mouse this is approximately 
550pm. The two methods used to measure the external diameter of the mouse carotid 
arteiy gave slightly different dimensions and one method, CLSM, revealed a difference 
between WT and KO. This difference (~10%) was substantial (WT = 575±7.8pm, KG = 
513.8±14,3pm). No differences were observed in the weights of WT and KG mice used 
throughout this project excluding a simple proportionate difference based on the size of 
the miee. The basis for the difference between the two measurement techniques was that 
the WT dimensions were similar using both methods but the KG dimensions were 
smaller using the CLSM. Video dimension analyser measurement is made prior to 
fixation so the difference with CLSM may be a result of shrinkage during fixation. If so, 
it is not obvious why this should occur in the KG carotid artery but not in the WT. This 
may point to a structural difference between the two arteries. Another explanation for 
the differences observed using these two methods is that the video dimension analyser 
introduces more experimental error than the CLSM. Whilst both methods rely on the 
experimenter to determine the boundaries of the vessel wall the CLSM allows 
visualisation of the artery in more detail than the video dimension analyser making it 
easier to define the edge of the vessel. Therefore, the external diameters of WT and KG 
carotid arteries as measured using CLSM may be a truer representation of the actual 
diameter of these vessels.
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The smaller external diameter of the KO carotid artery does not seem to be a 
consequence of the structural differences in the adventitia of this artery (discussed in 
detail below) which may indicate that there are also structural differences in the smooth 
muscle and endothelial layers of the artery. Due to the practical limitations of using 
CLSM to visualise the carotid artery, the images obtained of the smooth muscle and 
endothelial cell nuclei were not of a sufficient quality to allow any analysis to be carried 
out.
The Institute of Biophotonics within the Strathclyde Institute of Biomedical Science at 
Strathclyde University has developed lasers for dual photon confocal microscopy. This 
technique can produce images of better quality than those obtained using single photon 
confocal microscopy. Two photons of double the usual excitation wavelength, arriving 
close in time, excite the fluorophore. Since this occurs only at the point of focus, less 
unintended excitation occurs outside the plane of focus, making the image sharper. This 
is particularly suitable for visualisation of thick specimens such as intact blood vessels.
I am hopeful that I will be able to get access to this microscope to allow me to visualise 
the WT and KO carotid arteries in more detail than was possible using the CLSM.
Using this microscope I should be able to visualise the smooth muscle and endothelial 
layers of the vessels and so determine whether or not there are structural differences in 
these layers of the KO carotid artery, as well as in the adventitia.
The carotid arteries from WT and KO mice have been characterised pharmacologically 
in the previous chapter and were found to mediate contraction predominantly through 
the aiD-adrenoceptor, although there was some evidenee that the ais-adrenoceptor 
contributed to the contraction in the WT carotid artery. The cxi s -adrenoceptor has been
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implicated in the regulation of growth of vascular smooth muscle cells (Chen et al,
1995) and in the trophic effects in the adventitia following balloon injury of the rat aorta 
(Zhang and Faber, 2001). In addition, preliminary findings from our own laboratory 
indicate a smaller density of adventitial cell nuclei in KO mouse tail arteries when 
compared with WT arteries, which may result from the deletion of the «iB-adrenoceptor 
(Daly, unpublished observations). As a consequence of these studies I was interested in 
studying the adventitia of the carotid artery, to determine if deletion of the aie- 
adrenoceptor had any effects on the adventitia of KO carotid arteries.
Two protocols were used to investigate different aspects of the adventitia. The first 
protocol provided me with information on the shape factor and area of individual 
adventitial cell nuelei, as well as an estimate of the number of nuclei per mm^ of vessel. 
The second protocol allowed me to measure the thickness of the adventitial layer and to 
calculate the cross sectional area of the adventitia, the density of adventitial cell nuclei 
per mm^ and the number of adventitial cell nuclei in a 1mm length of artery.
The data obtained using the first protocol showed no significant differences in the 
shape, area or number of adventitial cell nuclei between WT and KO carotid arteries. 
However, a number of limitations exist with this protocol. A consequence of taking a 
series of images at one focal plane along the length of the vessel is that a percentage of 
the nuclei will not be completely within the focal plane. Alternatively two nuclei from 
different focal planes may overlap and appear as one nuclei, therefore a decision had to 
be made about whether or not to include these nuclei in the image analysis. To decide 
which nuclei were included and which were excluded, limits were set on the size and 
shape that a nuclei had to be if it was to be included in the image analysis. Therefore,
167
nuclei that were too small were those that were not sufficiently in the focal plane and 
those which were too large were classed as more than one nuclei and these were 
excluded from the analysis. This results in a skewed data analysis but was felt to be 
necessary if any meaningful information was to arise from this protocol.
The second protocol provided me with information on the thickness of the adventitia 
and the density of adventitial cell nuclei. The thickness’ of the adventitia of WT and KO 
carotid arteries were virtually identical, approximately 19pm. This is a similar 
adventitial thickness to that reported for the second order mesenteric arteries of the rat, 
which was found to be approximately 15 pm in WKY rats and approximately 21pm in 
SHRSP rats (Arribas et al, 1997). This is interesting given the different physiological 
roles that these vessels have and that these rat mesenteric vessels are smaller (external 
diameter ~ 250-300pm) than the mouse carotid artery. This may suggest that the 
composition of the adventitia is similar regardless of the size and physiological role of 
the individual vessels.
The density of adventitial cell nuclei and the number of cell nuclei in 1mm of vessel 
were found to be significantly smaller in KO carotid arteries compared with WT 
arteries. The difference between WT and KO vessels for these two parameters was 
similar in that the values in the KO artery were 85% of those in the WT. The smaller 
density that was observed in this study is similar to findings in the KO tail artery where 
the density of adventitial cell nuclei was also found to be smaller (Daly, unpublished 
observations). Adventitial fibroblasts from rat aorta and carotid artery have recently 
been shown to express the mRNA for all three «i-adrenoceptor subtypes (Faber et al, 
2001). At the protein level (as assessed by radioligand binding) the dominant subtypes
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expressed on the adventitial fibroblasts from these vessels appear to be the a\A- and 
aiB-adrenoceptors (Faber et al, 2001). The functional significance of ai-adrenoceptors 
being expressed on adventitial fibroblasts is at present unknown but stimulation with 
noradrenaline has been shown to induce proliferation and protein synthesis (Faber et al, 
2001), similar to the effects observed when smooth muscle cells are stimulated with 
noradrenaline (Xin et al, 1997). This has led to suggestions that the cxi -adrenoceptors on 
adventitial fibroblasts may signal a trophic action of catecholamines on vascular wall 
growth and remodelling. The trophic effect o f noradrenaline on the adventitia of the 
balloon injured rat aorta has been shown to be inhibited by the aiB-adrenoceptor 
antagonist, AHl 1110A, suggesting that this action is mediated by the am-adrenoceptor. 
aiA- and aio-adrenoceptor antagonists had no effect (Zhang and Faber, 2001).
Although the presence of ai-adrenoceptor subtypes on the adventitia of mouse blood 
vessels has yet to be demonstrated, it is possible that they too express all three ai- 
adrenoceptor subtypes. If the aie-adrenoceptor’s role is to mediate vascular growth, as 
has been suggested (Zhang and Faber, 2001), then it seems plausible that the decrease in 
the density and actual number of adventitial cell nuclei in the KO carotid arteiy is a 
direct result of deletion of the «iB-adrenoceptor from this tissue. Although the KO 
carotid artery has a significantly smaller external diameter when measured using a 
CLSM this does not explain the smaller density of adventitial cell nuclei or the smaller 
number of cell nuclei. There is no difference in the cross sectional areas of WT and KO 
adventitia therefore there is a smaller number and density of cell nuclei in the KO 
carotid artery in the same volume of tissue as there is in the WT. A reduction in the 
number of cells might have been an adaptation to a smaller circumference but the 
reduced density reported here suggests a change beyond this.
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Additional studies would be required to uncover the mechanism by which deletion of 
the aiB-adrenoceptor results in a smaller density of adventitial cell nuclei. In the first 
instance the presence of ai-adrenoceptors on adventitial cells should be investigated. 
This could be achieved by using a fluorescent analogue of prazosin, QAPB, which our 
laboratory has worked with for a number of years, in combination with confocal 
microscopy. If ai-adrenoceptors are present on adventitial cells then QAPB will 
fluoresce when bound to these receptors allowing visualisation and localisation of the 
receptors. If experiments such as these provided evidenee for ai-adrenoceptors on the 
adventitial cells of mouse blood vessels a further question might be “do these receptors 
in any way contribute to modulation of contraction in the artery?” Taking the carotid 
artery as an example, if the adventitia of the WT carotid artery contains an aiB- 
adrenoceptor population, it is possible that it could be these aiB-adrenoceptors which 
are influencing the oi]-adrenoceptor pharmacology in functional studies, possibly 
through the release of a mediator. Therefore, would removal of the adventitia result in 
the WT having the same pharmacology as the KO carotid artery i.e. contraction 
mediated solely through the am-adrenoceptor? There is some evidence to suggest that 
the adventitia can influence contraction. When the adventitia was removed from the rat 
carotid artery the response to noradrenaline was reduced, although it remains to be 
determined whether removal of the adventitia directly or indirectly affected contraction 
(Gonzalez et al, 2001). Alternatively the aiB-adrenoceptors could be present on the 
smooth muscle cells, from where they exert an influence over the adventitia. Overall it 
seems more likely that aiB-adrenoceptors will be found to be present on both the 
adventitia and the smooth muscle as Faber et al (2001) have reported for the rat aorta 
and carotid artery.
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The adventitia has traditionally been regarded as nothing more than a structural support 
for the media. However as the evidence mounts, it seems that the adventitia has a more 
direct influence on vascular activity than it has been credited with. In addition to a p  
adrenoceptors the adventitia has also been shown to express a 2D-adrenoceptors (Faber 
et al, 2 0 0 1 ) and has been shown to be capable of releasing nitric oxide in amounts 
comparable to that released from the endothelium, in response to endotoxin (Zhang et 
al, 1999; Kleschyov et al, 2000). Transfection of the endothelial nitric oxide synthase 
gene into the adventitia of blood vessels has been shown to improve relaxation of 
atherosclerotic arteries (Ooboshi et al, 1998) and to restore relaxation of arteries which 
have had their endothelium removed (Tsutsui et al, 1998). This ability of the adventitia 
to release nitric oxide and the success of adventitial transfections may have clinical 
implications for pathological conditions such as atherosclerosis where relaxation of 
blood vessels is impaired. The adventitia is also proving to be important in models of 
neointimal lesion formation caused by procedures such as angioplasty where studies 
have shown that one of the first stages in this process is proliferation of adventitial cells, 
with some groups also showing that adventitial cells migrate to the site of the neointima 
(Wilcox et al, 1996; Shi et al, 1996; Li et al, 2000). Studies such as these have, in the 
past, focused on the endothelium, but the emphasis is now shifting towards the 
adventitia as its importance in the pathology of these conditions is uncovered. Like the 
endothelium, which was once thought to be merely a barrier between the blood and 
blood vessels, it appears that the adventitia is directly involved in vascular biology and 
its importance in physiological and pathophysiological functions is certain to become a 
subject of great interest to researchers in the future.
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CHAPTER 5 -  GENERAL DISCUSSION
5. GENERAL DISCUSSION
Although pharmacology alone is not sufficient to clearly and confidently identify and 
subtype aradrenoceptors, when it is combined with transgenic technologies the process 
can be made easier. Transgenic mice have been used in pharmacological research for a 
number of years (Plump et al, 1992; Rohrer and Kobilka, 1998) but it was only in 1997 
that a transgenic mouse was designed which did not express the aiB-adrenoceptor 
(Cavalli et al, 1997). Although transgenic mice had been produced previous to this, 
which either overexpressed the aiB-adrenoceptor (Ahkter et al, 1997) or expressed a 
constitutively active aiB-adrenoceptor (Milano et al, 1994), the expression of these 
receptors was generally confined to the myocardium. The mouse designed by Cavalli et 
al was novel in that the aiB-adrenoceptor was not expressed in any o f the tissues of the 
mouse.
Much of the confusion that arises when attempting to functionally define ai- 
adrenoceptor subtypes is a result of there being no satisfactory drug to identify the am- 
adrenoceptor. Its presence in native tissues has often been suggested purely on the basis 
of eliminating the other oq-adrenoceptor subtypes from being present rather than a 
positive identification of the aie-adrenoceptor. (Testa et al, 1995c; Van der Graaf et al, 
1996a; Smith et al, 1997). The oiie-adrenoceptor KO mouse provides a unique 
opportunity in which to study the functional roles of the a  i-adrenoceptor subtypes, 
which provides, for the first time, an environment in which the functional presence of 
the aiB-adrenoceptor can be discounted.
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A novel ai-adrenoceptor antagonist proposed to be selective for the aiB-adrenoceptor 
(Patane et al, 1998) became available to me throughout the course of my project and it 
was hoped that this drug would succeed where many before have failed, in that it would 
be selective for the aiB-adrenoceptor. The binding studies carried out using L765,314 
by Patane et al (1998) looked promising. At aib-adrenoceptors L765,314 had 10-fold 
higher affinity than the oiid-adrenoceptor and 1 0 0 -fold higher affinity for the aia- 
adrenoceptor. L765,314 also appeared to be selective for native aiB-adrenoceptors 
showing 35-65 fold differences in affinity at the aiB-adrenoceptors in rat liver and 
spleen compared to the aiA-adrenoceptors of rat and human prostate. However, my 
own experience of using this drug is that the selectivity claimed by Patane et al (1998) 
simply does not exist. The tissue in which I expected a significant difference in the pKi 
values with this drug was in the WT and KO liver. Unfortunately, L765,314 was found 
to bind with similar affinity in both the WT and KO liver, similar affinities were also 
obtained in WT and KO brain tissue. This poor performance was witnessed once again 
in the functional studies in the WT and KO carotid artery. L765,314 does seem to be 
capable of binding to ai-adrenoceptors with a high affinity but it fails to discriminate 
between subtypes. This is a similar story for many of the ‘am-adrenoceptor antagonists’ 
discovered to date whereby the original paper shows evidence that the drug is selective 
for the aiB/b-adrenoceptor but future studies fail to repeat this.
P r e lim in a r y  s t u d ie s  c a r r ie d  o u t  b y  C a v a l l i  et al (1997) in v e s t ig a t in g  th e  fu n c t io n a l  
c o n s e q u e n c e s  o f  d e le t in g  th e  a iB - a d r e n o c e p t o r  r e v e a le d  th a t  th e  o t iB -a d r e n o c e p to r  w a s  
a b s e n t  f r o m  a l l  th e  t i s s u e s  in  w h ic h  i t  w a s  b e l i e v e d  to  b e  e x p r e s s e d .  In t h o s e  t i s s u e s  
w h e r e  th e  (X iB -a d ie n o c e p to r  w a s  b e l i e v e d  to  b e  e x p r e s s e d  in  c o n j u n c t io n  w i t h  a n o th e r  
s u b t y p e  i .e .  th e  b r a in , th e  c x i-a d r e n o c e p to r  n u m b e r  w a s  r e d u c e d  w h i l s t  th e  l iv e r , w h ic h
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has been proposed by Cavalli et al (1997) and Yang et al (1998) to possess a pure 
population of aiB-adrenoceptors, was found to have virtually no oii-adrenoceptors in the 
KO. The binding studies in the brain presented in chapter 2 are in agreement with those 
of Cavalli et al. A reduced receptor number was reported in the KO brain compared 
with the WT and subtyping studies revealed that the WT brain contained a mixture of 
aiA- and aiB-adrenoceptors in a ratio of 36%: 64%, similar to the ratios reported by 
Cavalli et al (1997) and Yang et al (1998). The KO brain contained a pure population of 
ai A-adrenoceptors.
The phenotypic changes associated with the loss of the aiB-adrenoceptor from the brain 
were not investigated in this project. However, with the recent results of Zuscik et al
(2000) demonstrating the neurodegenerative effects of overexpression of the am- 
adrenoceptor, it would definitely be worthwhile examining the brains of KO mice for 
any physical manifestations o f deletion o f the otiB-adrenoceptor.
The binding studies in the KO liver, which are presented in this thesis and those 
reported by Cavalli et al (1997) are different. Cavalli et al (1997) found there to be no 
a  1-adrenoceptors present in the livers of KO mice whereas my own studies found that 
there were ai-adrenoceptors expressed in the liver which were subsequently subtyped to 
be aiA-adrenoceptors. These differing results appear to be due to methodological 
differences that have been discussed in Chapter 2, Section 2.4.2.
The data obtained Jfrom the KO liver suggests that the mouse liver is capable of 
upregulating and expressing an alternative ai-adrenoceptor subtype if the normal ai- 
adrenoceptor subtype fails to function.
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The liver is a unique organ. It is well known it has a massive regenerative potential. In 
fact, repopulation studies investigating the regeneration of the liver and replication of 
hepatocytes have discovered that the hepatocyte has a proliferative potential that may 
even exceed that of stem cells in haemopoietic tissues (Fausto, 1999). Another unusual 
characteristic of the liver, that has been well doeumented for the rat liver, is that there is 
an age-related changeover in the adrenoceptor that controls glucose metabolism. In the 
immature animal, glucose mobilisation is mediated through p2-adrenoceptors whilst the 
mature animal mediates glucose metabolism through ai-adrenoceptors (Rossby and 
Cornett, 1991; Thai et al, 1996). While it is possible that the mouse liver responds in a 
similar manner during maturation this has yet to be confirmed and would require further 
studies. However, my own studies show that not only is the liver able to change the ai- 
adrenoceptor subtype it expresses but it seems that the murine liver does not require an 
« 1-adrenergic component in the first few months of life for it to function effectively; at 
3 months of age there is a negligible amount of ai-adrenoceptor protein in the KO liver. 
Does this mean that the |3-adrenergic component is present in the mouse liver until 3 
months of age? Or is this a consequence of the deletion of the am-adrenoceptor? In rats, 
the density of (3-adrenoceptors had fallen to a low level by postnatal day 6  (Rossby and 
Cornett, 1991). If this phenomenon is also observed in mice does the deletion of the 
aiB-adrenoceptor delay this changeover from ^ to aj?
The liver is a useful tissue in which to study oti-adrenoceptors because it is one of the 
few tissues that appears to possess a homogeneous population of ai-adrenoceptors and 
in the light of the findings in the KO liver may prove to be a valuable tissue in which to 
investigate the regulation of expression of ai-adrenoceptor subtypes.
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However most tissues, in particular blood vessels, express multiple subtypes, the 
functional significance of which remains unknown. In addition, there is a lot of 
confusion surrounding the identity o f the subtypes which are expressed in blood vessels 
whereby different groups identify different subtypes as being functionally present in the 
same vessel. The use of a transgenic mouse, such as the aiB-adrenoceptor KO mouse 
provides a means by which at least one subtype can be eliminated from the equation 
before any experiments are carried out and simplifies the daunting task o f determining 
the subtypes responsible for contraction in blood vessels.
The pharmacological analysis of the a  i-adrenoceptor mediating contraction in the WT 
carotid artery was made easier because the experiments could be lun in parallel with the 
KO carotid artery and comparisons made between the two arteries. The overall 
pharmacology of the two arteries was broadly similar. However, the KO carotid artery 
was found to have an increased sensitivity to phenylephrine, while the WT carotid 
artery appeared to express a heterogeneous population of ai-adrenoceptors, producing 
shallow Schild slopes with L765,314 and BMY7378. The pharmacology of the KO 
carotid artery suggested that contraction was mediated by a pure population of cxid 
adrenoceptors whereas the WT carotid artery appeared to mediate contraction 
predominantly through aio-adrenoceptors with a component mediated by the aiB- 
adrenoceptor. The loss of the aiB-adrenoceptor from the KO carotid artery did not alter 
the pharmacology of this artery substantially but eliminated the heterogeneity alluded to 
by the shallow Schild slopes in the WT carotid artery and resulted in an increase in the 
apparent affinity of BMY7378 in the KO carotid artery.
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The functional role o f the aiB-adrenoceptor in the WT carotid artery appears to be 
minor, which corresponds with popular opinion at this time that the primary role o f the 
aiB-adrenoceptor is not to mediate contraction of blood vessels. The sensitivity of 
phenylephrine in mice that either overexpress the aiB-adrenoceptor or have a 
constitutively active ais-adrenoceptor provides further evidence that the am- 
adrenoceptor’s contribution to contraction in blood vessels is minor. Mesenteric arteries 
from these mice were found to display no differences in sensitivity or size of response 
to phenylephrine providing no evidence for a role of the aiB-adrenoceptor in these 
vessels. Cavalli et al (1997) proposed a role for the aiB-adrenoceptor in the 
maintenance o f blood pressure when they found that the KO mouse had a decreased 
pressor response to phenylephrine and a decreased response to phenylephrine in the 
mouse aorta in vitro. This was not reflected in the observations from mesenteric arteries, 
which might have been expected to reflect the in vivo pressor response. Further work is 
required to explain this discrepancy between in vivo and in vitro observations.
As the evidence increases it seems that the ai e-adrenoceptor’s role, rather than being 
one of contraction in blood vessels, may be in an involvement in the growth response of 
arteries. Chen et al (1995) demonstrated an aiB-like adrenoceptor mediated hypertrophy 
in rat aortic smooth muscle cells while Zuscik et al (2001) reported that mice which 
overexpressed the aiB-adrenoceptor showed early signs of cardiac hypertrophy. Zhang 
and Faber (2001) found that the trophic effects on the adventitia caused by balloon- 
injury of the rat aorta could be inhibited by an aiB-adrenoceptor antagonist. Faber et al
(2001) have also recently reported that the adventitial fibroblasts, as well as the smooth 
muscle cells, of the rat aorta express ai-adrenoceptor subtypes and, when stimulated
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with noradrenaline, were found to mediate proliferation, although the identity of the 
subtype was not determined.
The density and number of adventitial cell nuclei in the KO carotid artery were found to 
be significantly smaller when compared with the WT carotid artery. The mechanism 
underlying this reduction remains to be determined. However, the discovery that a p  
adrenoceptors are expressed on adventitial cells (Faber et al, 2001) raises the possibility 
that the decrease in the density of cells may be directly related to the deletion of the «ib- 
adrenoceptor from adventitial cells. The presence of ai-adrenoceptors on the adventitia 
of mouse blood vessels has not been confirmed but would seem likely given that they 
are expressed on the adventitia of rat blood vessels. Further studies are required to 
determine the mechanism through which the adventitia of the KO carotid artery has a 
smaller cell density and number. It would be of interest to examine the adventitia of 
carotid arteries from the mice that overexpress the aiB-adrenoceptor and those that 
express a constitutively active aiB-adrenoceptor to determine the density of adventitial 
cell nuclei in each of these arteries. Gonzalez et al (2001) describe a method to remove 
the adventitia from blood vessels which leaves the smooth muscle intact and functional. 
Using this method they reported that removal of the adventitia altered the pharmacology 
of the rat carotid artery. This technique could be applied to the carotid arteries of WT 
and KO mice to determine if removal of the adventitia affected the pharmacology of 
these vessels.
Our knowledge and understanding of the physiology and pharmacology of oti- 
adrenoceptors has advanced considerably since the initial discovery of subtypes over 15 
years ago. The discovery of the gene products for three ai-adrenoceptor subtypes
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confirmed what pharmacologists had been arguing about for years. Since then, a 
combination of molecular biology and pharmacology has brought us to a point at which 
it is now agreed that at least three subtypes of ai-adrenoceptor exist and much of their 
biochemistry and pharmacology has been defined. However, the gap in our functional 
knowledge of these subtypes still remains, particularly with regard to the am- 
adrenoceptor. This project, while far from filling the gap, has gone some way to 
advancing our understanding of the am-adrenoceptor. I have demonstrated that the am- 
adrenoceptor plays a minor but definite role in the contractile response of the murine 
carotid artery. This project also shows that the am-adrenoceptor may have an influence 
on the density and number of adventitial cells in the WT carotid artery, which may have 
implications for the proposed role of the am-adrenoceptor in the growth and 
development of blood vessels. Additionally, I have shown that the am-adrenoceptor, 
although the a  i-adrenoceptor normally expressed in the liver at 4 months, is not 
indispensable to the mouse. If conditions are such that the am-adrenoceptor is not 
expressed the liver is capable of upregulating another ai-adrenoceptor subtype, 
presumably to compensate. This observation raises many questions. For example, is the 
liver the only organ capable of this upregulation or do all tissues have this ability? 
Would such a mechanism be present in tissues that express multiple subtypes? What are 
the factors which switch this upregulation off or on? There is evidence for an age- 
dependent change in the functional expression of ai-adrenoceptor subtypes in blood 
vessels. Gurdal et al (1995) reported that expression of the aiA-subtype increased with 
age in the rat aorta whereas the expression of the am-subtype decreased while the am- 
adi enoceptor was unchanged. In contrast to the findings of Gurdal et al (1995), an 
investigation into the alteration of ai-adrenoceptor subtypes in the rat vasculature with
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age found that the contribution of the am-adrenoceptor increased with age (Ibarra et al, 
1997). Therefore, it appears that blood vessels are also capable of altering the 
expression of ai-adrenoceptor subtypes with age. It would be of interest to investigate 
this phenomenon in the WT and KO carotid artery at different age points to determine 
the effect of age on the expression of ai-adrenoceptor subtypes.
Many fundamental questions have been given a new direction by the present 
observations and time will tell of the relevance of these observations to the 
physiological role of ai-adrenoceptor subtypes. Studies such as this demonstrate the 
potential that transgenic animals provide to further the knowledge and understanding we 
have gained from more traditional pharmacological methods. I hope I have shown that 
in a complicated area of pharmacological research, such as that of ai-adrenoceptors,
KO mice can simplify the situation to one that is manageable and can often end up 
taking us in an unexpected direction, in our attempts to understand this field of research. 
Pharmacogenomics looks set to be the way pharmacological research is undertaken in 
the 21®^ century where mice such as the am-KO and the recently developed am-KO and 
aiB/c KG’s will bring us to an understanding of a  i-adrenoceptors that would have never 
been possible through pharmacology alone.
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APPENDIX
APPENDIX - Counts per minute for binding experiments
Cone (log M) CPM S.E.M.
NSB 106.0000 15.0000
-4.0000 114.0000 25.0000
-4.5228 104.5000 7.5000
-5.0000 114.0000 3.0000
-5.5228 202.5000 76.5000
-6 . 0 0 0 0 151.5000 37.5000
-6.5228 139.5000 0.5000
-7.0000 157.5000 1.5000
-7.5228 204.0000 3.0000
-8 . 0 0 0 0 290.5000 2.5000
-8.5228 419.0000 32.0000
-9.0000 1116.5000 6.5000
-9.5228 1678.0000 133.0000
-1 0 . 0 0 0 2225.0000 6 8 . 0 0 0 0
-10.5228 2109.5000 38.5000
-1 1 . 0 0 0 2355.5000 65.5000
-11.5228 2336.0000 34.0000
-1 2 . 0 0 0 2382.5000 16.5000
TOTAL 2349.5000 65.5000
WT BRAIN - PRAZOSIN
Cone (log M) CPM S.E.M.
NSB 154.6667 8.301271
-5.000 150.500 8.313643
-5.5228 197.6667 11.64951
-6 . 0 0 0 263.3333 33.02895
-6.5228 530.3333 81.27635
-7.000 783.8333 54.69517
-7.5228 1202.333 12.60071
-8 . 0 0 0 1514.333 69.07371
-8.5228 1796.333 180.3832
-9.000 1903.833 97.66386
-9.5228 2209.667 172.6628
-1 0 . 0 0 0 2411.667 194.6413
-10.5228 2444.000 199.0635
-1 1 . 0 0 0 2520.167 199.1374
-11.5228 2450.167 192.3219
-1 2 . 0 0 0 2542.833 205.4836
-12.5228 2497.000 223.4329
-13.000 2569.500 275.4347
TOTAL 2401.833 233.4673
WT BRAIN - RSI00329
A l
Cone (log M) CPM S.E.M.
NSB 208.500 1.500
-3.000 163.500 12.500
-3.5228 224.000 3.000
-4.000 301.500 15.500
-4.5228 531.000 32.000
-5.000 836.500 25.500
-5.5228 1219.000 16.000
-6 . 0 0 0 1550.500 3.500
-6.5228 1751.500 4.500
-7.000 2159.500 160.500
-7.5228 2288.000 67.000
-8 . 0 0 0 2280.500 21.500
-8.5228 2290.500 94.50001
-9.000 2242.500 50.500
-9.5228 2366.500 61.500
-1 0 . 0 0 0 2361.500 19.500
-10.5228 2357.000 37.000
- 1 1 . 0 0 0 2088.500 66.500
TOTAL 2197.500 1.500
WT BRAIN - (R)-A-61603 (-GTP)
Cone (log M) CPM S.E.M.
NSB 166.5000 14.563080
-2 . 0 0 0 0 178.7500 16.754970
-2.5228 176.0000 15.577760
-3.0000 163.0000 10.885770
-3.5228 181.7500 9.620941
-4.0000 293.5000 8.411302
-4.5228 472.2500 19.490920
-5.0000 861.7500 15.542280
-5.5228 1209.7500 10.403330
-6 . 0 0 0 0 1503.2500 26.603180
-6.5228 1772.2500 17.307870
-7.0000 2135.0000 61.515580
-7.5228 2221.7500 46.087550
-8 . 0 0 0 0 2269.2500 27.956440
-8.5228 2273.7500 52.950250
-9.0000 2251.0000 38.650140
-9.5228 2191.5000 45.651760
-1 0 . 0 0 0 0 2205.7500 73.057480
-10.5228 2226.7500 53.965070
-1 1 . 0 0 0 0 2281.5000 31.624090
TOTAL 2217.0000 50.518970
WT BRAIN - (R)-A-61603 (+GTP)
A2
Cone (log M) CPM S.E.M.
NSB 79.100 4.600
-4.000 60.200 3.000
-4.5228 75.200 2 . 2 0 0
-5.000 138.400 6.500
-5.5228 348.700 18.600
-6 . 0 0 0 481.100 1 1 . 0 0 0
-6.5228 1125.700 39.700
-7.000 1331.200 57.100
-7.5228 1377.200 40.000
-8 . 0 0 0 1518.000 65.300
-8.5228 1539.700 2 0 . 0 0 0
-9.000 1596.900 47.600
-1 0 . 0 0 0 1604.000 74.800
-1 1 . 0 0 0 1609.800 105.800
TOTAL 1601.500 79.800
WT BRAIN-L765,314
Cone (log M) CPM S.E.M.
NSB 106.500 2 . 0 0 0
-3.000 122.250 3.750
-3.5228 129.8575 19.3575
-4.000 146.750 5.250
-4.5228 200.500 12.500
-5.000 297.750 0.250
-5.5228 537.250 21.250
-6 . 0 0 0 827.750 10.750
-6.5228 1164.250 110.250
-7.000 1315.250 50.750
-7.5228 1341.250 46.250
-8 . 0 0 0 1322.000 8 . 0 0 0
-8.5228 1382.750 15.250
-9.000 1318.500 45.500
-9.5228 1322.250 32.250
-1 0 . 0 0 0 1371.750 43.250
-10.5228 1332.500 2 2 . 0 0 0
-1 1 . 0 0 0 1424.250 89.250
TOTAL 1323.250 55.250
WT BRAIN - BMY7378
A3
Cone (log M) CPM S.E.M.
NSB 119.125 5.429541
-4.000 134.875 5.005131
-4.5228 153.000 5.05682
-5.000 151.500 3.245877
-5.5228 168.375 4.161634
-6 . 0 0 0 177.125 6.682701
-6.5228 199.500 7.136426
-7.000 205.750 7.71073
-7.5228 280.500 16.23928
-8 . 0 0 0 418.875 39.47125
-8.5228 524.875 21.85458
-9.000 878.000 35.7686
-9.5228 1160.500 51,70348
-1 0 . 0 0 0 1303.250 52.97633
-10.5228 1370.875 67.91393
-1 2 . 0 0 0 1383.250 76.38081
-11.5228 1362.875 85.0908
-13.000 1376.250 71.16348
TOTAL 1344.250 62.96109
KO BRAIN - PRAZOSIN
Cone (log M) CPM S.E.M.
NSB 152.000 51.500
-5.000 133.500 35.000
-5.5228 153.750 47.250
-6 . 0 0 0 163.750 59.250
-6.5228 171.000 36.500
-7.000 188.250 46.750
-7.5228 223.250 54.750
-8 . 0 0 0 259.000 106.500
-8.5228 365.000 206.500
-9.000 631.250 211.250
-9.5228 883.500 391.000
-1 0 . 0 0 0 1089.750 518.750
-10.5228 1136.250 554.750
-1 1 . 0 0 0 1183.250 573.250
-11.5228 1224.500 612.500
-1 2 . 0 0 0 1238.500 615.000
-12.5228 1223.750 629.250
-13.000 1186.250 663.250
TOTAL 1154.250 543.250
KO BRAIN-RSI 00329
A4
Conc (log M) CPM S.E.M.
NSB 183.1667 35.65124
-3.000 190.1667 34.71903
-3.5228 204.0833 32.18887
-4.000 238.0833 36.28232
-4.5228 248.000 44.19596
-5.000 296.1667 47.09205
-5.5228 376.9167 57.12419
-6 . 0 0 0 504.3333 78.42987
-6.5228 690.1667 113.2425
-7.000 932.000 160.3949
-7.5228 1034.000 159.771
-8 . 0 0 0 1176.333 192.6259
-8.5228 1175.250 182.2304
-9.000 1187.333 176.1287
-9.5228 1199.500 187.573
-1 0 . 0 0 0 1199.833 176.3132
-10.5228 1200.083 172.9198
-1 1 . 0 0 0 1186.167 184.5774
TOTAL 1184.083 179.7314
KO BRAIN - (R)-A-61603 (-GTP)
Conc (log M) CPM S.E.M.
NSB 200.4167 31.26217
-3.000 212.8333 33.75467
-3.5228 226.0833 28.71336
-4.000 237.000 22.17469
-4.5228 270.4167 36.62818
-5.000 298.500 41.01565
-5.5228 400.000 41.92911
-6 . 0 0 0 544.8333 76.48863
-6.5228 750.750 90.61243
-7.000 1037.667 125.9242
-7.5228 1138.000 151.6821
-8 . 0 0 0 1243.917 164.2207
-8.5228 1294.167 191.6507
-9.000 1270.833 182.9063
-9.5228 1251.000 175.9752
-1 0 . 0 0 0 1265.833 191.3732
-10.5228 1269.417 173.0185
-1 1 . 0 0 0 1255.417 183.9226
TOTAL 1292.583 177.6881
KO BRAIN - (R)-A-61603 (+GTP)
A5
Conc (log M) CPM S.E.M.
NSB 58.800 4.600
-4.000 54.600 3.000
-4.5228 53.900 2 . 2 0 0
-5.000 76.900 6.500
-5.5228 169.700 18.600
-6 . 0 0 0 236.100 1 1 . 0 0 0
-6.5228 441.200 39.700
-7.000 512.500 57.100
-7.5228 507.200 40.000
-8 . 0 0 0 553.400 65.300
-8.5228 617.800 2 0 . 0 0 0
-9.000 646.200 47.600
-1 0 . 0 0 0 594.700 74.800
-1 1 . 0 0 0 594.500 105.800
TOTAL 597.700 79.800
KO BRAIN-L765,314
Conc (log M) CPM S.E.M.
NSB 188.500 13.500
-3.000 2 1 1 . 0 0 0 23.500
-3.5228 191.250 16.750
-4.000 204.000 27.500
-4.5228 253.250 25.750
-5.000 306.250 5.250
-5.5228 415.000 27.000
-6 . 0 0 0 515.000 84.000
-6.5228 660.000 94.50001
-7.000 712.500 74.500
-7.5228 744.750 92.750
-8 . 0 0 0 768.250 123.750
-8.5228 778.750 140.750
-9.000 773.000 72.000
-9.5228 779.750 94.250
-1 0 . 0 0 0 775.750 98.75001
-10.5228 799.000 95.00001
-1 1 . 0 0 0 759.750 58.250
TOTAL 749.250 71.750
KO BRAIN - BMY7378
A6
Conc (log M) CPM S.E.M.
NSB 1 1 2 . 0 0 0 1 2 . 0 0 0
-4.000 138.250 18.750
-4.5228 158.250 6.750
-5.000 108.500 2.500
-5.5228 123.500 2.500
-6 . 0 0 0 120.250 4.750
-6.5228 125.500 2.500
-7.000 136.750 3.250
-7.5228 182.750 7.250
-8 . 0 0 0 169.250 4.250
-8.5228 224.500 4.500
-9.000 225.500 4.500
-9.5228 434.500 19.000
-1 0 . 0 0 0 432.750 9.250
-10.5228 519.750 37.250
-1 1 . 0 0 0 488.250 34.750
-11.5228 525.750 13.750
-1 2 . 0 0 0 507.750 34.250
TOTAL 463.750 10.250
WT LIVER - PRAZOSIN
Conc (log M) CPM S.E.M.
NSB 408.250 16.250
-5.000 409.250 16.250
-5.5228 430.250 5.750
-6 . 0 0 0 516.000 30.000
-6.5228 807.750 25.250
-7.000 1347.750 18.250
-7.5228 2337.500 86.500
-8 . 0 0 0 3013.000 58.000
-8.5228 3330.750 41.750
-9.000 3565.500 95.49999
-9.5228 3573.250 55.250
-1 0 . 0 0 0 3635.750 2.250
-10.5228 3647.000 30.000
-1 1 . 0 0 0 3566.750 32.250
-11.5228 3526.750 28.750
-1 2 . 0 0 0 3715.250 22.750
-12.5228 3618.500 69.500
-13.000 3599.000 17.500
TOTAL 3470.250 39.250
WT LIVER-RSI 00329
A7
Conc (log M) CPM S.E.M.
NSB 314.500 19.500
-3.000 483.000 33.500
-3.5228 934.000 32.500
-4.000 1431.250 83.250
-4.5228 1776.500 52.500
-5.000 1913.500 25.500
-5.5228 1949.000 18.000
-6 . 0 0 0 1921.000 7.000
-6.5228 1924.500 52.500
-7.000 2043.750 65.750
-7.5228 2076.250 38.750
-8 . 0 0 0 2129.500 22.500
-8.5228 2098.000 24.000
-9.000 2107.000 6 . 0 0 0
-9.5228 2099.000 14.000
-1 0 . 0 0 0 2051.000 15.500
-10.5228 2074.500 1 . 0 0 0
- 1 1 . 0 0 0 2052.750 27.750
TOTAL 2091.500 49.500
WT LIVER - (R)-A-61603 (-GTP)
Conc (log M) CPM S.E.M.
NSB 320.750 15.250
-2 . 0 0 0 363.000 2 2 . 0 0 0
-2.5228 387.500 12.500
-3.000 464.500 35.000
-3.5228 876.750 12.250
-4.000 1252.250 35.250
-4.5228 1531.750 153.250
-5.000 1661.500 97.000
-5.5228 1662.250 55.250
-6 . 0 0 0 1670.250 57.250
-6.5228 1610.000 62.000
-7.000 1860.250 116.750
-7.5228 1792.250 86.750
-8 . 0 0 0 1772.000 101.500
-8.5228 1723.000 114.000
-9.000 1771.250 139.750
-9.5228 1663.250 210.750
-1 0 . 0 0 0 1708.500 146.500
-10.5228 1767.250 137.250
-1 1 . 0 0 0 1698.750 134.750
TOTAL 1693.750 149.750
WT LIVER - (R)-A-61603 (+GTP)
A8
Cone (log M) CPM S.E.M.
NSB 41.83333 4.094033
-4.000 42.515 3.214647
-4.5228 49.34667 1.331329
-5.000 64.19333 6.049585
-5.5228 94.445 5.749992
-6 . 0 0 0 125.4233 7.372498
-6.5228 494.2417 10.26778
-7.000 980.8117 9.726798
-7.5228 1658.153 31.20791
-8 . 0 0 0 2205.767 25.79542
-8.5228 2362.785 45.48272
-9.000 2351.620 17.67497
- 1 0 . 0 0 0 2306.535 31.69616
-1 1 . 0 0 0 2372.653 30.16128
TOTAL 2381.739 35.06498
WT LIVER-L765,314
Cone (log M) CPM S.E.M.
NSB 110.500 2.500
-3.000 108.250 0.749
-3.5228 110.250 2.250
-4.000 142.500 2.500
-4.5228 257.250 8.250
-5.000 463.500 7.000
-5.5228 1047.750 17.750
-6 . 0 0 0 1935.500 73.00
-6.5228 3346.750 5.750
-7.000 3802.000 181.0
-7.5228 4049.250 60.250
-8 . 0 0 0 4153.750 63.750
-8.5228 4141.000 87.500
-9.000 4244.500 95.999
-9.5228 4119.250 55.750
- 1 0 . 0 0 0 4267.750 35.750
-10.5228 4246.250 130.750
-1 1 . 0 0 0 4335.750 87.750
TOTAL 4126.500 149.000
WT LIVER - BMY7378
A9
Cone (log M) CPM S.E.M.
NSB 103.750 11.250
-4.000 108.750 13.750
-4.5228 108.750 7.750
-5.000 118.500 23.000
-5.5228 116.000 20.500
-6 . 0 0 0 140.750 24.750
-6.5228 158.750 43.750
-7.000 180.750 18.250
-7.5228 193.750 20.750
-8 . 0 0 0 213.750 31.750
-8.5228 241.000 52.500
-9.000 290.000 92.000
-9.5228 337.750 109.250
-1 0 . 0 0 0 308.000 88.500
-10.5228 306.750 75.750
- 1 1 . 0 0 0 319.750 111.250
-11.5228 323.500 102.500
- 1 2 . 0 0 0 311.500 95.999
TOTAL 301.500 81.500
KO LIVER - PRAZOSIN
Cone (log M) CPM S.E.M.
NSB 2 1 0 . 0 0 0 6 . 0 0 0
-5.000 251.500 7.500
-5.5228 226.500 7.500
-6 . 0 0 0 230.500 0.500
-6.5228 235.500 6.500
-7.000 228.000 8 . 0 0 0
-7.5228 234.500 20.500
-8 . 0 0 0 259.500 6.500
-8.5228 292.500 6.500
-9.000 316.500 8.500
-9.5228 338.000 6 . 0 0 0
-1 0 . 0 0 0 374.000 8 . 0 0 0
-10.5228 365.000 15.000
- 1 1 . 0 0 0 372.500 0.500
-11.5228 373.000 7.000
-1 2 . 0 0 0 379.000 3.000
-12.5228 366.500 13.500
-13.000 374.000 17.000
TOTAL 398.000 48.000
KO LIVER - RS100329
AlO
Cone ( log M) CPM S.E.M.
NSB 524.250 1.750
-3.000 535.500 9.000
-3.5228 578.500 48.000
-4.000 556.000 27.500
-4.5228 571.250 13.750
-5.000 591.750 20.750
-5.5228 567.250 3.250
-6 . 0 0 0 554.000 1 . 0 0 0
-6.5228 554.000 6 . 0 0 0
-7.000 639.000 31.500
-7.5228 688.250 36.750
-8 . 0 0 0 716.000 43.000
-8.5228 757.500 75.500
-9.000 742.250 60.250
-9.5228 743.000 72.500
-1 0 . 0 0 0 742.000 69.500
-10.5228 781.500 62.000
- 1 1 . 0 0 0 733.000 56.500
TOTAL 741.500 66.500
KO LIVER - (R)-A-61603 (-GTP)
Cone (log M) CPM S.E.M.
NSB 754.500 71.000
-3.000 834.250 142.250
-3.5228 863.000 119.000
-4.000 912.750 138.750
-4.5228 869.750 120.250
-5.000 897.750 154.250
-5.5228 926.500 62.500
-6 . 0 0 0 879.750 73.250
-6.5228 934.500 39.500
-7.000 939.750 60.750
-7.5228 1082.250 117.750
-8 . 0 0 0 1238.750 193.250
-8.5228 1184.250 18.750
-9.000 1275.500 94.50001
-9.5228 1352.000 1 0 1 . 0 0 0
-1 0 . 0 0 0 1293.500 53.000
-10.5228 1326.750 96.750
-1 1 . 0 0 0 1380.500 220.500
TOTAL 1240.750 72.250
KO LIVER - (R)-A-61603 (+GTP)
A l l
Cone (iog M) CPM S.E.M.
NSB 110.000 10.000
-4.000 134.300 12.100
-4.5228 113.000 16.600
-5.000 125.400 20.900
-5.5228 143.900 18.600
-6.000 137.100 18.900
-6.5228 250.700 13.500
-7.000 377.100 19.500
-7.5228 447.100 24.900
-8.000 466.100 34.400
-8.5228 583.700 35.500
-9.000 579.400 8.800
-9.5228 608.800 29.300
-10.000 567.400 16.500
TOTAL 559.000 25.000
K0LIVER-L765,314
Cone (log M) CPM S.E.M.
NSB 108.000 7.000
-3.000 126.000 3.500
-3.5228 128.750 5.750
-4.000 117.750 2.750
-4.5228 139.750 0.250
-5.000 145.750 0.749
-5.5228 162.000 3.500
-6.000 204.250 2.750
-6.5228 240.750 17.750
-7.000 230.000 8.000
-7.5228 229.000 5.000
-8.000 248.750 24.250
-8.5228 256.750 10.250
-9.000 253.500 25.000
-9.5228 242.500 22.500
-10.000 247.000 16.000
-10.5228 246.750 27.750
-11.000 241.000 20.500
TOTAL 253.750 15.250
KO LIVER - BMY7378
A12
